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ABSTRACT
This thesis presents studies on the epidemiology of vaccine preventable VIruS
infections investigated by oral fluid testing. It involved studies of both rubella and
hepatitis B virus infections by the detection of specific IgG in oral fluid and of rubella
virus by PCR detection and genotyping of viral nucleic acid. To select an oral fluid
collection device with optimal performance for these studies three (Orasure, Omni-
SAL, Oracol) were compared. Each device collected oral fluid of sufficient quality for
qualitative analysis of virus specific IgG, but DracoI was most acceptable to the
subjects being tested. IgG capture ELISA (GACELISA) tests were developed for
detection of rubella and anti-HBc specific IgG in oral fluid. Their sensitivity was less
than that of corresponding serum ELiSAs, with sensitivity decreasing with increasing
age of subjects. Whilst the performance of the rubella GACELISA was shown to be
an improvement over the existing radioimmunoassay and was particularly sensitive
with samples from paediatric populations, the performance of the anti-HBc
GACELISA was not considered good enough for further use. The development of an
RT-PCR assay targeting the El gene of rubella virus enabled the molecular
epidemiology of rubella to be investigated using samples from the UK, China, Greece,
and Brazil. By comparison to previously reported strains, the majority of strains were
assigned to three banches of a phylogenetic tree. Those assigned to branches 1 (UK,
Greece, China) and 2 (China) were not closely related to any previously reported
strains. The timing of oral fluid collection and subsequent storage was critical for
PCR detection. Ideally oral fluid samples should be collected within 14 days of the
onset of symptoms and stored at least at -20°C prior to testing.
INTRODUCTION
Vaccination is one of the most cost-effective measures that modem medicine has to
offer for preventing infectious diseases that represent important causes of morbidity
and mortality (90). When used appropriately and with a suitable epidemiological
strategy, vaccines have had great success. Vaccination was responsible for the
eradication of smallpox on a global scale, poliomyelitis from the Western hemisphere
and under the guidance of the WHO Expanded Program on Immunization (EPI) has
greatly reduced the incidence of several childhood infections including measles,
diphtheria, tetanus and pertussis (97).
The word "immunity" comes from the Latin "immunitas" meaning exemption from
public services, burdens or charges. It has now become associated with protection
from infection and study of immunity forms a branch of the science of immunology
(50). The concept of immunisation, vaccination and its ability to protect the public
from infectious disease was pioneered by Edward Jenner in the late 18th century. His
work was inspired by smallpox which, at this time, was endemic and often assumed
epidemic proportions. Itwas a disease that was greatly feared as it was often fatal and
left characterisitc disfiguring scarring from lesions in surviving cases.
Edward Jenner essentially carried out a study that experimentally tested the concept of
vaccination against smallpox. Jenner had noted that persons infected with cowpox
could not become infected with smallpox. He concluded that cowpox not only
protected against smallpox but could also be transmitted from person to person as a
"deliberate mechanism of protection" and therefore set out to investigate this. In May
1796 Jenner examined a dairy maid with fresh cowpox lesions on her finger and using
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matter from these lesions inoculated an eight-year-old boy, James Phipps. Several
weeks later he inoculated the boy again but this time with smallpox matter. No disease
developed demonstrating complete protection. The Latin word for cow is "vacca" and
cowpox "vaccinia", hence Jenner's procedure was named "vaccination" (50, 191).
Initially Jenner's work met with some skepticism and a paper describing his results
was refused by the Royal Society. The reaction of the public was also not immediately
favorable, early volunteer studies being unsuccessful. However, vaccination
eventually became popular in London and "The Vaccination Act" of 1853 laid down
that all infants must be vaccinated, though had no powers of enforcement whilst an
earlier Act in 1840 introduced free vaccination following a three year epidemic of
smallpox. These measures produced a marked decrease in the annual mortality from
smallpox after only a few years and later vaccination acts saw the introduction of
public vaccinators and compulsory vaccination. Compulsory vaccination was repealed
in 1946 by the NHS Act and on 8th May, 1980, the World Health Assembly declared
that smallpox was eradicated worldwide (191).
For nearly a century Jenner's smallpox vaccine was the only vaccine known until,
during the 1880s, Louis Pasteur developed both an anthrax and a rabies vaccine. This
led to a wide extension of immunizing methods against many diseases with
correspondingly widened meanings of the terms ''vaccination'' and ''vaccine'',
applying them to the use of both living and dead material. By the start of the First
World War, typhoid vaccines were available and in 1921 Calmette and Geurin
produced the BCG vaccine against tuberculosis, the first live bacterial vaccine for
general human use (50).
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Since the work of Pasteur in the late nineteenth century little development in viral
vaccines occurred until, in 1930, Theiler announced a safe and effective vaccine
against yellow fever which was further refined in 1937. Large scale production was
carried out using embryonated hens eggs. The use of chick embryos to produce
vaccine paved the way for production of other vaccines, particularly viral vaccines, on
a large scale including a killed influenza vaccine produced in the early 1940s. A
further technological advance important for vaccine development and large scale
production was the establishment of cell culture methods for virus propagation. In the
1940s and 1950s poliomyelitis vaccines were made, and measles, rubella and mumps
vaccines were pioneered in the 1950s and 1960s (135).
Enders, Weller and Robbins made a major technical advance in 1949 by
demonstrating that, contrary to popular belief, poliomyelitis virus could be grown
outside the primate central nervous system so enabling effective poliovaccines to be
produced. In 1953 Salk and his co-workers prepared a poliomyelitis vaccine by
growing three serotypes of the virus in monkey kidney cells followed by inactivation
with formaldehyde. At the same time Sabin, Koprowski and Cox developed live
attenuated poliovaccines for oral administration which became the vaccine of choice.
and has been used worldwide since 1959, mainly because it is the easier of the two to
administer. It does however have the disadvantage of causing a small number of cases
of paralysis in recipients or contacts as the vaccine strain spontaneously reverts to the
wild type virus at a very low rate (135, 156).
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Combining several vaccines into a single formulation for immunization against
different diseases has been commonly used. Successful examples include that of
polioviruses serotypes 1, 2 and 3 into a single vaccine against poliomyelitis and the
combination of measles, mumps and rubella vaccines into a triple vaccine. In 1978 the
island of Grenada claimed, by using the "Dermojet" gun and combined vaccines, to be
the first nation in the world to have 100% of its children immunized against
diphtheria, Whooping cough, tetanus, polio, tuberculosis, measles and typhoid (50).
The use of combined vaccines offers a number of obvious advantages, the first being a
decrease in the number of vaccine inoculations and consequent clinic visits which
should result in an increased compliance to vaccination schedules. Secondly,
combining vaccines reduces the cost of storage, transport and administration. Thirdly,
combining vaccines simplifies vaccine schedules, facilitating record keeping and
providing the opportunity for a universal approach to global vaccination (153).
Attenuation can be defined as a method for reducing the virulence of a live virus
vaccine. Vaccine efficacy refers to its effectiveness under optimized conditions.
Traditionally, vaccines have been attenuated by either serial passage in tissue culture
or inactivation by physical or chemical means. Although such vaccines have been and
remain effective they do possess several disadvantages. The genetic modifications
responsible for attenuation are often undefined leaving the possibility of reversion and
possible vaccine induced disease (45). When producing killed vaccines, great care
must be taken to ensure that each batch produced has been inactivated sufficiently so
that virulence is reduced but protective efficacy is not lost. This presents considerable
challenges to the manufacturer (35).
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Advances in recombinant DNA technology, molecular biology and immunology
potentially enables a vaccine against any infectious disease to be developed, given
sufficient resources, and should eliminate many of the problems associated with
traditionally produced vaccines (97).
The principle directions in which vaccine development is now being pursued include:
1. Purified component vaccines (35, 45)
2. Synthetic antigens (6,35, 190)
3. Neoglycoconjugates (35)
4. Genetically modified strains (35, 113)
5. Nucleic acid vaccines (35, 170)
6. Novel antigen delivery systems (35)
The most recent developments with measles vaccine have concentrated on aerosol
delivery. This form of delivery is painless, rapid and non-invasive and therefore
suitable for mass campaigns. Results in comparison to vaccine given subcutaneously
suggest the aerosol route evokes a better humoral response which remains
significantly higher, and may also induce superior mucosal immunity (46). Since this
technique also avoids the risks associated with injections, aerosol delivery of measles
vaccine could therefore help with the eradication of measles.
The World Health Organization (WHO), the Expanded Program on
Immunization (EPI) and the Global Program on Vaccination (GPV)
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During the late 19th century it became clear that current vaccination strategies were
not adequate to control smallpox as evident from its incidence which, though in
decline, persisted. During the 1950s eradication efforts were intensified and smallpox
was eliminated from several regions of the world but was still endemic in 31
countries, prompting the 1958 World Health Assembly to propose the idea of global
eradication. The World Health Organization began work on this project in 1967 and,
on 8th May 1980, the 33rd World Health Assembly was able to declare smallpox
eradicated (191).
When it was apparent that the smallpox campaign was going to succeed, the WHO
initiated the Expanded Program on Immunization (EPI) whose aim was to deliver on a
global basis vaccines for diphtheria, pertussis, tetanus, poliomyelitis, measles and
BCG for tuberculosis. Later it was decided to include hepatitis B and yellow fever for
those countries where it occurs. National Immunization Days are encouraged where
all children under 5 years of age are immunized regardless of previous vaccination
history which is an effective way of catching children who miss routine infant
immunization (130).
Following progress that has been made with EPI the WHO decided, in 1993, that if
vaccination was to be used efficiently and effectively to combat infectious disease on
a world wide scale the following needed to be carefully coordinated and managed as a
whole: research and development; liaison with industry; the introduction of new
vaccines into EPI; securing a stable supply of quality vaccines and monitoring the
progress of the control of various diseases (90). Therefore the Global Program on
Vaccination (GPV) was created which combined two existing programs, EPI and
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Vaccine Research and Development, with one new program on Vaccine Supply and
Quality Control. GPV has four goals (90):
1. to aid development of new vaccines which can be incorporated into EPI extending
immunization to diseases not currently vaccine preventable but which cause
significant morbidity and mortality in developing countries.
2. the development of new vaccination approaches so simplifying the immunization
process using combined vaccines and alternative routes of administration and to
improve vaccination efficiency using novel immunization approaches such as
nucleic acid vaccines and new adjuvants.
3. to introduce new vaccines into EPI and evaluate their efficacy in field trials and
advise on immunization strategies.
4. the development of simple diagnostic tools to monitor the progress and
effectiveness in EPI.
The work described in this thesis has a direct relevance to the goals of GPV,
particularly the fourth, since one aim of the study is to develop simple assays which
use oral fluids as a substitute for serum to measure IgG responses to vaccine
preventable virus infections. The use of oral fluids allows larger study populations and
those populations previously inaccessible to be reached. Coupled with simple specific
assays suitable for field use, this will enable the progress and effectiveness of viral
vaccines within EPI to be monitored more easily and widely. Two vaccine
preventable virus infections, rubella and hepatitis B, were investigated in studies
described in this thesis.
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RUBELLA
Historical Perspective
Postnatal rubella is a mild illness and for many years was considered to be a disease of
minor importance. Rubella was first described as a disease distinct from other
exanthemata by the German physician de Bergen in the early 1800s and was termed
"Rotheln". The first person to describe rubella in the UK was Dr. William Maton
who reported an outbreak of an illness resembling a mild form of scarlatina in a boys
public school in 1815. Several years later Maton again observed an outbreak of a rash
associated illness and was able to describe the characteristic clinical features of
rubella including mild illness followed by a generalized, often tingling rash lasting for
a few days with enlarged and tender glands. In 1866 Dr. Henry Veale, a Scottish
physician, described in the Edinburgh Medical Journal 30 cases of rubella (184) and
as an alternative to Rotheln, proposed the Latin name "rubella" as an easily
pronounceable alternative, meaning "little red" (184). (Reviewed in (34), (58), (109),
(195)).
For almost a century rubella received very little attention until, in 1941, an Australian
ophthalmologist named Norman Gregg made a very important finding following a
rubella outbreak in New South Wales. He reported an association between rubella in
pregnancy and congenital abnormalities, many of which were serious (66). Initially
his findings were met with skepticism but during the next twenty years his
observations were confirmed by others (189)(reviewed in (195)). A pandemic of
rubella began in Europe in the early 1960s and spread to the United States which
experienced a huge rubella epidemic in 1964/5 resulting in an estimated 20,000
rubella damaged babies. This led to a better understanding of congenital rubella
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syndrome and emphasized the need to develop a vaccine and suitable immunization
programme (33, 132) (reviewed in (71».
Biology and virological properties
Rubella virus (RV) is the sole member of the genus rubivirus which is classified
within the Togaviridae family. Unlike other members of the Togaviridae family, RV
has no known invertebrate host with man being the only known natural reservoir.
Electron microscopy shows RV virions to be small, pleomorphic, 50-70 nm in
diameter, and consist of a 30 nm electron dense core surrounded by an envelope
(134). The genome is a single strand of positive sense RNA. It is encapsulated in an
icosahedral protein shell (T = 4) (24) composed of the capsid protein (C), enveloped
by a lipid bilayer derived from the host cell plasma membrane (8). Projecting through
the envelope are viral encoded glycoproteins E1 and E2. These are thought to interact
with host cell receptors during adsorption and much of the hosts immune response is
directed against them (167).
The positive sense single stranded RNA genome is 9,762 nucleotides in length (93)
and is arranged into two parts: the 5' end codes for nonstructural proteins needed for
the transcription and translation of RNA; the 3' end codes for the capsid (C), El and
E2 structural proteins (see page 21) (reviewed in (56, 93». During replication a
discrete subgenomic mRNA species, identical to the 3' terminal sequence of the
genomic RNA is synthesized, capped and polyadenylated and acts as the mRNA for
the synthesis of viral structural proteins (reviewed in (167». A number of
cotranslational and post translational modifications occur to the rubella glycoproteins
before they are incorporated into virus particles (reviewed in (167, 195».
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Clinical Features of Rubella
Rubella virus is spread by the respiratory route. Infection may be asymptomatic or
cause clinical symptoms which include a maculopapular rash, lymphadenopathy, low
grade fever, conjunctivitis, sore throat and arthralgia. The rash is the most prominent
feature, usually appearing on the face and spreading outwards. Symptoms are
preceded by an incubation period of between 7 and 9 days followed by the appearance
of virus in the serum after which virus is shed into the nasopharynx. The
maculopapular rash begins 13-21 days after exposure and coincides with the detection
of rubella specific antibody suggesting the rash may be an immune mediated
phenomenon. An IgM antibody response predominates at the onset of illness and
within a week antibodies to all immunoglobulin classes are detectable (reviewed in
(195)).
Congenital Rubella Syndrome
In contrast to postnatal rubella, rubella virus infection acquired during pregnancy
often has severe consequences because fetal development may be impaired giving rise
to the congenital rubella syndrome (CRS) (reviewed in (195)). The early fetus
(embryo) is at risk from rubella infection very shortly after conception. Some infected
fetuses can escape damage but fetal death is a considerable risk following infection
before the 16th week of gestation and 67-85% of neonates show clinical sequelae
following maternal infection in the first trimester (121). Maternal infection after the
second trimester does not usually result in fetal damage. The effects of fetal rubella
range from those that are obvious at birth such as neonatal cataracts and other physical
defects to those which do not become clinically apparent for several years including
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retinopathy, mental retardation and hearing loss. In developing countries, fetuses with
severe multiple defects probably die unrecognized during pregnancy or as infants
soon after birth (reviewed in (36, 108, 118, 195».
The mechanisms of rubella virus teratogenesis remain unknown and suggestions
include the possibility of damage due to viral replication in focal clones of cells at
critical stages of the development of fetal organs. The prolonged persistence of rubella
virus in fetal tissues suggests that neither maternal IgG nor the developing fetal
immune system can eliminate the virus in utero despite the ability of both maternal
IgG and fetal IgM to neutralize the virus in vitro (106). How the virus is able to
escape and establish persistent infections in the fetus is yet to be determined (195) and
may possibly be related to the ability ofRV to mature in intracellular vacuoles and so
avoid the immune system.
In 1984, the WHO Regional Committee for Europe set the year 2000 as a target date
for the elimination of congenital rubella from the Region. It was decided that by 1990
all European countries should include rubella vaccine in their national programs, by
1995 should have achieved at least 90% coverage of the target population and by 1996
should have investigated every case of congenital rubella syndrome (58).
Epidemiology
Since man is the only known host for rubella virus, the virus must continually cycle
within the human population for perpetuation of the disease. As infection with rubella
virus is often sub clinical or symptoms being generally mild, clinical diagnosis may
be unreliable so compromising the accuracy of studies of rubella incidence. Medical
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attention is often not sought and even when it is, laboratory confirmation is often not
obtained nor a specific diagnosis made. Seroepidemiological studies have been used
to provide more representative data and, despite the difficulty of obtaining completely
reliable information, it seems likely that rubella is endemic worldwide. Before the
advent of rubella vaccination, pools of susceptibles accumulated in such a way as to
give rise to epidemics at intervals of 3-9 years in different geographic locations with
major world epidemics every 10-30 years. In some European countries epidemics
were recorded at more frequent intervals than in the USA. In Taiwan, rubella was not
endemic but occurred in epidemic cycles at ten year intervals (59). A major problem
in identifying epidemics of rubella, particularly in developing countries with poor
health-care facilities, is the lack of apparent clinical symptoms which may cause
rubella outbreaks to pass unrecognized (195).
The age at which rubella virus infection occurs varies geographically. For the majority
of industrialized nations with temperate climates infection peaks among young school
children between the ages of five and nine years. In contrast, a considerably higher
proportion of this age group are seropositive in equatorial countries, suggesting a
higher attack rate amongst preschool children. In much of Africa the majority of
children are immune by the age of 10 years. Population densities and socioeconomic
factors greatly influence the appearance and spread of epidemics and serology has
been used to show that rubella infection is highest amongst the densely housed (43,
109, 161).
Populations considered to be at particular risk, especially amongst child-bearing age-
groups, are island communities and migrant populations from rural areas. This is due
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to the lower proportion of seropositive individuals within these groups as a result of a
lower risk of exposure to rubella during childhood (108, 110).
Rubella Vaccines
Attempts to produce a chemically inactivated rubella vaccine during the early 1960s
were unsuccessful and were discontinued when it was reported that rubella virus could
be attenuated by multiple passage in tissue culture. The first attenuated strain of
rubella virus was produced using an isolate from a US military recruit in 1961 (73). It
was passaged 77 times in vervet monkey kidney cell cultures to give a prototype
vaccine referred to as high-passage virus-77 or HPV77. This was then given a further
5 passages in duck embryo fibroblasts as they are thought less likely to contain
extraneous agents. This strain was called HPV77. DE5 (73) and was introduced for
use in many European countries and the United States in 1969170. Another vaccine
strain, DKI2, was produced by passaging HPV77 12 times in dog kidney cell cultures
and was also licensed in 1969 but its use was discontinued as it caused an
unacceptably high number of adverse reactions after administration (173).
Another attenuated rubella vaccine, the Cendehill strain, was licensed for use in the
USA and UK in 1969 and 1970 respectively. This strain was isolated from a urine
sample from a case of postnatally aquired rubella and attenuated by 51 passages in
primary rabbit kidney cultures (77). A further attenuated rubella vaccine, the RA27/3
strain was licensed for use in the UK in 1972 and is now the most widely used rubella
vaccine strain. The name RA27/3 refers to "rubella abortus, 27th specimen, third
explant" and the vaccine strain was derived from the kidney of a rubella infected
fetus and attenuated by 4 passages in human embryonic kidney cells and 17-25
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passages in human diploid cell culture (WI-38 fibroblasts), avoiding the use of
nonhuman cells (147). RA27/3 replaced the HPV77. DES vaccine strain in the USA in
1979 and is currently incorporated into the MMR vaccines produced in the USA and
Western Europe as the antibody response and protection it affords most closely
resembles that induced by naturally aquired infections. Another five attenuated strains
of rubella virus have been developed, four of which are used in Japan and the fifth, the
BRD-2 vaccine strain, has been developed in China (reviewed in (11) and (71». A
summary of rubella vaccine strains is shown in table 1.
Table 1. Origin and passage history of attenuated rubella virus vaccine strains
(11)
AttenuationlPassage history in
cell cultures
Strain Origin of strain
designation
HPV77
HPV77.DES
Cendehill
RA27/3
DCRB19
KRT
TO-336
SK
BRD-2
VMK(77)
VMK (77); duck embryo (5)
natal VMK (3); primary rabbit kidney
US Army recruit
As above
Urine from case of post
rubella
Kidney of rubella infected fetus
Throat swab from patient In
Tokyo
Throat swab from patient In
Matsue, Japan
Throat washing from patient in
Osaka, Japan
Pharyngeal secretion from post
natally infected child, Toyama,
Japan
Throat washing from patient in
Kumamato, Japan
Child with post natal rubella,
China
Human embryonic kidney (4); WI-
38 fibroblasts (17-25)
VMK (1); Bovine kidney (53);
rabbit kidney (3)
VMK (4); primary rabbit testicle
(36); primary rabbit kidney (1)
VMK (14); Chick amnion (65);
quail embryo fibroblasts (11)
VMK (7); primary guinea pig
kidney (20); primary rabbit kidney
(3)
VMK (1); swine kidney (60);
rabbit kidney (6)
Human diploid cells (30)
VMK = vervet monkey kidney, (x) = number of passages
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Rubella Immunisation Programmes
Rubella immunization programs are designed to prevent maternal rubella infections
and the subsequent teratogenic effects on the fetus. The development of rubella
vaccines has created a unique situation in that the primary group of people who
contract and spread post natal rubella differ from those who benefit most from the
vaccine, namely the unborn children of pregnant mothers. Consequently ethical
consideration has led to different countries using different immunization strategies so
the achievement of the main goal of vaccination has varied (102, 103).
Despite the availability of rubella vaccine, it has not been recommended for use in
EPI in developing countries. This is mainly because a sustained high coverage cannot
be guaranteed in such countries so a strong possibility exists for the slowing rather
than complete interruption of rubella transmission. This would result in an increase in
the average age of infection therefore increasing the suceptability of adult women of
child bearing age. However, many industrialized countries include rubella vaccine in
their programmes and approximately a third of all countries worldwide report a
national policy of rubella vaccination (141).
Three strategies for rubella vaccination have been used (58, 138, 161):
1. The first approach was used in the USA and started with a mass vaccination of
children under 12 years of age and was followed by routine vaccination of children
of both sexes at the age of one year. This approach is designed to interrupt
transmission of rubella virus amongst young children, who represent the primary
transmission group, so minimising the possibility of exposure of susceptible
pregnant women. This strategy requires a very high vaccine coverage in excess of
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90%. Rubella vaccine is delivered as part of the combined MMR vaccine and
sufficient coverage is maintained in the USA as a result of the USA school
immunization law which requires documentary evidence of immunization against
specific diseases prior to school entry.
2. A second approach was used in the UK until 1988 and has also been used in some
other European countries. It is a selective approach targeting prepubertal girls and
non-immune women, either before or after pregnancy, with one dose of
monovalent rubella vaccine. The aim of this strategy is to protect individuals and
prevent maternal rubella infections rather than to diminish natural circulation of the
wild type virus which is thought to contribute to maintaining the level of immunity
in women of child-bearing age. This approach is particularly appropriate where
there is evidence to suggest that vaccine coverage in mass campaigns is poor. Since
a rubella epidemic in 1986, the vaccination programme in the UK was expanded in
1988 to include preschool children of both sexes with rubella being included in a
combined MMR vaccine.
3. The third approach was first successfully implemented in Sweden. It was
introduced in 1982 and involves a two-dose schedule using a combined MMR
vaccine. Vaccination is optional, free of charge and is offered to children at 18
months and again at 12 years of age with the second dose given irrespective of
history of disease or previous vaccination. By immunizing those not vaccinated at
18 months and those who responded poorly to the first dose of vaccine this
programme is designed to prevent an accumulation of susceptibles in older age
groups, and the ultimate aim of this strategy is to eliminate rubella as well as
measles and mumps.
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Epidemiological evidence suggests that whilst selective vaccination strategies can
achieve a considerable reduction in the incidence of rubella infection in pregnancy the
risk still remains unacceptably high as the strategy is designed to enable some
circulation of natural rubella virus amongst non-immunised children and adults.
Therefore selective immunization strategies are being replaced by combined strategies
which include mass immunization of young children which quickly reduces the
circulation of rubella virus, and the effectiveness of this approach is demonstrated by
the considerable reduction in CRS cases in the UK between 1971 and 1996 (182).
These strategies are, however, not without problems and mathematical models predict
that vaccine coverage must exceed at least 70% to avoid large pools of susceptibles in
older age groups and therefore a potential risk ofCRS. Several approaches are used to
maintain vaccination coverage at a suitably high level including an increased
professional commitment towards vaccination, adequate amounts of vaccine and
funding and the introduction of legislation that requires evidence of immunization for
entry to school as in the USA.
If a mother is inadvertently immunized with rubella vaccine during early pregnancy a
concern is any risk this poses to the developing fetus. Of 712 documented cases of
susceptible women vaccinated during pregnancy, none of the resulting children have
shown malformations compatible with congenital rubella syndrome. This suggests the
vaccine strains of rubella virus do not have the teratogenic capacity of natural rubella
virus (9, 148).
Due to the potential problems that are associated with insufficient vaccine coverage it
is important that rubella control programmes have built in monitoring systems.
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Vaccine coverage of target age-groups should be monitored and in countries using
MMR vaccine, measles, mumps and rubella should all be notifiable diseases (116,
164, 194).
Laboratory diagnosis
Due to the difficulties associated with accurate clinical diagnosis and because viral
cell culture is difficult and time consuming, serological investigation remains the
diagnostic method of choice. Accurate laboratory diagnosis of past or recent rubella is
essential both for the individual patient, especially the woman presenting with a rash
(or history of contact with rash) in early pregnancy, and for the design and monitoring
of vaccination programmes. Screening for rubella antibody is also important to
ascertain whether immunization should be advised, though only pregnant women are
universally screened. The current policy is to recommend rubella immunization
should level of rubella specific IgG antibody be lower than 10 IV/mL, which is
considered to be the minimum protective level of antibody (172). Previously, 15
IV/ml was considered to be the minimum protective level (117). However, in 1992 the
Rubella Subcommittee of the National Committee for Clinical Laboratory Standards
in the USA elected to use 10 Ill/ml as the breakpoint to define rubella immunity. This
recommendation was based upon epidemiological studies, anecdotal reports and the
already widespread use of this lower limit in the United States without apparent
adverse effect (172).
Classical serological tests such as the complement fixation test (CFT), indirect
immunofluoresence (IF) and haemagglutination-inhibition (HI) were introduced for
the laboratory diagnosis of rubella in the late 1960s, with the HI test becoming the
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assay of choice as it used a commercially available freeze dried antigen and could
reliably detect all classes of rubella specific antibody. The HI test is, however,
technically demanding and time consuming so is no longer recommended for rubella
antibody screening but despite its problems, remains the reference standard against
which newer assays are compared. Subsequently, in the UK, radial haemolysis (RH)
as described by Kurtz et al (89}was introduced to meet the need for a simple and
economical screening test which was both sensitive and specific in anticipation of a
national rubella vaccination campaign. Red cell-based assays, however, are now being
superseded by commercially available enzyme linked immunosorbent assays
(ELISA), which can detect rubella specific IgG and IgM antibody and are highly
sensitive and specific. Latex agglutination (LA) is also recommended as a rapid and
sensitive screening assay for immunity. In reference laboratories, radioimmunoassays
(RIA) have been used, especially those with IgM capture formats which detect the
proportion ofIgM specific for rubella (37, 104, 195).
THE MOLECULAR BIOLOGY OF RUBELLA VIRUS
The genomic structure of rubella
The RV genome is 9,762 nucleotides in length, excluding a poly adenosine (A) tract
situated terminally at the 3' end. The base composition is 14.9% adenosine (A),
15.4% uracil (U), 30.8% guanosine (G) and 38.7% cytidine (C), with the total rubella
G + C content of 69.5% being the highest of any RNA virus sequenced to date.
Semliki Forest virus, also a member of the Togaviridae family, with a G + C content
of 53% is the RNA virus with the next highest G + C content so far determined
(reviewed in (56, 167)}.The unusually high G + C content of the RV genome presents
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a difficulty for both the design of specific primer sequences for polymerase chain
reaction (peR) assays and sequence determination of the RV genome (17,25,48,57).
RNA is labile and vulnerable to the effects of degredative enzymes such as
ribonuclease (RNase). The RV genome is no exception. This suggests that virion
RNA may be exposed on or near the surface of the capsid or that RNase can easily
penetrate into the capsid. Alternatively, virion RNA may form a structural component
of the capsid so making it vulnerable to the effects of RNase (56). The fact that the
RV genome is labile and sensitive to the effects of RNase has implications for the
collection of samples and this is addressed later. When collecting samples for RNA
testing important considerations are therefore any prior treatments to which a sample
may have been subjected, the manner in which samples have been stored and the
number of freeze thawing cycles a sample may have undergone.
The RV genome contains two non-overlapping open reading frames (ORFs), as shown
in Fig. 1.
The genomic organisation of rubella virus (195)
Non-structural proteins Structural proteins
5'
Fig. I
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The 5' ORF encompasses approximately two thirds of the genome being 6345
nucleotides in length and encodes non-structural proteins involved in viral RNA
replication. The second ORF is 3' proximal and is 3189 nucleotides long
encompassing the other one third of the genome, encoding three virion proteins
consisting of the nucleocapsid (C) and the glycoproteins El and E2. Both these
glycoproteins are described as class Imembrane proteins in that they contain a single
potential transmembrane sequence. Both are further classified as type Iglycoproteins
as the predicted transmembrane sequence is near the carboxy terminus, in contrast to
type II glycoproteins where the transmembrane sequence is found near the amino
terminus. El and E2 are 481 and 282 amino acids in length respectively, and of the
two, E2 is more heavily glycosylated. The function of these glycoproteins is thought
to be involved with the binding ofRV to specific host cell surface receptors (reviewed
in (12, 56».
Electron microscopy suggests that El and E2 project from the RV lipid envelope to
form surface spikes approximately 6 - 8 nm in length. Further studies using antisera
specific for El and E2 after non-ionic detergents have been used to disrupt the RV
virion suggest that El and E2 form a heterodimer complex stabalized by multiple inter
chain disulphide bonds (reviewed in (56». Studies show that the majority of E2 is
poorly accessible at the surface of the virion to the actions of glycosidases,
neuraminidase and trypsin and is inaccessible to monoclonal antibodies specifically
reactive with the amino-terminus region (reviewed in (195». Therefore it is likely that
El is the more exposed of the two glycoproteins in the herterodimer. A humoral
response in the host is induced by both El and E2 with El being immunodominant. A
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number of linear epitopes recognised by murine monoclonal antibodies, some of
which are neutralising, have been mapped between amino acids 210 and 286 of the
total of 481 that make up El and RV immune human sera have been shown to react
with this region (56).
Genomic sequencing
The basis for sequence variation in the nucleotides of both RNA and DNA viruses is
thought to be that genomic variation enables viruses to adapt to changes in the
environment and conditions of replication. Such nucleotide variation may lead to
changes in the amino acid composition of the virion which is often reflected as
antigenic variation. Alternatively, as is often the case, there is no structural change,
the sequence variation helping the virus to optimise its replication. The advent and
development of the polymerase chain reaction (peR), automated sequencing
technology and the necessary computer software needed to analyse the resulting data
has opened up the possibility of studying the molecular epidemiology of viruses
(107). Such techniques have recently been successfully used to investigate the
molecular epidemiology of measles virus, an important vaccine preventable virus
infection (80,81).
The investigation of genetic heterogeneity by genomic sequencing has important
implications for both epidemiologists and clinicians. Firstly, molecular studies of
important antigenic regions may lead to the characterisation of a new strain
antigenic ally different from strains currently known to be circulating and so disclose
the presence of a virus with the potential for transmission within a population
considered immune. This is particularly important for vaccine preventable virus
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infections. Secondly, a detailed knowledge of virus nucleotide sequence and its
genetic heterogeneity enables the tracking of chains of transmission of infection
which can lead to the tracing of the origin of infection in an outbreak and
investigation of unusual cases (143).
RubellaPCR
When developing a suitable PeR-based assay for the detection of RV RNA there are
several technical aspects which need consideration. Firstly, the RV genome consists
of RNA and so must be reverse transcribed to copy DNA (cDNA). Secondly, to obtain
a necessary level of sensitivity a double amplification or nested peR is needed where
the initial amplified sequence, or first round product, is re-amplified to produce a
second round product in sufficient quantities for visualisation by staining with
ethidium bromide after electrophoresis on an agarose gel.
The choice of primers is critical when designing a peR assay. This is largely
dependant upon the specific purpose for which the peR assay is used such as clinical
diagnosis or investigating molecular epidemiology. Any information on the nucleotide
sequence of the virus in question that is already known should be taken into account.
Each primer should ideally be 20-30 nucleotides in length, chosen within a nucleotide
region of the virus genome that is known to be well conserved and contain an optimal
ratio of G+e and A+T residues. Ideally the G+e content of a primer should be within
the range of 35-55% of the total nucleotides making up the primer (30, 163). The
length of nested peR product that is generated between the second round 3' and 5'
primers should be chosen to suit the purposes of the peR assay. If the peR is required
for diagnosis only it is not necessary to generate a large product, the determining
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factors being those needed to produce a result with maximum sensitivity and
specificity, speed, and efficiency. If, however, the peR is to be used for molecular
phylogeny it should be designed so that a substantially longer second round product is
produced to enable differences in nucleotide sequence of the genome to be observed
and their significance determined. However, choosing a product greater than 700
nucleotides in length may result in decreased efficiency of the peR assay. To
determine the extent of genomic heterogeneity it is essential that the region of genome
chosen for peR is one that encodes amino acids on which there is sufficient selection
pressure to produce variation, in particular antigenic variation (56, 57, 79, 81, 86,
107).
Of the three structural proteins of RV, the El glycoprotein is the most exposed
antigen and the majority of the host's humoral response appear to be directed against
it. Since the information on RV genome variation is limited, a reasonable assumption
has been made that there is most pressure on the El glycoprotein to vary. Of the genes
making up the two RV ORFs it is probable, therefore, that most nucleotide variation
will be seen within the El gene. Therefore, when developing a peR based assay
specifically for investigating the molecular epidemiology of rubella, primers should
be designed that encompass a region of the El gene. They should ideally include the
region between amino acids 210 and 286 which encodes epitopes against which RV
immune human serum has been shown to react (56,57, 143, 195, 196).
Three published peR assays have been described for detecting RV RNA for the
clinical diagnosis of fetal rubella infection. All three target a region of the El gene
and produce a relatively short second round product adequate for diagnosis but of
relatively little value for molecular epidemiological studies. That described by Bosma
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et al (18) produces a second round product 143 nucleotides in length. Revello et al
(I55) described a PCR-assay with a second round product slightly smaller at 125
nucleotides in length whilst that described by Tanemura et al (175) produces a larger
product of 283 nucleotides.
The molecular epidemiology of rubella
To date three studies have been published on the molecular epidemiology of rubella.
The first was carried out by Bosma et al (17) in 1996 using a 309 nucleotide amplicon
that targeted the El glycoprotein. A total of 22 rubella virus isolates from Europe,
Asia and the USA obtained between 1963-1995 were used. Nucleotide sequence
divergence for these strains ranged from 0.65% to 7.14%, with greatest divergence
seen in two rubella viruses of Indian origin compared to the Therien strain. The
second study was conducted by Katow et al (86) and used 26 strains of rubella virus.
The majority were obtained from Japan, China and Hong Kong including the vaccine
strains TCRB19 and To-336 from Japan and the BRD2 vaccine strain produced in
1980 by the National Vaccine and Serum Institute in Beijing, China. Three strains
were obtained from the USA and two from the UK. The peR amplification and
sequencing protocol used was developed to determine the sequence of 1483
nucleotides of the El gene. This study found that the interstrain variation of the
nucleotide sequence of the RV genome (0.1% - 10%) was comparable to that found
for other RNA viruses (e.g. 0.5% - 7.2% in measles virus and 0.1%-6.6% in influenza
type C). The study yielded several other points of interest. Firstly, of three Chinese
strains, two - the BRD2 vaccine strain and a strain isolated from an adult from Hong
Kong in the 1980s - showed considerable diversity from the other 24 strains.
Secondly, all strains analysed which were isolated in the 1960s - which included five
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isolates from Japan and all those from the USA and UK - were classified into a single
group which suggests that this genotype may have been involved in a worldwide
epidemic. A further strain isolated from a case of CRS in Hong Kong in 1985 was
closely related to strains isolated from north eastern Japan. Lastly, two strains isolated
from Japan during 1990 were assigned to different positions on a phylogenetic tree
suggesting that at least two RV strainswere co-circulating in Japan during this period.
The third study was conducted by Frey et al (57) and is the largest of the three. It
describes the molecular epidemiology of RV using 63 isolates from North America,
Europe and Asia collected between 1961 and 1997. The study is based on sequence
analysis of the entire El gene, determined using PCR amplification of six fragments
encompassing the whole gene using pairs of internal overlapping primers. The
collection of rubella viruses sequenced included all the strains whose complete El
sequences had been described in previous studies (17, 86). The RV strains were
divided into two genotypes which differed from each other by 8% - 10% in their
nucleotide sequences. Those designated genotype I consisted of the majority of the
virus isolates in the collection and contained strains from Europe, North America and
Japan. The second genotype, genotype II, was represented by three isolates - two from
China and one from India - with the diversity of the two Chinese isolates having been
previously noted by Katow et al (86). El amino acid sequences were observed to
differ by no more than 3% which suggests that RV is not prone to major antigenic
variation within this gene.
The geographical range of isolates used to date to study the molecular epidemiology
of rubella is limited and both genotypes, particularly genotype II, need to be
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investigated further using samples from all continents of the world. Isolates from
South America, Africa and Australia have yet to be sequenced and a minimal number
of isolates from China and India are currently represented. Further studies should
determine the geographic extent of the two genotypes and whether other genotypes
exist.
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HEPATITISB
Historical background
Australia antigen, now referred to as hepatitis B surface antigen (HBsAg), was
discovered by Dr. Baruch Blumberg in 1965 (13, 15). He observed an
immunodiffusion precipitin line between HBsAg in the serum of an Australian
Aborigine and HBsAg antibody present in the serum of a hemophiliac who had
received multiple transfusions. The link to clinical illness was made when a laboratory
technician working with Australia antigen developed acute hepatitis, and rapid
progress in the understanding of hepatitis B virus (HBV) has subsequently been made,
reviewed by Lee, 1997 (94). Infection with HBV results in a broad range of liver
disease ranging from sub-clinical infection to acute or chronic hepatitis, cirrhosis, and
hepatocellular carcinoma and accounts for approximately one million deaths annually
worldwide (94, 115). Early evidence suggesting that the liver damage sustained as a
result of HBV infection is immune mediated as a consequence of the cellular immune
response against viral antigens present in infected hepatocytes has been confirmed
(95) (reviewed in (92, 115». The WHO estimate that the world population is currently
approximately 5000 million and of these, about 2000 million people have serological
markers ofHBV infection (84).
The carrier state
The carrier state is defined as the persistence of HBsAg in the circulation for at least
six months. Itmay be lifelong and is associated with liver damage ranging from minor
changes in the nuclei of hepatocytes to hepatocellular carcinoma. The carrier state
ensures the survival of HBV and is established in approximately 5-10 % of infected
adults (82, 175). The WHO estimate there to be 350 million chronic carriers
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worldwide, of whom approximately 65 million will die as a result of liver disease (85)
(reviewed in (84».
Epidemiology
The distribution of HBV infection varies greatly worldwide. The prevalence is very
high in Southeast Asia, China and sub-Saharan Africa where over half the population
will be infected at some time in their lives and over 8 percent of the general
population are chronic carriers of the virus. In these areas the majority of infection
occurs during childhood, either from an infected mother to her baby (vertical
transmission) or from one child to another (horizontal transmission). In contrast,
North America, Western Europe and Australia (amongst persons of European decent)
are areas of low endemicity where only a minority of people come into contact with
the virus mainly as a result of horizontal transmission between young adults from
sexual activity, injection-drug use, or occupational exposure (reviewed in (84, 94)).
HBV may be present in serum in large quantities, with up to 109 virions per milliliter.
It can also be detected in saliva and semen and there is much evidence to suggest
transmission of HBV occurs by intimate contact and the sexual route (reviewed in
(94)). Therefore, on a global basis, HBV can be regarded as one of the most important
infectious diseases in the world and should be viewed as no less important than any
other vaccine-preventable diseases in view of the number of people affected and
severity ofliver disease (reviewed in (84)).
Biology and virological properties
HBV belongs to a family of closely related DNA viruses called the hepadnaviridae
which includes the woodchuck hepatitis virus, the duck hepatitis B virus and several
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other avian and mammalian viruses. All hepadnaviridae have a similar hepatotropism
and life cycle within their hosts and can be a cause of hepatocellular carcinoma (61,
76).
The genome of HBV is a partially double stranded circular DNA molecule. With a
size of approximately 3200 base pairs it is one of the smallest DNA viruses known.
One strand, almost a complete circle, is termed" minus" , and the other" plus" , which
is shorter and variable in length. The HBV genome has four overlapping open
reading frames encoding the surface (S) and core (C) structural genes and the
replicative polymerase (P) and X gene, which encodes two proteins that act as
transcriptional transactivators. The S and C genes have upstream regions termed preS
andpreC (reviewed in (92, 94».
Electron microscopy of HBV positive serum shows three morphologically distinct
forms of particle. Two forms of particle are characteristically present in excess as
small spheres and tubular structures, both approximately 20 nm in diameter. The third
type of particle, the whole virion, is seen as a spherical double shelled structure, 42
nm in diameter and is referred to as the Dane particle after its discoverer (44, 76). All
three particles have a common antigen on their surface, termed hepatitis B surface
antigen (HBsAg), which is present at a high concentration in the serum of infected
hosts (reviewed in (61, 76, 94».
The Dane particle, which is the infectious virion ofHBV, is comprised of the genome
enclosed by a nucleocapsid, the major structural protein of which is hepatitis B core
antigen (HBcAg). In turn, the nucleocapsid is enclosed by a lipoprotein envelope
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containing the viral surface proteins, including HBsAg. A third protein, the "e"
antigen (HBeAg), is found in soluble form in virus-positive sera and is a peptide
derived from the core antigen (reviewed in (76,94)).
Diagnosis and immunology of BBV
The presence of HBV DNA and antigens or their antibodies can be used as diagnostic
markers to determine the status of HBV infection, both current and past (Table 2).
One indicator of active viral replication is the presence of HBV DNA in serum which
can be detected by hybridisation methods or by sensitive polymerase-chain-reaction
(peR) techniques (76, 94). However, HBsAg is more often used as a marker of
current infection since its presence in the blood, sometimes in large amounts, is often
the first sign of HBV infection and current technology for its detection is cheaper and
simpler than that for HBV DNA. In acute infections HBsAg levels decline and it is
eventually replaced by antibody to HBsAg (anti-HBs) which is assumed to be
produced during the earliest stages of infection but remains undetectable because of
binding to excess HBsAg. Progession to the chronic state is associated with the
persistence ofHBsAg with little change in concentration in the serum (75). Anti-HBs
confers protective immunity and is detectable in patients who have recovered from
HBV infection and in persons immunized with HBV vaccine. However, anti-HBs is
not always long lasting and may become undetectable in patients who have made a
full recovery from infection (76).
In contrast to HBsAg, free HBcAg is rarely seen in HBV infected patients since the
nucleocapsid is surrounded by HBsAg. When HBcAg derived peptides are expressed
on the surface of hepatocytes an immune response is induced which kills infected
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cells. Antibody to HBcAg (anti-HBc) does not confer protective immunity though
anti-HBc IgG is long lasting and can be detected in almost all patients who have been
exposed to HBV so can be used as a marker of previous HBV infection. Anti-HBc is
also present in patients with acute and chronic HBV infection and in acute disease is
predominantly of the IgM immunoglobulin class which remains detectable for six to
eight months and is gradually replaced by IgG. However, the detection of IgM cannot
be used as an entirely reliable marker of acute illness since patients with chronic HBV
may become anti-HBc IgM positive during flares in their disease (76).
The hepatitis B e antigen (HBeAg) serves as a marker of active viral replication and is
present only in persons with circulating serum HBV DNA. In acute hepatitis B,
antibody to HBeAg (anti-HBe) replaces HBeAg during the early stages of
convalesence which signals a reduction in viral replication and a beginning of the
resolution of disease (75, 76, 94).
Table 2. Interpretation of diagnostic markers in patients with hepatitis B virus
infection, modified from Zuckerman et al1995 (198)
HBsAg HBeAg Anti-HBe Antl-HBc Anti-HBs Interpretation
IgM IgG
+ + Incubation period
+ + + + Acute HBV or carrier
+ + + Persistent carrier
+ + +/- + Persistent carrier
+ +/- + + Convalesence
+ + Recovery
+ HBV infection, no
detectable HBsAg
+ Recovery, loss of anti-
HBs
+ Immunization; recovery
with loss of anti-HBc;
repeated exposure but
no infection
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Immunization against HBV
The current goals of HBV immunization are three fold: to prevent clinical disease, to
prevent the development of chronic HBV and to prevent transmission of the virus
(75). These are being met through the expanded programme for immunisation (EPI)
and should result in a reduction in the number of cases of hepatocellular carcinoma.
Hepatitis B vaccines were introduced in the early 1980s and elicit the production of
anti-HBs which confers protective immunity (96). Two types of vaccine have been
widely used. The first is a plasma-derived vaccine (Heptavax B, Merck, Sharpe and
Dohme, 1982) and consists of inactivated HBsAg particles purified from plasma of
chronic carriers of HbsAg (47, 53, 60, 96). This vaccine was not widely accepted by
the medical profession because it is derived directly from human plasma so may
contain other human pathogens and is no longer produced in the USA. These issues
prompted the development and production of a second type of vaccine developed by
recombinant DNA technology (4, 47, 53). Until recently two recombinant vaccines
were marketed. The first, called Recombivax HB, was produced by Merck, Sharpe
and Dohme in 1986 and the second, called Engerix-B, was made by Smithkline
Beecham Pharmaceuticals in 1989. Both are derived from yeast expression vectors
transformed by plasmids bearing the HBsAg gene. They comprise non-glycosylated
HBsAg particles that have been purified, adsorbed onto aluminium hydroxide, and
preserved with thimerosal (53, 60, 96) (Recombivax HB. West Point, Pa.: Merck,
1995 [package insert]; Engerix-B, Philadelphia: SmithKline Beecham
Pharmaceuticals, 1995 [package insert]). They represent the only products of
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recombinant DNA technology so far commercially developed as vaccines against
human viral disease (113).
The efficacy of both the plasma-derived and recombinant vaccines has been
demonstrated by clinical trials using a three dose intramuscular immunization
schedule which results in levels of antibody regarded as protective, defined as anti-
HBs serum levels equivalent or greater than 10 mill/mL (60). Since the introduction
of HBV vaccines several immunization strategies have been adopted by different
countries with varying degrees of success. While vaccination has been highly
effective in decreasing the prevalence of HBV carriers, initial recommendations based
on targeting high risk groups only failed to decrease the burden of hepatitis B disease.
The current policy is one of universal immunization of infants in countries where
there is a recognised risk of infection with HBV (14, 60). In the UK the prevalence of
HBsAg is estimated to be less than 1% (72). However, the WHO has recommended
that all countries adopt HBV vaccination into their respective national immunisation
programmes (84). Therefore in the UK immunisation is recommended for people who
are at risk ofHBV infection which include the following groups (164):
• Babies born to mothers who are chronic carriers of HBV or to mothers who have
had acute HBV during pregnancy
• Parenteral drug misusers
• Individuals who change sexual partners frequently
• Close family contacts of a case or carrier
• Families adopting children from countries with a high prevalence ofHBV
• Haemophiliacs
• Patients with chronic renal failure
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• Health care workers including students and trainees
• Staff and residents of residential accommodation for those with severe learning
disabilities (mental handicap)
• Other occupational risk groups (e.g. morticians, enbalmers)
• Inmates of custodial institutions
• Those travelling to areas of high prevalence
From April 2000, health authorities in the UK are to ensure that all pregnant women
are offered screening for HBV. This will enable the immunisation of babies born to
infected mothers and reduce the risk of perinatal transmission (7, 52).
HBV vaccine is expensive and this has been a major problem in acheiving widespread
use and a universal vaccination policy. This has made prevaccination screening an
important issue which relates directly to the cost effective use of the vaccine (60).
Serological assays for HBV
Sensitive and specific laboratory tests such as enzyme linked immunosorbent assay
(ELISA) and radioimmunoassay (RIA) are now available for the detection of specific
serological markers of infection with HBV and to assess the immune status of the
patient. Many assays are licensed and the most commonly used now are ELISA rather
than RIA in format.
Assays for HBsAg and anti-HBs : Assays are available which enable HBsAg to be
detected in the 0.25 to 0.5 ng/ml, range and anti-HBs down to a level of 1mIU/mL.
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The types of assay available for detecting HBsAg include RIA, ELISA and reverse
passive hemagglutination (RPHA). Both RIA and ELISA work on a "sandwich"
principle with an anti-HBs coated solid phase used to capture HBsAg which is then
detected by an anti-HBs probe labelled with either 1251 (RIA) or horse-radish
peroxidase (ELISA). A range of commercially available ELISAs are widely used to
detect HBsAg. RPHA uses red blood cells coated with highly purified anti-HBs so the
presence ofHBsAg in the test serum will cause the red blood cells to agglutinate
For detecting anti-HBs, RIAs and ELISAs are also commonly used and are
commercially available, again using the "sandwich" principle but with a HBsAg
coated solid phase (76).
Assays for anti-HBc : assays detecting anti-HBc in both ELISA and RIA format are
available and usually based upon a competitive or inhibition principle. Bound to the
solid phase is HBcAg with which a labelled antibody and anti-HBc, if present in the
serum sample, compete to bind. Hence the higher the concentration of anti-HBc in the
sample, the lower the signal measured. Three types of assay measuring anti-HBc have
been described: those that detect total anti-HBc antibody and those which detect anti-
HBc IgG or IgM. A commercially available competitive radioimmunoassay (CORAB;
Abbott Laboratories, North Chicago, Ill.) is sensitive and specific for the detection of
total anti-HBc and the Murex ICE ELISA is an example of a commercial assay which
detects total anti-HBc using a "sandwich" principle. Cohen et al (28) described a
competitive RIA for detecting anti-HBc IgG and a commercially available ELISA, the
Hepanostika anti-HBc Uni-Form kit produced by ORGANON Teknika, detects anti-
HBc antibody using a similar competitive principle. Anti-HBc IgM can be detected
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using a "sandwich" principle as described by Gerlich and Luer (65) and Angarano et
al (3) describe a modification of the CORAB assay for the determination of anti-HBc
IgM. However, capture assays for detecting anti-HBc IgM (76) have become more
widely used for the diagnosis of acute HBV infection.
Assays for HBeAg and anti-HBe : Commercial RIAs for detecting HBeAg and anti-
HBe were first produced by Abbott Laboratories in the 1980's (122) but have been
largely replaced by a range of commercial ELlS As detecting either or both HBeAg
and anti-HBe. To detect HBeAg in a serum sample a "sandwich" procedure may be
used. Test serum is added to the anti-HBe solid phase followed by labelled anti-HBe,
the binding of which is then measured. Anti-HBe assays use a neutralization principle
where the test sample is mixed with an equal volume of HBeAg of precalibrated
potency, which is neutralized by the presence of anti-HBe in the test sample. A
"sandwich" method is then used to determine the presence (= anti-HBe negative) or
absence (= anti-HBe positive) ofHBeAg in the mixture.
38
SALIVA AS A DIAGNOSTIC FLUID
Most body fluids contain antibody but at a generally much lower concentration than is
found in blood. This has limited their use as diagnostic specimens for viral antibody
tests. It is well known that secretory IgA (sIgA) antibody is found in saliva but it is
now recognised that other classes of immunoglobulin are able to gain entry into the
oral cavity and are present in saliva at concentrations which, whilst being lower, do
reflect those found in plasma (119, 120, 139).
Saliva is a mixture of several components including immunoglobulins (Table 3).
Salivary antibodies come from two sources. The majority of antibody of diagnostic
importance is present as a transudate from the capillary bed beneath the margin that
separates the teeth and gum known as the gingival crevice. The antibody content of
this crevicular fluid closely reflects the immunoglobulin class and specificities of
antibody found in plasma. It contains both IgG and IgM with the same specificities as
those antibodies already present in plasma (120, 127).
Table 3. The mean concentrations (mgIL) of immunoglobulin components of
saliva (120).
Specimen IgG IgM IgA
Plasma 14730 1280 2860
Parotid saliva 0.36 0.43 39.5
Crevicular Fluid 3500 250 1110
Whole saliva 14.4 2.1 19.4
The development of sensitive" antibody capture" assays enabled saliva to be used as
the basis for successful and reliable diagnosic antibody tests. Antibody capture assays
were first described by Flehmig et al (54) and Duenneyer et al (49) in the late 1970s
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and are now extensively used in the diagnosis of virus infection. Capture formats are
based upon the principle that a particular class of human immunoglobulin (IgO, IgM
or IgA) is "captured" or bound by an antiserum to that immunogloblin previously
fixed to a solid phase such as a polystyrene bead or the well of a microtitre plate. This
solid phase can then be probed for the desired antibody specificity by the addition of a
specific viral antigen, followed by the addition of a detector system. This commonly
comprises a mouse monoclonal antibody, specific for the virus antigen under test, to
which a 1251 labelled (RIA) or enzyme (e.g. horse raddish peroxidase) conjugated
antibody (ELISA) is then directed. Signals generated using an RIA format are
measured in a gamma counter. In the case of ELISA they are measured
colourimetrically by a plate reader after the addition of a chromogenic substrate, such
as tetra methyl benzidine (TMB).
When considering antibody capture assays it is important to recognise that the size of
signal generated reflects the proportion of the total immunoglobulin of the class being
captured that is specific for the antigen under test rather than the concentration of the
specific antibody. Since saliva is composed partly of plasma transudate, the
proportion of specific to total immunoglobulin will be similar in both serum and
saliva; signals generated by such salivary assays can thus be considered independent
of immunoglobulin concentration and therefore representative of serum (120, 127,
139). Moreover, in antibody capture assays, very low concentrations of IgO or IgM
antibody are required to saturate the solid phase and they can therefore be successfully
used with body fluids other than serum, such as saliva or even urine (32, 119, 139).
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For large epidemiological studies collecting blood can be difficult, particularly for
those populations outside the clinical environment and those disliking the invasive
nature of venepuncture (119, 128). Saliva collection represents a non-invasive
alternative to serum collection with clear advantages (Table 4) over venepuncture.
Saliva collection is convenient, cheap and does not require the participation of trained
personnel. It is also painless and less hazardous than venepuncture thus giving better
access to large populations, hard to reach groups and children (119, 128, 139, 186).
Table 4. The potential advantages of saliva over serum specimens (139)
Advantage Reason
More Acceptable
More Convenient
More Versatile
Noninvasive; painless; fewer refusals
self-collected; cheap; rapid; simple; no sterile precautions
reaches difficult populations e.g. IVDUs, isolated rural
communities
The means by which saliva specimens are collected is an important practical
consideration if saliva is to be used as a reliable alternative to serum collection for
antibody testing. Since crevicular fluid contains most of the diagnostically important
plasma-derived IgG and IgM antibodies it seems logical that crevicular fluid is well
represented in the sample collected and is diluted as little as possible by the presence
of other components of oral fluid during the collection process (139).
Collection devices
Saliva specimens are easily collected and several commercially available devices have
been developed specifically for this purpose (Fig. 2) (119, 139). The devices used for
this study include the Oracol (previously known as the Foam Swab) (19) (Malvern
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Medical Developments, Worcester, UK), Omnisal (Saliva Diagnostics Systems Ltd,
Singapore) and OraSure (Epitope Inc, Beaverton, UK) (Table 5) and are shown in Fig.
2. They all collect saliva using absorbent material placed in the mouth from which
oral fluid can be eluted at a later date and have been demonstrated to yield samples
that give a better quality of result compared to collecting by simply dribbling into a
specimen container (124). The Foam swab and OraSure differ from the Omnisal
device in that they are designed to be rubbed along the gums and so directly target the
crevicular fluid. Samples collected by these absorbtive devices are correctly termed
oral fluid (185). They should be distinguished from saliva secreted from glands
discharging into the oral cavity which requires different devices for collection. For the
remainder of this thesis, therefore, the term oral fluid is used.
Table 5. A comparison of the features of three saliva coUection devices (121)
Feature Oracol Omnisal OraSure
stability (room temperature) 5 days > 5 days 21 days
lab manipulation add buffer, compress centrifuge
recover eluate filters
Total IgG quantification essential desirable essential
unit cost* £0.50 £1.80 £2.50
*current costs as of March, 2000
Figure 2: Saliva collection devices
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(From top to bottom: OraSure, Omni-SAL and Oracol)
Oral fluid IgG and IgM capture assays have been developed against a range of viral
antigens and lead to the realisation that oral fluid testing could have broad
applications in viral diagnosis, surveillance, outbreak investigation and vaccine
monitoring (64, 139). Initially many of these tests used radioimmunoassay technology
to provide the desired level of sensitivity and specificity but several, particularly
assays that detect IgG specific for human immunodeficiency virus (HIV) surveillance,
have now become available as commercial ELISA tests (74,82, 139).
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Anti-HIV assays are amongst the most widely used oral fluid assays and their use has
been well described and evaluated (31, 74, 82, 101, 105, 140, 178). Other oral fluid
assays that detect virus specific antibodies include IgG and IgM specific antibody
capture radioimmunoassays for measles, mumps and rubella (144), parvovirus B19
(40, 157), hepatitis A and B (141), and an IgG specific antibody capture
radioimmunoassay for Epstein Barr virus (EBV) (39, 186).
Assays described using formats other than antibody capture include an indirect ELISA
to detect oral fluid IgG to cytomegalovirus (CMV) (187), an ultrasensitive EIA for
detecting hepatitis A virus-specific IgG (131) and a commercial EIA for total antibody
to hepatitis C virus (HCV), adapted for use with oral fluid samples (180). Commercial
EIA assays designed for use with serum have also been adapted for use with oral fluid
samples by modifcation of the protocol for the detection of HCV antibodies (10, 20)
and measles, mumps and rubella IgG (179). In addition to the detection of virus
specific antibodies in oral fluid, commercially available EIA assays designed for use
with serum have also been adapted for use with oral fluid for the detection of specific
IgG antibody against the human stomach bacterial pathogen Helicobacter pylori (142,
171).
Oral fluid assays for rubella and HBc specific IgG.
Assays have been described which are designed to detetct rubella specific IgG and
HBc specific IgG in oral fluids (139-141). Perry et al (144) described an IgG antibody
capture radioimmunoassay (GACRIA) for rubella specific IgG which has
subsequently been used for epidemiological surveys (51, 124). A prototype rubella
specific IgG antibody capture ELISA (GACELISA) was described by Parry et al
44
(140) but required further refinement and evaluation to supersede the
radioimmunoassay. Parry et al (140) also described a radioimmunoassay for anti-HBc
IgG in saliva samples which was adapted to an ELISA format though was found to be
less sensitive when testing weakly seropositive subjects. Murex have since developed
an EIA (ICE Hbc Detection Pack) which detects both IgG and IgM to the core protein
of HBV. This assay has been adapted for use with oral fluid samples and has
subsequently replaced the IgG capture radioimmunoassay for HBV described by Parry
et al (141).
The requirement for simpler oral fluid assays
Population-based surveys of antibodies to both viral and bacterial antibodies have
important and well established uses in immunity surveillance and epidemiological
research, especially when assessing the impact of vaccination and identifying target
groups for vaccination. Where community-based studies of antibody prevalence are
required the collection of oral fluid samples has clear practical advantages providing
suitable assays are available (150, 151). Currently many of the assays available for
testing oral fluids are only available in a radioimmunoassay format and, whilst they
are sensitive and well characterised, they do have several disadvantages.
Radioimmunoassay techniques are often time consuming, technically demanding,
expensive, require special equipment (e.g. gamma counter), are not easily transferable
between laboratories and produce radioactive waste. Therefore there is a clear need
for the development of simple, sensitive and robust ELISA assays which produce less
hazardous waste products and are suitable for field use and in basic laboratories,
especially in developing countries. Here the requirement for identification of target
groups for vaccination is an essential element of disease control programmes (42).
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MATHEMATICAL MODELLING
The theoretical basis by which communicable diseases are transmitted has been well
understood since the beginning of the 20th century and has been described using
mathematical models. The mathematical modelling of the transmission of infectious
diseases aims to describe the various stages of a disease through which an individual
may pass, from susceptibility through to immunity, and the associated factors that
may determine the transmission from an infected to a susceptible individual. Perhaps
the greatest challenge faced by the mathematical modeller is trying to define and
represent those factors which can be used to precisley define a contact between a
susceptible and infectious individual and is especially difficult in the case of
respiratory transmitted diseases (112, 160).
The accuracy of mathematical models is able to be tested using epidemiological data
obtained from community based studies. Mathematical models can be used to help
design vaccination programmes and predict the impact they are likely to have.
However, it is only with the advances made in computer science over the last two
decades that sufficient computing power has been available to implement simulations
sufficiently large and detailed to make practical predictions possible. Developments
made in the use of oral fluids as an alternative to serum sampling are of great interest
to mathematical modelers since they should greatly facilitate the ease and accuracy
with which these models can be tested in order to gain a true insight into the effect
present or future vaccination programmes may have.
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OBJECTIVES OF THE STUDY
1. Technical development of oral fluid antibody assays
1.1. Evaluation of oral fluid collection devices
1.2. Development of ELISA for detecting rubella IgG in oral fluid
1.3. Development of ELISA for the detection ofanti-HBc in oral fluid
1.4. The use of these ELISA assays in field studies
2. Rubella molecular epidemiology
2.1. The development and optimisation of a rubella PCR suitable for both diagnosis
and molecular epidemiology
2.2. The use ofPCR to investigate the phylogeny of rubella
2.3. The extent to which oral fluid may be used as a clinical specimen for the
detection of virus genome
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CHAPTERl
EVALUATION OF ORAL FLUID
COLLECTION DEVICES
OBJECTIVES
There were three main objectives for this part ofthe study:
• to demonstrate the utility of oral fluid collection in epidemiological studies.
• to compare three oral fluid collection devices (Oracol, OraSure and Omnisal) in
terms of the quality of oral fluid collected.
• to determine the collection device most suitable for viral specific IgG antibody
screenmg.
Introduction
The collection devices were evaluated in two contrasting populations. The first was
from the rural district of Butajira in south western Ethiopia (Fig. 3). This region is
approximately 130 km south of Addis Ababa. The population is approximately
250,000 and consists predominantly of subsistence farmers. There is currently no
HBV or rubella immunization and EPI vaccination coverage for measles varies
considerably and is related to distance from the town of Butajira. This study involved
subjects aged <5 years to 2:50 years.
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Figure 3: A map showing the Butajira region of Ethiopia
-____,,_ Addis Ababa
Butajira
The second population were children aged 3.5 - 5 years living in north Hertfordshire,
UK. All had recently received MMR vaccine as part of a "pre-school boost" (PSB)
study to assess the response to a second dose. These are therefore two populations in
which the epidemiological study of certain vaccine preventable virus infections was
important and represented markedly different epidemiological and vaccination
contexts.
The first study population, covering a wide age spectrum, is from a rural region in a
developing country where vaccination coverage is poor and limited to a few infectious
diseases. In order to extend vaccination coverage for other vaccine preventable
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infections in this population, it is important that their epidemiology is fully
understood. If oral fluid samples are to be usedfor this purpose, it is important that the
optimal collection device is chosen. This study enabled a household-based oral fluid
collection system to be established in the Butajira region. A major reason in the
choice of this region for this study is that it has been monitored continuously by the
Department of Community Health, Faculty of Medicine, University of Addis Ababa
as part of the long-term Butajira Rural Health Project (BRHP) since 1986 (128, 168).
To assess the consistency of samples collected by different devices a representative
number of oral fluid samples collected by both the OraSure and Oracol devices were
obtained.
The second population were young children from the UK where an extensive
vaccination schedule is in place and oral fluid sampling has been used for the
surveillance of measles, mumps and rubella (MMR) since 1994. Whilst there are a
variety of methods now available for collecting oral fluid, there have been few studies
investigating which is optimal for community use and none exclusively involving
young children. This has permitted the effect of the childhood MMR vaccination
programme to be monitored. MMR vaccine was introduced in 1988 as a single dose at
12-15months, supplemented by the MR campaign in 5 to 15 year old children in 1994
and more recently, in 1998, was augmented by a two dose schedule, with a second
dose being offered to pre-school children aged 3.5 to 4 years (62, 63, 111). Itmay be
that the optimal device for each of the populations used in this study are not
necessarily the same.
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The part of the study involving children from the UK. was performed by collecting
oral fluid samples using all three devices plus a matching serum from each individual.
Total IgG and IgM antibody concentrations of the oral fluid collected by each device
were measured and the rubella specific IgG concentration of oral fluid compared to
that of the matching serum sample as measured by a sensitive commercially available
ELISA kit. Serum and matching oral fluid samples from the children involved in the
PSB study were also screened for parvovirus B 19 specific IgG. All parvovirus B 19
serology was carried out by the Immunisation and Diagnosis Unit, ERNVL, CPHL
and the results made available by Dr BJ Cohen. As a result of vaccination a high
proportion of the population of children in this study were expected to have antibody
to rubella (133). By contrast, the antibody prevalence to parvovirus B 19 is low
amongst this age group (27) enabling an assessment of the specificity of oral fluid
testing to be made. In investigating acceptability of each collection device to study
participants, ease of administration and comfort were assessed by questionnaire.
Results of the questionnaire were analysed by Dr Mary Ramsay of the Immunisation
Division, PHLS Communicable Disease Surveillance Centre, London.
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MATERIALS AND METHODS
Evaluation of oral fluid collection devices in rural Ethiopia
Oral fluid collection and extraction.
Oral fluid was collected and extracted from sterile foam swabs ('Oracol', Malvern
Medical Developments, Worcester, UK) as previously described (19, 186) and from
the OraSure (Epitope Inc, Beaverton, UK) and Omnisal (Oral fluid Diagnostics
Systems Ltd, Singapore) devices according to the manufacturers instructions. All
samples were stored at -20°Cuntil required for testing.
The Oracol device consists of an expanded polystyrene foam swab fixed to a plastic
stick (Fig.2). It was used to collect oral fluid by rubbing the swab along the sides of
the gums, both inside and out, for one minute which was then placed into an
accompanying tube. To extract the oral fluid 1 ml of transport medium (Phosphate
Buffered Saline [PBS] containing 10% fetal calf serum [FCS], 0.2% Tween 20,0.5%
Gentamicin 50mg/ml stock, 0.2% Fungizone 250ug/ml stock) was added to the tube
containing the swab and thoroughly mixed. The swab was then inverted, returned to
the tube, and centifuged at 2000rpm for 5 min. The swab was then removed and
discarded and the fluid at the bottom of the tube pipetted into a storage vial.
The OraSure device was used to collect oral fluid by gently moving the absorbent pad
along the gum twice and then holding it stationary against the lower gum on one side
for 2 minutes. To extract oral fluid the small plastic tip at the base of the OraSure tube
was broken off and discarded and the remainder of the tube containing the used
absorbent pad centrifuged at 2000rpm for 5 min. The oral fluid was then pipetted and
stored.
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The Omnisal was used to collect oral fluid by placing and keeping the absorbent swab
under the tongue until the stem indicator of the device turned blue. The flat lint swab
was then detached and placed in the accompanying tube into which an Omnisal filter
plunger was also inserted and depressed to extract the oral fluid which was pipetted
and stored. A summary of the method of use for each of the three collection devices is
shown in Table 6.
Table 6. Methods for oral fluid collection by each device
Device Description of use Cost
OraSure Move pad gently along gum twice. Place against lower gum on 1 side
and keep stationary for 2 min
£2.50
Omni-SAL Place pad under tongue and keep still until indicator of device turns blue £1.80
Oracol Rub sponge firmly along the base of the gums (inside and out) of the
upper and lower jaw, for 1 min, using an action similar to tooth brushing
£0.50
Serum collection.
Venous blood was collected in the home from each participating individual by
medical personnel from the Butajira Health Clinic using the Vacutainer system (Sml
Vacutainers and Green or Black needles, Becton Dickinson). Blood samples were
allowed to clot for 2-3 hours at room temperature and serum then transferred into a
2ml screw-cap storage vial using a plastic pasteur pipette, and stored at -20°C.
Samples collected
Samples were obtained from 58 participants in 14 households from the village of
Dirama, 2km from Butajira town. A serum sample, with matching oral fluid samples
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of sufficient volume for all laboratory tests obtained using each of the three oral fluid
collection devices, was provided by 38 individuals. A total of 13/38 individuals and
24/38 individuals provided duplicate oral fluid samples collected by the Oracol and
OraSure devices. Individuals were asked to provide an oral fluid sample using a
different device on each of three consecutive days in which collection took place, at
approximately the same time during each day. The order of collection was randomised
for each household. Blood was collected on the third day of the collection period
(128).
Analysis of total antibody concentration.
Total IgG concentration (mgIL) in oral fluid samples was measured by ELISA as
described by Connell et al (32). The method is detailed in Appendix 1.1 (pp. 80-82).
This method was adapted to measure the total IgM concentration (mgIL) in oral fluid
(Appendix 1.1,pp. 80-82).
Measurement of rubella specific IgG antibody.
The measurement of rubella specific IgG in oral fluid samples was carried out by
radioimmunoassay as described by Perry et al (144) and is described in detail in
Appendix 1.2 (pp. 83-84).
The concentration of rubella specific IgG in matching serum samples was measured
using a commercial ELISA kit (Behring Enzygnost, Behringwerke AG, Marburg,
Germany) which is described in detail in Appendix 1.3 (pp. 85-87).
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Statistical Methods.
To assess the quality of oral fluid collected by each make of device three methods
were used.
1. Geometric mean (GM). Mean concentrations of total IgG and total IgM, with
95% confidence intervals, were calculated using the geometric mean [log., (mgIL)]
(5).
2. Spearman's rank correlation (r), The degree of association between the rubella
specific IgG concentration in serum and matching oral fluid was calculated, with
95% confidence intervals, for each of the three collection devices using
Spearman's rank correlation (5).
3. Single factor analysis of varience (ANOVA). The hypothesis that the mean
logarithm of total IgG and IgM antibody concentrations for oral fluid samples
collected by each device are the samewas tested using single factor ANOVA (5).
Evaluation of oral fluid collection devices amongst children aged 3.5 - 5 years in
north Hertfordshire, UK.
Survey Details
One hundred and forty three children aged 3.5-5 years living in north Hertfordshire,
UK, participated. All had recently received MMR vaccine as part of a pre-school
boost (PSB) study primarily designed to assess the response to DTaP vaccine also
given at this age. The children were randomised to use one of the three types of oral
fluid collection devices being assessed, namely Orasure, Omni-SAL and DracoI
(Table 1). A parent used the device to obtain an oral fluid sample from the child, and
completed a short questionnaire recording information on ease of use and willingness
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to use the device again. Parents were asked to respond using a Likert scale which
scored the acceptability of use of each device on a scale of 1 - 5. General comments
regarding the use of each of the devices were also recorded.
Sample collection and processing
Instructions for oral fluid collection were supplied on the packaging by the
manufacturer (Table 6). After collection of oral fluid, devices were placed into the
appropriate transport container and labelled with a unique identification number.
Collected samples were then transported by post to the Enteric and Respiratory Virus
Laboratory (ERVL), CPHL, where the oral fluid was extracted according to the
manufacturers' instruction for OraSure and Omni-SAL and as previously described
for the Oracol (19) and stored in labelled screw capped microtubes at -20°C until
required for testing.
Venous blood samples were collected by nursing personnel using a Vacutainer
System. Bloods were allowed to clot and serum aspirated into labelled screw capped
microtubes and stored at -20°Cuntil required for testing.
Laboratory Methods
Serum samples were screened for rubella specific IgG by ELISA (Rubella IgG
Enzygnost, Behring Diagnostics, Behringwerke AG, Marburg, Germany) according to
the manufacturer's instructions as previously described, with the results expressed as
International Units (IU)/ml (Appendix 1.3). Serum samples were screened for
parvovirus B19 specific IgG using ELISA (Dako, Ely, UK) and a detailed method is
described in Appendix 1.5 (pp. 99-92)
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Oral fluid samples were screened for rubella specific IgG by IgG capture
radioimmunoassay as previously described with results expressed as the test sample to
negative (TIN) ratio (144). Oral fluid samples were screened for parvovirus B19
specific IgG by IgG antibody capture radioimmunoassay (GACRIA) as described by
Rice and Cohen (1996) (157). A detailed method is described in Appendix 1.4 (pp.
87-88).
The total IgG and total IgM content of oral fluid samples was measured using an
indirect ELISA assay as previously described (32) (Appendix 1.1).
Statistical Methods.
The quality of oral fluid collected by each make of device and acceptability of each to
participants was evaluated by four methods.
1. Geometric mean (GM). GM concentrations of total IgG and total IgM, with 95%
confidence intervals, were calculated using the geometric mean [log., (mgIL)] (5).
2. Spearman's rank correlation (r), The degree of association between the rubella
specific IgG result in serum and matching oral fluid for each of the three collection
devices was calculated, with 95% confidence intervals, using spearman's rank
correlation (5).
3. Chi-squared Fisher's exact test. In assessing the acceptability of each device the
proportion of parents responding to each question was compared using Chi-squared
Fisher's exact test as appropriate (5).
4. Single factor analysis of varience (ANOV A). The hypothesis that the mean
logarithm total IgG and IgM antibody concentrations for oral fluid samples
collected by each device are the same was tested using single factor ANOVA (5).
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RESULTS
Evaluation of oral fluid collection devices in rural Ethiopia
A matching serum and oral fluid sample of sufficient volume for all required
laboratory testing using each of the three collection devices was provided by 38 of
the 58 persons who participated in the study. Of these, 13 persons provided duplicate
oral fluid samples collected using the Oracol and 24 persons provided duplicate oral
fluid samples collected using the OraSure device. A total of 34/38 (89.5%) had IgG
antibody to rubella by serum ELISA.
Quality of sample
The total IgG and IgM concentrations of the oral fluid samples provided by each of
the three collection devices is compared in Table 7.
Table 7. A comparison of immunoglobulins in oral fluid collected by each device
(Ethiopian population)
Number
OraSure Omni-SAL Oraeol
38 38 38
22.65 24.71 41.23
(18.00 - 28.51) (18.04 - 33.86) (27.36 - 62.12)
1.39 2.52 3.12
(1.039 - 1.867) (1.76 - 3.61) (2.41 - 4.02)
0.434 0.604 0.565
(0.13 - 0.71) (0.31 - 0.83) (0.30 - 0.79)
Total IgG (mgIL):
Geometric Mean
(95% Cl)
Total IgM (mgIL):
Geometric Mean
(95% Cl)
Rank correlation (rJ:
rubella specific IgG -
serum vs oral fluid
(95% Cl)
Rubella specific IgG
results in paired
serum and oral fluid
samples:
overall agreement 28/38 (74%) 29/38 (76%) 29/38 (76%)
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The Oracol device provided oral fluid samples containing the highest geometric mean
(GM) concentrations of both total IgG and IgM, followed by the Omni-SAL, with the
OraSure device yielding oral fluid samples with the lowest GM total IgG and IgM
concentrations. Single factor ANOV A showed the difference between the three
collection devices to be significant for the GM concentration of total IgG (p = 0.026)
and total IgM (p = 0.001) obtained for each.
A comparison of the rubella specific IgG result in serum determined by ELISA with
that in oral fluid collected by each device as determined by GACRIA is shown in
Table 7. There is little difference between each device using rank correlation, though
the Omni-SAL and Oracol devices provided marginally improved rank correlation
with serum antibody levels over OraSure results. This is supported by the scatter
graphs shown in Fig. 4 which compare the rubella specific IgG results in matching
serum and oral fluid samples for each of the collection devices.
An assessment of the performance of oral fluid samples collected by each of the
devices was also made by calculating the agreement between results by comparing
those of the GACRIA to a commercial ELISA (Behring) which was used to screen
corresponding serum samples for rubella specific IgG (Table 7). The agreement was
very similar for each of the three devices, being 74%, 76% and 76% for the OraSure,
Omni-SAL and Oracol respectively. It was not appropriate to estimate sensitivity and
specificity values relative to the serum ELISA due to the small numbers of samples
available for each of the collection devices. However, a 2x2 table showing how oral
fluid results compared to matching serum results is shown in Table 8.
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Table 8. Rubella specific IgG results in sera and corresponding oral fluids for
each of the oral fluid collection devices used by the rural Ethiopian population.
ORAL FLUID result (GACRIA)
POS NEG
OraSure POS
NEG
Omni-SAL POS
NEG
Oracol POS
NEG
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SERUM result (Behrmg)
24 0
10 4
26 1
8 3
2S 0
9 4
Fig. 4 A comparison of rubella specific IgG results in matching serum and oral
fluid samples for each collection device (Ethiopian population) [broken lines
represent assay cut off values]
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Comparison of duplicate oral fluid samples collected by Oracol and Orasure
Total IgG and IgM concentration and rubella specific IgG concentration in duplicate
oral fluid samples collected using the Oracol and Orasure devices were compared
using rank correlation (Table 9).
Table 9. A comparison of duplicate oral fluid samples using rank correlation.
Category Oracol (9S%CI) OraSure (9S%CI)
[n = 13] [0 = 24]
TotalIgG r = 0.907 (0.77 - 0.98) r=0.471 (0.15 -0.79)
TotalIgM r = 0.483 (-0.16 - 0.89) r = 0.701 (0.38 - 0.89)
Rubella specific IgG r = 0.940 (0.84 - 0.99) r = 0.580 (0.16 - 0.88)
These data show that for total IgG concentration and rubella specific IgG
concentration, correlation of results from duplicate samples of oral fluid collected by
Oracol were considerably higher than for duplicate samples collected by the OraSure
device. The correlation between duplicate samples for total IgM antibody was higher
for the OraSure device than the Oracol, though the 95% confidence intervals were
wide in all cases.
Acceptability of oral fluid collection devices
The acceptability to participants of each oral fluid collection device was assessed by
Dr D J Nokes, Department of Biological Sciences, University of Warwick (128).
Briefly, all participants found each make of device simple to use. The results are
summarised in Table 10.
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Table 10. Acceptability of oral fluid collection devices to participants from rural
Ethiopia*
Comments OraSure Omni-SAL Oracol
Uncomfortable to use 4122 (18%) 11143 (26%) 3/41 (7%)
Disliked taste 16/28 (57%) 2/28 (7%) 2/28 (7%)
(Bitter/salty/hot/dusty)
No. children <10 years 3/9 (33%) 5/9 (56%) 3/12 (25%)
who chewed device
* Includes all oral fluid samples collected regardless of whether a matching serum
was also obtained.
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Evaluation of oral fluid collection devices amongst 3.5 - 5 yr old children living in
north Hertfordshire
A matching serum and oral fluid sample of sufficient volume for all required
laboratory testing was provided and the type of oral fluid collection device used
recorded for 126 of the 143 children in this study. By serum ELISA 126/126 (100%)
had rubella IgG and l3/126 (9.7%) had parvovirus B19 IgG.
Quality of sample
The total IgG and IgM concentrations of the oral fluid samples provided by each of
the three collection devices is summarised in Table 11.
The Oracol device provided oral fluid samples containing the highest geometric mean
(GM) concentrations of both total IgG and IgM, followed by the OraSure, with the
Omni-SAL device yielding oral fluid samples with the lowest GM total IgG and IgM
concentrations. Single factor ANOV A showed the difference between the three
collection devices to be significant for the GM concentration of total IgG (p < 0.0001)
and total IgM (p = 0.03) obtained for each.
A comparison of the rubella specific IgG result in serum determined by ELISA with
that in oral fluid for each collection device as determined by GACRIA is shown in
Table 11. Rubella specific IgG TIN values in oral fluid and IV/ml in serum correlated
most closely when oral fluids were collected by Oracol, followed by Omni-SAL
samples with the poorest correlation obtained with oral fluids collected by OraSure.
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Table 11. An assessment of the oral fluid quality collected by three collection
devices
OraSure Omni-SAL Oracol
Number 45 38 42
Total IgG (mg/L):
Geometric Mean 4.40 1.99 6.08
(95%CI) (3.56 - 5.43) (1.60 - 2.47) (4.69 - 7.88)
Total IgM (mg/L):
Geometric Mean 0.79 0.90 1.39
(95%CI) (0.61 - 1.02) (0.62 - 1.32) (1.01 - 1.90)
Rank correlation (r J:
rubella specific IgG - 0.454 0.647 0.742
serum vs oral fluid (0.22 - 0.66) (0.40 - 0.82) (0.61 - 0.85)
(95% Cl)
Rubella specific IgG
results in paired
serum and oral fluid
samples:
Overall agreement 44/45 (98%) 36/39 (92%) 41142 (98%)
Mean ratio of rubella
specific IgG result in
serum (Behring
ELISA, IV/mI) to that 2.9 5.8 3.7
in matching oral fluid (2.3 - 3.6) (4.4 - 7.6) (3.1 - 4.4)
(GACRIA, TIN)
(95% Cl)
B19 specific IgG
results in paired
serum and oral fluid
samples:
Overall agreement 41145 (91%) 38/38 (100%) 41142 (98%)
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The scatter graphs shown in Fig. 5 show a comparison of rubella specific IgG results
in matching serum and oral fluid samples for each of the collection devices. These
suggest that there is little to discriminate between the three devices when comparing
the rubella specific IgG in oral fluid samples to that in serum. The mean ratio of
rubella specific IgG concentration in sera (IU/ml) to that of matching oral fluids (TIN)
collected by each make of device was highest for those samples collected by Omni-
SAL (Table 11). This suggests that of oral fluid samples collected by each of the three
devices, the rubella specific IgG result (TIN) measured in those collected by Omni-
SAL compares least favourably to that measured in the matching serum by ELISA
(IU/ml).
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Fig. 5 A comparison of rubella specific IgG results in matching serum and oral
fluid samples for each collection device (children, north Herts, UK) [broken lines
represent assay cut off values]
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An assessment of the performance of oral fluid samples in virus specific antibody
assays was made by calculating the agreement between results by comparing those of
the GACRIA to a commercial ELISA which was used to screen corresponding serum
samples. A similar high agreement (>90%) was seen for each of the three devices for
both rubella specific IgG and parvovirus B19 results when the oral fluid and serum
results were compared (Table 11). Since 100% and 9.7% of serum samples were
demonstrated to contain rubella specific IgG and parvovirus B19 specific IgG
respectively this suggests that the sensitivity and specificity was high for each of the
three devices. However, it was not appropriate to estimate actual sensitivity and
specificity values relative to serum ELISA due to the small numbers of samples
available for each of the collection devices. A 2x2 table showing how oral fluid
results compared to matching serum results is shown in Table 12.
Table 12. Rubella and parvovirus B19 specific IgG results for sera and
corresponding oral fluids for each of the oral fluid collection devices used by the
population of children from north Hertfordshire.
SPECIFIC leG ORAL FLUID result (GACRIA)
POS NEG
SERUM result (ELISA}
OraSure
Rubella Omni-SAL
POS
NEG
POS
NEG
POS
NEG
Oracol
44 0
1 0
36 0
2 0
41 0
1 0
OraSure POS 0 37
NEG 4 4
Parvovirus B19 Omni-SAL POS 0 34
NEG 4 0
Oracol POS 0 37
NEG 4 1
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Acceptability of oral fluid collection devices.
The proportion of parents answering that they found the oral fluid collection device
either quite easy or very easy to use was 45/47 (96%) for both the Oracol and the
OraSure, higher than for the Omni-SAL (20/37 [54%], p<O.OOI). The proportion who
would probably or definitely not take another" saliva" test was higher for the Omni-
SAL (6/37 [16%]) than for the Oracol (0/47 [0%], p = 0.006) and the OraSure (2/47
[4%], p=0.07). These results are summarised in Table 13.
Table 13. Acceptability of oral fluid collection devices to children from north
Hertfordshire, UK.
Comments OraSure Omni-SAL Oracol
Quite/very easy to
use
45/47 (96%) 20/37 (54%) 45/47 (96%)
Probably/definitely
not take another
"saliva" test
2/47 (4%) 6/37 (16%) 0/47 (0%)
Minor comments were offered in relation to all devices, mainly about the size and
appearance of the swabs. For the OraSure and the Omni-SAL additional comments
related to difficulty because of the the length of time that the child was required to
keep the collection device in the mouth. One parent, who used the Omni-SAL,
commented how much easier it was than vene-puncture.
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A comparison of results from the rural Ethiopian population and children from
north Hertfordshire
A comparison of results obtained from samples collected from the two populations
used in this study is shown in Table 14.
Table 14. A comparison of results from the rural Ethiopian population and
children from north Hertfordshire
LOCATION Rural Ethiopia North Herts (UK)
Age range (yrs) <5-~50 3.5 -5
No. TESTED
• OraSure 38 4S
• Omni-SAL 38 38
• Oracol 38 42
Total IgG (mgIL) [95% Cl)
• OraSure 22.7 [18.0-28.5) 4.4 [3.6-5.4)
• Omni-SAL 24.7 [18.0-33.9) 2.0 [1.6-2.5)
• Oracol 41.2 [27.4-62.1) 6.1 [4.7-7.91
Total IgM (mgIL) [95% Cl)
• OraSure 1.4 [1.0-1.9) 0.8(0.6-1.0)
• Omni-SAL 2.5 (1.8-3.6) 0.9 [0.6-1.3)
• Oracol 3.1 [2.4-4.0) 1.4 [1.0-1.9)
Rank correlation (rs): rubella
specific IgG - serum vs oral
fluid (95%CI)
• OraSure 0.434 (0.13 - 0.71) 0.454 (0.22 - 0.66)
• Omni-SAL 0.604 (0.31 - 0.83) 0.647 (0.40 - 0.82)
• Oracol 0.565 (0.30 - 0.79) 0.742 (0.61 - 0.85)
A&re~m~nti Rubella specific
IgG results in paired serum and
oral fluid samples
• OraSure 74% 98%
• Omni-SAL 76% 92%
• Oracol 76% 98%
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DISCUSSION
The following will be discussed:
• the quality of oral fluid obtained using each collection device and its suitability for
antibody testing
• the consistency of oral fluid samples by a comparison of duplicate samples from
the same individual
• the acceptability of each collection device to the participants
Results from each of the two populations that provided oral fluid samples will be
compared and contrasted before conclusions are drawn about which collection device
is optimal. Whilst data from the two populations was analysed in a similar way, two
aspects of the study design were different for the two populations. These were taken
into consideration when comparing results and drawing conclusions:
• The population from rural Ethiopia consisted of persons aged <5 years to ~50 years
of age, whilst the population from north Hertfordshire was made up entirely of
children aged 3.5-5 years.
• Each of the 38 individuals from rural Ethiopia used in the analysis provided an oral
fluid collected using each of the three devices being assessed. In contrast the
children from north Hertfordshire were randomised to use one of the three types of
oral fluid collection device being assessed.
Therefore a more strictly accurate comparison of the quality of oral fluid collected by
each device being assessed can be made using data from the Ethiopian population,
since the same individual provided an oral fluid sample collected using all three
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devices. Also, the effect age may have on results was considered using samples
provided by the Ethiopian population since a wide age range is covered.
QUALITY OF SAMPLE
The quality of oral fluid sample collected by each device for antibody testing was
assessed by measurement of total IgG and IgM concentration and by measurement of
rubella specific IgG concentration in comparison to that in a matching serum sample.
Total IgG and IgM concentration
Measurements of both the total IgG and IgM concentration in oral fluid samples
provided by both populations suggested that there was sufficient present for oral fluid
samples to be useful in antibody studies, confirming the findings of previous studies
(19,31,39,40,51,70,82,105,119,120,128,129, 139-141, 150, 151, 157, 178, 186,
187). A significant difference between the three devices was found when total IgG
and IgM geometric mean (GM) concentrations were ompared. the patterns were
similar for samples from both the rural Ethiopian population and the children from
north Hertfordshire. Both the total IgG and IgM GM concentrations in oral fluid
samples collected by the Oracol were higher than for those collected by OraSure and
Omni-SAL (Table 7). This observation may be accounted for by the way in which the
devices are used, though it is possible that the efficiency of antibody elution from
absorbent material may vary between devices. The Draco I is designed to target the
gums, the part of the oral cavity most likely to be rich in crevicular fluid, and is used
vigorously. The OraSure, which also targets the gums, is used more passively than the
Draco I which may account for the lower total antibody concentrations found in oral
fluid samples collected by this device. The Omni-SAL, which is designed to be placed
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under the tongue and is also used passively, provided oral fluid with a similar total
IgG and IgM concentration to that of the OraSure device.
The suggestion that oral fluid collection devices which target crevicular fluid and are
designed to be used vigorously provide a higher quality of sample for antibody testing
and is supported to some degree by an earlier study by Parry et al (139). They (139)
compared OraSure and Salivette, a device consisting of a cotton wool wad which is
chewed to collect oral fluid from all parts of the oral cavity rather than crevicular fluid
specifically. OraSure yielded oral fluid samples with a higher mean total IgG
concentration than Salivette, consistent with the results of our study in that collection
devices which target areas of the mouth rich in crevicular fluid provide a better quality
of sample for antibody testing.
An interesting observation is that in the Ethiopian study population, the total IgG GM
concentration was approximately seven times higher than that obtained in samples
from children from north Hertfordshire, UK. This difference may be due to the age of
the two study populations, as the Ethiopian population covered a broad age range and
included a large proportion of adults, whereas the subjects from north Hertfordshire
were all children aged between 3.5 and 5 years. The results may therefore reflect the
developmental stage or maturity of the immune systems ofthe participants.
The different results in the two studies may also reflect socio-economic status which
result in a higher exposure to infectious diseases and therefore higher antibody levels
in developing countries. This is also consistent with the higher total IgM
concentration found in subjects from rural Ethiopia. Being persons from a developing
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country they are more likely to have been recently exposed to an infectious agent than
their counterparts in the developed world. Ethnic origin is a further factor which may
effect the immunoglobulin concentrations in oral fluid. Susceptibility to infectious
disease and the extent to which a humoral immune response occurs is genetically
determined and may vary between ethnic groups (46).
In a recent study by Wilson et al (193) using oral fluid from 121 school children from
the UK (age range 7-11 years, mean age 8.0 years) collected by Salivette the total IgG
concentrations were found to range from 3.8 mgIL to 165 mgIL. These data appear to
correspond more closely to that from the Ethiopian population than children from
north Hertfordshire. This is consistent with total antibody levels detected in oral fluid
being related to the maturity and state of development of the subjects immune system.
A further factor that may have influenced the levels of total antibody found in oral
fluid samples from the two populations is how samples were stored until the oral fluid
could be extracted from the device and frozen at -zo-c in the laboratory. In Ethiopia,
transport medium was added to Oracol samples on the same morning of collection and
all samples stored at 2-10oe until processed by the laboratory. In contrast, samples
collected in the UK were kept at room temperature until processed and transport
medium added when they were received in the laboratory for processing. There is a
possibility therefore that the immunoglobulin content of those oral fluid samples
collected in the UK may have deteriorated at a faster rate than in those collected in
Ethiopia which is consistent with the considerably lower total immunoglobulin
content, particularly IgG, found in samples from UK subjects.
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Rubella specific IgG
Figures 4 and 5 show that the concentration of rubella specific IgG in oral fluid as
measured by GACRIA was lower and varied more than that in matching sera as
measured by ELISA. The oral fluid test may therefore be used reliably to give a
qualitative result only.
Obtaining a quantitative result from oral fluid in the manner that is currently possible
for serum with ELISA assays (e.g. Behring) represents a considerable challenge that
may never be successfully met with current technology. There are a number of
variable factors that must be considered when collecting and testing oral fluid samples
which make it extremely difficult to determine precisely how both total and specific
antibody concentrations relate to that in the individuals serum. These include the
efficiency of absorption and elution of oral fluid from the collection device and the
extent to which the antibody rich crevicular fluid is targeted by the collector when
using the device (139). It is also likely that the extent to which antibody transudes into
the oral cavity from blood capillaries beneath the gingival crevice will vary between
individuals. Therefore antibody levels in oral fluid may be regarded only as a
reflection of those in the subject's plasma. However, a degree of quantitation may be
achieved if the specific antibody result is compared to the total antibody concentration
of the oral fluid sample. Careful evaluation using an appropriate panel of paired sera
and oral fluids will determine whether this approach is feasible.
The agreement between results of oral fluid samples and matching sera provided by
the children from north Hertfordshire was sufficiently high for both rubella and
parvovirus B19 specific IgG oral fluid tests to be useful for epidemiological purposes.
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For the Ethiopian population, the agreement of rubella specific IgG results from oral
fluid with those on matching sera was considerably lower. This suggests that the use
of oral fluid for measuring rubella specific IgG lacks sensitivity for the Ethiopian
study population. Nokes et al (1998) (128)observed a trend of decreasing rubella
specific IgG in oral fluid with increasing age for this population. This suggests that if
older age groups (>20 years) are to be screened for rubella specific IgG using oral
fluid more sensitive virus specific antibody assays will be required. This issue is
considered in more detail in Chapter 2 as the relatively small number of samples
spanning the wide age range for the Ethiopian population makes a formal
investigation of the effect of age on assay performance inappropriate here. The higher
agreement for rubella specific IgG in oral fluids and matching sera found when
evaluating the oral fluid samples provided by the children from north Hertfordshire is
most likely the result of these participants having recently received MMR vaccine,
these individuals therefore having a relatively high proportion of total antibody that is
rubella specific.
There was little to discriminate between the three devices in terms of obtaining a
qualitative rubella specific IgG result in both study populations. The results from the
samples from the Ethiopian population are more likely to be reliable, however, as
each of the 38 individuals provided an oral fluid collected using each of the three
devices being assessed whilst the children from north Hertfordshire were randomised
to use only one of the three devices.
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A comparison of duplicate oral fluid samples
Duplicate oral fluid samples were collected from the rural Ethiopian population using
the Oracol and OraSure devices. Comparisons of total IgG, IgM and rubella specific
IgG antibody in duplicate oral fluids for each device was made using rank correlation.
Results summarised in Table 9 show the correlation of total IgG concentration and
rubella specific IgG for duplicate oral fluids collected using the Oracol was
considerably higher than for oral fluids collected using the OraSure device. The
correlation of total IgM was higher for duplicate samples collected by OraSure than
for Oracol, though the confidence intervals were wide. These results therefore suggest
that the Oracol device provided oral fluid samples of more consistent quality than the
OraSure. This may reflect the way in which the Oracol device is used. It targets the
gums and is used vigorously suggesting that it may be more likely to absorbe antibody
rich crevicular fluid and so provide samples that contain more consistent levels of
antibody. However, further investigations are required to examine consistency of
sample due to the relatively small numbers of duplicate samples studied, particularly
for the Oracol device (n = 13).
ACCEPTABILITY
All participants from both populations in this study found each make of oral fluid
collection device simple to use. The Oracol device was preferable for use in the field
as it was the easiest to administer and most acceptable to participants. Some
participants from rural Ethiopia expressed a dislike of the taste of the OraSure device
and some difficulty was experienced by younger participants in complying with the
manufacturers instructions to position the Omni-SAL under the tongue for the
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necessary time for the saturation indicator to turn blue. There was also a potential risk
with young children chewing and biting off the Omni-SAL swab (128).
Further considerations which may be neccessary concern the laboratory processing
needed to extract the oral fluid from each type of collection device. Whilst the
procedures are relatively simple for all three devices, that for the Oracol is most time
consuming and complex which may be a limiting factor that needs to be considered
for basic laboratories in the developing world. There is also no preservative fluid
provided with the Oracol device which may be a disadvantage when the used device
cannot be quickly transfered from the field to the laboratory for processing.
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CONCLUSIONS
• This study has confirmed that oral fluid may be used as a substitute for serum for
sero-epidemiology and has high potential for determining the need for
immunisation and the vaccine delivery strategy.
• There was little difference in the rubella specific IgG concentration in oral fluid for
each type of collection device for qualitiative analysis.
• The Oracol device provided oral fluid samples with the highest concentrations of
total IgG and IgM.
• The Oracol device provided the most consistent sample in terms of the total and
specific immunoglobulins examined.
• The Oracol device was acceptable to the most participants.
Coupled to its lower cost compared to OraSure and Omni-SAL, these data suggest
that the Oracol is the oral fluid collection device of choice for studies involving rural
Ethiopia and young children in the UK.
79
APPENDIX 1
1.1 Measurement of total JgG and JgM concentration in oralfluid.
1.1a Preparation of JgG standard curve
• A calibration curve using doubling dilutions from 2.5 mg/L to 0.039 mg/L is
prepared in PBST as described below. Each standard is tested in duplicate in each
assay or each plate.
• Check the concentration of the standard in use. In a separate microtitre plate
prepare a 2.5 mg/L standard. For example dilute a 45 mg/L calibrant 1 in 18 (10ul
to 170ul PBST).
• Prepare the remaining standards by doubling dilutions, from the 2.5 mg/L diluted
standard, in PBST (50ul standard + 50ul PBST). A new pipette tip must be used for
the preparation of each dilution.
I.lb Assay procedure
• This assay is only accurate in the approximate range of 0.1 mgIL to 10 mgIL.
Therefore, if a sample is likely to contain a concentration of IgO outside this range
it must be tested at a different dilution. Further advice on appropriate sample
dilutions is provided at the end of this section.
• A microtitre plate is coated with rabbit antibody to human IgO (gamma chain
specific, Dako Ltd., Ely, United Kingdom) diluted 1:1000 in coating buffer (see
1.2a for coating buffer preparation) for 2 hours on a rotary shaker at room
temperature. Leave overnight at 4°C prior to use.
• Add 40ul of PBST to the wells. Add 10ul of oral fluid to its allocated microtitre
well.
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• After the addition of all the samples add a further 1DuI of PBST to wells Al and
A2 to act as blanks for the assay. Add 10ul of each of the standards (in duplicate)
to their allocated wells in columns 1 and 2.
• Cover the plate with a plate sealer and incubate at 37°C for 2 hours.
• Wash the microtitre plate 4 times with a Wellwash (or similar), ensuring "top
aspiration" is occurring.
• Prepare a 1 in 10,000 dilution of rabbit HRPO conjugated anti-human IgG (Dako)
[1ul + 10ml, IOmls per plate], and add IOOulto each well.
• Cover the plate with a plate sealer and incubate at 37°C for 30 minutes.
• Wash as descibed previously but include an additional wash, giving a total of 5
washes.
• Add 100ul of TMB substrate to each well, cover the plate with a plate sealer and
incubate in the dark at room temperature for 25 minutes.
• Stop the reaction with 0.25M H2S04 and read in a plate reader at 450nm (reference
620nm) using wells Al and BI as blanks. It is recommended that a reader capable
of reading OD values >3.0 is employed in order to extend the dynamic range.
• Appropriate software (e.g. Mikrotek-Laborsysteme) should be used to analyse the
data and to produce the standard curve against which oral fluid sample
concentrations are determined.
Quantification of total IgG in oral fluid samples with concentrations> IOmgIL: As the
assay is capable of accurate quantification over only a relatively small linear region, if
actual concentrations are required it is necessary to pre-dilute the samples which have
given OD values above the linear range of the assay. Therefore prepare a dilution of
the samples in PBST outside of the reaction tray, transfer them, and test as described
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above. The actual dilution required will be dependant upon the actual concentration of
the sample.
This method was adapted for measuring the total IgM concentration (mgIL) in oral
fluid by using a test plate coated with an anti-human IgM antibody (Dako Ltd) at
1:1000, and diluting the oral fluid 1:10 in PBST. The human IgG calibrator was
substituted with a human IgM calibrator (The Binding Site Limited, Birmingham,
UK) and a calibration curve constructed with human IgM concentrations ranging from
2 mgIL to 0.0035 mgIL. An anti-human IgM peroxidase conjugate (Dako Ltd) was
used at a dilution of I :3000 and the TMB substrate added for 15 minutes before the
colour reaction was stopped.
Limitation of the procedure: At present there is no feasible way of confirming the
specificity of reactions. It has to be assumed that, as for any immunoassay, there may
be some false reactions.
Useful notes:
• The critical part of this assay is the preparation of the calibration curves. Great care
is needed when preparing the dilution series.
• When calculating the actual IgG and IgM concentration do not forget to
compensate for the sample dilution.
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1.2 JgG antibody capture radioimmunoassay (GACRIA) for rubella
1.2a Bead coating
• Preparation of coating buffer: Dissolve 0.8g of sodium carbonate N~C03 (I5mM)
and I.47g of sodium hydrogen carbonate NaHC03 (35mM) in 500mls sterile
distilled water. The pH should be 9.6.
• Take an appropriate number of polystyrene beads (Northumbria Biologicals P20I).
• Coat beads with rabbit antibody to human IgG (gamma chain specific, Dako Ltd.,
Ely, United Kingdom) diluted I: 1000 in coating buffer for 2 hours on a rotary
shaker at room temperature. Leave overnight at 4°C prior to use.
1.2b Preparation of calibration curve
• A serum sample, strongly positive for rubella IgG, is used as an arbitary IOOu
control.
• Further dilutions of this IOOucontrol in human serum negative for rubella specific
IgG (NHS) are made to give 33u, IDu, 3.3u, I.Ou and 0.33u controls.
1.2c Testing serum and oralfluid samples
• For each assay run 4 wells ofNHS and a calibration curve are used. Where serum
and oral fluid samples are tested in the same assay duplicate control plates are
required.
• Specimens: serum samples are diluted I: 100. The diluent used is phosphate
buffered saline (PBS) containing 10% foetal calf serum (FCS) and 0.2% Tween 20
(T20). Oral fluid samples are tested neat.
• Coated beads are washed 3 times in PBST (T20 0.05%) and added to sample and
control wells.
• Incubate at 37°C for 3 hours.
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• Wash xl using Qwikwash (Abbott Laboratories) in PBST.
• Add 200ul rubella haemagglutinin antigen (Judith Strain) prepared by DMR,
CPHL, diluted 1:15 in PBS containing 10% FCS and 1% T20.
• Incubate overnight at 4°C.
• After washing beads as described previously, add 200ul anti-rubella monoclonal
antibody to each sample diluted 1:50,000 in PBS containing 10% FCS, 2% NHS,
5% normal rabbit serum (NRS) and 0.1% T20.
• Incubate for 2 hours at 37°C.
• After washing beads as described previously, add 1125 labelled anti-mouse IgG
(Amersham code no. IM131) diluted to give approximately 80,000 - 100,000
counts per minute in 200ul. Dilute in PBS containing 10% FCS, 2% NHS, 5%
NRS, 5% normal goat serum (NGS) and 0.2% T20.
• Incubate for 2 hours at 37°C.
• After washing as before, transfer the beads to counting tubes and measure the
bound 1125 for 2 minutes in a gamma counter.
• Test results are calculated as the total bound radioactivity of each specimen divided
by the mean radioactivity bound by the negative serum controls and expressed as
test:negative (TIN) ratios. A cut off TIN of 2.1 was used. Results can also be
expressed in units by reference to the calibration curve.
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1.3 Behring Enzygnost anti-rubella virus IgG ELISA: enzyme immunoassay for the
detection and quantitative determination of human IgG antibodies to rubella virus
in serum and plasma.
1.3a Preparation of the reagents
• Bring all the reagents and test samples to 18 - 25°Cbefore starting.
• For each test plate dilute 20ml Washing Solution POD to 400ml with distilled
water.
• Pre dilute the reference(s}and test samples I+20 with Sample Buffer POD and mix
well.
• Working Conjugate Solution: dilute the Anti-human IgGIPOD Conjugate with
Conjugate Buffer Microbiol (1+50), shaking gently to mix.
• Working Chromogen Solution: for each test plate, dilute Iml Chromogen TMB
with 10ml Buffer/Substrate TMB in the empty bottle supplied with the kit and
store protected from light.
1.3b Test Procedure
• Assay scheme: ascertain the required number of wells (= No. test samples + No.
determinations of the reference PIN). Reference PIN is run as the first and last
sample in the assay series, or as the first and last sample in each test plate in a large
assay series.
• Introduce buffer: pipette receiving volumes of 200ul Sample Buffer POD into each
well needed in the test plate(s}.
• Dispense samples: pipette 20ul/well of the prediluted Reference PIN into the first
pair of antigen (Ag}/control antigen (CoAg) wells (All and Al2). Afterwards
pipette 20ul/well of prediluted sample into the next pair of Ag/CoAg wells,
continuing in the same manner for each sample. At the end of the series or test
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plate again pipette 20uVwell of the prediluted Reference PIN into a pair of
AgiCoAg wells. Seal the finished test plate.
• Incubate for 1 hour at 37°C.
• Wash: aspirate all wells; introduce approx 0.3ml of diluted Washing Solution POD
into each well, aspirate and repeat the cycle three more times.
• Dispense conjugate: into each well pipette 100ui of the Working Conjugate
Solution, seal plate.
• Incubate for 1 hour at 37°C.
• Wash as previously described.
• Dispense substrate: add 100ui of Working Chromagen Solution to each well and
seal plate.
• Incubate for 30 minutes at 18 - 25°C protected from light.
• Stop reaction: add 100ul of Stopping Solution POD to each well.
• Photometric evaluation: the measurement wavelength is 4S0nm, and the
recommended correction wavelength is 65Onm. For each test sample and reference
sample calculate the difference in absorbance, M {=A.ntiIlCD - Aconlrol antilleJ, obtained
with the sample diluted as prescribed.
l.3c Internal Quality control
• The A values for each pair of Reference PIN well must be within the range defined
by the lower and upper margins given in the table of values enclosed with the kit.
• The A values of the Reference PIN at the start and the end of the series must not
deviate from the mean of these values by more than ± 20%.
1.3d Results (Quantitative Evaluation)
86
• Measurement correction: calculate the mean A value of the Reference PIN. Divide
the nominal value of the Reference PIN (given in the Table of Values) by the mean
A value. This gives the correction factor.
• Use the correction factor to multiply the absorbances of the samples in the series
for which the correction factor was calculated. If several test plates are assayed, the
correction factor has to be determined for each plate separately and used to correct
the values for the corresponding plate.
• Calculation of the result: calculate the antibody activities by using the corrected
M readings of the following formula (o-method): loglO IU/ml = <x• .1AP
• The values for the lot-dependant constants alpha (u) and beta (~) are given in the
enclosed table of values.
• The antibody activity is stated in "IU/ml" based on the International Standard for
Anti-Rubella Serum (2nd International Standard Preparation) of WHO.
• The limit of detection of the test is 4 IU/ml, equivalent to a signal of 0.1 A.
1.4 JgG antibody capture radioimmunoassay (GACRIA) for parvovirus B19
1.4a Bead coating (as described for rubella GACRIA using Dako anti-human IgG
diluted 112000)
1.4b Preparation of calibration curve (as described for rubella GACRIA using a
serum strongly positive for parvovirus B 19 IgG as an arbitary 100u control)
1.4c Test Procedure
• For each assay run 4 wells ofNHS and a calibration curve are used. Where serum
and oral fluid samples are tested in the same assay duplicate control plates are
required.
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• Specimens: serum samples are diluted 1:100. The diluent used is phosphate
buffered saline (PBS) containing 10% foetal calf serum (FCS) and 0.2% Tween 20
(T20). Oral fluid samples are tested neat.
• Coated beads are washed 3 times in PBST (T20 0.05%) and added to sample and
control wells.
• Incubate at 37°C for 2 hours.
• Wash xl using Qwikwash (Abbott Laboratories) in PBST.
• Add 200ul baculovirus expressed B19 VPl and VP2 capsids (provided by Dr S.
Kajigaya, NIH Bethesda) diluted 1:10,000 in PBS containing 10% FCS and 1%
T20.
• Incubate overnight at 4°C.
• After washing beads as described previously, add 200ul anti-VPINP2 monoclonal
antibody to each sample diluted 1:100,000 in PBS containing 10% FCS, 2% NHS,
5% normal rabbit serum (NRS) and 0.1% T20.
• Incubate for 2 hours at 37°C.
• After washing beads as described previously, add 1125 labelled anti-mouse IgO
(Amersham code no. 1M131) diluted to give approximately 80,000 - 100,000
counts per minute in 200ul. Dilute in PBS containing 10% FCS, 2% NHS, 5%
NRS, 5% normal goat serum (NOS) and 0.2% T20.
• Incubate for 2 hours at 37°C.
• After washing as before, transfer the beads to counting tubes and measure the
bound 1125 for 2 minutes in a gamma counter.
• Test results are calculated as the total bound radioactivity of each specimen divided
by the mean radioactivity bound by the negative serum controls and expressed as
test:negative (TIN) ratios. A cut-off TIN of 4.0 was used.
88
1.5 Dako IDEIATMparvovirus B19 IgG ELISA: enzyme immunoassay lor the
detection and qualitative determination 01 human IgG antibodies to human
parvovirus B19 in serum samples.
l.5a Preparation: determine the number 01microwell strips needed. Given duplicate
tests, between 12 and 45 specimens can be tested per kit, dependant on the number of
specimens per run. One strip allows assaying of 1 patient specimen, with duplicate
tests plus controls. Each additional strip allows duplicate tests of 4 specimens. All
steps are performed at room temperature (20 - 25°C).
1.5b Incubation of samples
• Place the required number of microwell strips in the plastic frame
• Dilute patient sera 1 + 100 by adding 10uL of serum to 1 mL of working strength
Sample Diluent and Washing Buffer in a test tube
• First microwell strip: add 50uL of working strength Sample Diluent and Washing
Buffer (vial No.2) to wells Al and Bl; Cut-OfflgG Control (vial No.3) to wells
Cl, Dl and El; Positive IgG Control (vial No.4) to well FI; and 50 uL of diluted
patient serum to GI and HI.
• Additional microwell strips: add patient specimens only. For each patient, pipette
50 uL of diluted serum into each of two adjacent wells. If more than one strip is
used in an assay, the volumes must be multiplied by the number of strips.
• Add 300 uL of working strength Sample Diluent and Washing Buffer to a test tube.
• Mix the contents of vial No.5 (biotinylated B 19 Antigen, previously reconstituted)
and add 200 uL to the test tube. Mix.
• Add 50 uL of diluted Biotinylated B 19 Antigen to each well. Return vial No. 5 to
the refrigerator immediately after use.
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Cover the microwell strips with a plastic lid and incubate for 30 minutes at room
temperature (20 - 25°C) on an orbital shaker set at 500 rpm.
l.Sc Washing
• Wash the wells with 4 times with working strength Sample Diluent and Washing
Buffer using an ELISA washer. Good washing with complete filling and emptying
of the wells is essential for optimal results.
1.5d Incubation with Conjugate, Anti-IgG
• Add 100 uL of Conjugate, Anti-IgG (vial No.6) to each well.
• Cover the microwell strips with a plastic lid and incubate for 1 hour at room
temperature (20 - 25°C) on an orbital shaker set at 500 rpm.
1.5e Washing
• Wash the wells as described previously
1.5f Incubation with Substrate A and B, reading 0/ results: it is recommended to use
an 8-channel pipette throughout the following steps. Use separate reagent
reservoirs for substrate A and Substrate B with only the requisite amount of
reagent.
• Add 50 uL of Substrate A (vial No.7) to each well.
• Add 50 uL of Substrate B (vial No.8) to each well.
• Incubate the microwell strips for 10 minutes at room temperature (20 - 25°C),
covered with a plastic lid and protected from the light.
• Stop the reaction by adding 100 uL of Stop Solution (vial No.9) to each well.
• Read the absorbance (OD) of each microwell at 450 nm. Blank on air. For dual
wavelength readers use a reference filter at 630 - 650 nm. Read the absorbance
within 60 minutes after the addition of Stop Solution.
1.5g Calculation of results
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• Buffer control: calculate the mean absorbance value (OD value) of the two buffer
control wells.
• Cut-off Control: calculate the mean OD value of the three Cut-off Control wells.
The OD value of the individual wells should not differ more than 15% from the
mean. If one of the three OD values differs by more than 15% from the mean, it
should be omitted and the mean value re-calculated.
• Patient specimens: calculate the mean OD value for each patient specimen. The
OD values should not differ more than 15% from the mean. However, a difference
of more than 15% may be accepted if both test wells show a negative result (low
OD values are measured with less precision).
• Quality control: check that the mean OD value of the buffer control is less than
0.100 but greater than 0.000. If the value is above 0.100, inadequate washing or
contamination of Substrate A or B may be the cause. If the value is less than 0.000,
the ELISA reader should be re-blanked on air, and the well re-read. The difference
between the OD value of the Positive Control and the Cut-Off Control should be at
least 0.800. If the difference is less than 0.800, inadequate washing, contamination
of conjugate with serum, or incubation at too low temperature, in particular during
substrate incubation, may be the cause. The shaker must also comply with the
specifications stated in the working procedure in order to assure the test quality. If
the quality control requirements are not satisfied the test results are invalid and the
assay should be repeated.
J.5h Interpretation of results: Compare the OD values of specimens directlt with the
OD value of the Cut-off Control. Interpret as follows:
• Negative for IgG antibodies to parvovirus B 19: Specimen OD ~ OD of Cut-off
Control x 0.8
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• Equivocal for IgG antibodies to parvovirus B19: Specimen Ol) is> than Ol) Cut-
off Control x 0.8, but < the Cut-off Control x 1.2
• Positive for IgG antibodies to parvovirus B19: Specimen aD is 2: Ol) of the Cut-
off Control x 1.2
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CHAPTER2
THE DEVELOPMENT OF SIMPLE ELISA
ASSAYS FOR USE WITH ORAL FLUID
Objectives:
• To develop simple, sensitive and robust ELISA-based oral fluid antibody detection
methods for rubella and anti-HBc IgG which can be used to replace existing
radioimmunoassays and will be suitable for use in both developing and developed
countries.
• The rubella ELISA developed will be suitable to replace the radioimmunoassay
currently used to detect rubella specific IgG antibody in oral fluid samples within
the MMR surveillance programme in England and Wales.
• To assess, evaluate and compare against well established commercial serum
ELISA the performance characteristics of ELISA-based oral fluid antibody assays
developed in this study.
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MATERIALS AND METHODS
Rubella GACELISA
Oral fluid collection.
Oral fluid was collected and extracted as previously described, using the Oracol,
OraSure and Ornnisal devices.
Sera, oral fluid and paired serum/oral fluid panels.
All samples were stored at -20°C until required for testing.
Control Sera.
RV IgG positive (256 IV/ml) and negative sera « 4 IV/ml) from healthy blood donors
were identified using a commercial ELISA kit (Behring Enzygnost, Behringwerke
AG, Marburg, Germany), as previously described. The WHO 80 IV/ml 2nd
international RV antibody standard (National Institute of Biological Standards and
Controls [NIBSC], Potters Bar, UK) was used to assess assay sensitivity.
Serum/oral fluid pairs.
Assay development and evaluation
Four panels comprising of 197 serum/oral fluid pairs were used (Table 17). All sera
were tested using the Behring ELISA as described above.
• Panel 1 consisted of 97 pairs positive for serum RV IgG antibody from children
(aged 3.5 - 5 years) who had recently received MMR vaccine as part of a pre-
school boost (PSB) study previously described in chapter 1. In total 36 of the oral
fluids were collected using Oracols; 30 using the Orasure device (Epitope Inc,
Beaverton, UK); 26 using the Omni-SAL TM device (Oral fluid Diagnostics Systems
94
Ltd, Singapore) and for five oral fluids the collection device used was not recorded.
The oral fluids were also tested by RV IgG capture radioimmunoassay (GACRIA)
as previously described.
• Panel 2 consisted of 24 pairs negative for serum RV IgG antibody from a study of
congenital rubella in southern India (51), the oral fluids having been collected
using the Orasure device and tested by RV GACRIA.
• Panel 3 consisted of 76 pairs, 14 negative and 62 positive for serum RV IgG
antibody, from the Christian Medical College, Vellore, India. The oral fluids were
collected using the Omni-SALTM device and tested by RV GACRIA. This panel
was categorized by age and subdivided into two further panels:
panel3a 55 serum/oral fluid pairs from subjects aged 17-34 years
panel 3b 21 serum/oral fluid pairs from subjects aged 5 months to 10 years.
Assay use in a field study
A panel of 831 paired serum/oral fluid samples were obtained from persons aged
between 0 and 84 years from the rural district of Butajira, Ethiopia. Oral fluid was
collected and extracted as previously described, using the Oracol device. All sera were
tested using the Behring ELISA as described above and oral fluid samples were
screened for anti-RV IgG by FITC/anti-FITC GACELISA.
Anti rubella-FITC conjugate.
Monoclonal antibody (MAB) to RV haemagglutinin (177) (Laboratory of
Microbiological Reagents (LMR), Central Public Health Laboratory) was purified by
a modification of the caprylic acid precipitation method as described by Steinbuck and
Audran (174) and Samuel et al (165). Briefly, ascitic fluid was clarified by
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centrifugation and filtration and the pH adjusted to 4.8 using 0.1 M acetic acid. Whilst
continuously stirring at room temperature, 77ul of caprylic acid per ml of ascitic fluid
was added and the resulting precipitate removed by centrifugation. The supernatant
was collected and the pH adjusted to neutral with TRIS buffer. An equal volume of
saturated ammonium sulphate was then added and the solution left to stand overnight
at 4°C. The resulting precipitate was recovered by centrifugation and redissolved in a
0.1 M carbonate-bicarbonate buffer (PH 9.25) containing 0.15 M NaCl. 1ml of the
purified monoclonal antibody was dialysed against 100ml of the O.IM carbonate-
bicarbonate buffer.
Conjugation with fluorescein isothiocyanate (FITC) was carried out as described by
Samuel et al (165). Briefly, 1 mg of purified monoclonal antibody was added to 0.5
ml aliquots of continuously stirred 0.1 M carbonate-bicarbonate buffer, pH 9.25,
containing 0.15 M NaCl. To these a 5 mg/ml solution ofFITC in absolute ethanol was
then added over a 5 minute period and the conjugation reaction allowed to proceed for
45 minutes at room temperature whilst being continuously stirred. The FITC
conjugated monoclonal antibody was separated from free FITC by gel filtration on a
PD 10 column (Pharmacia) and stored at 4°C.
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Rubella FITC/anti-FITC GACELISA.
Development and Optimisation
The assay format is shown in Fig. 6.
Fig 6: Conventional ELISA and the FITC/anti-FITC amplification system
FITC/anti-FITC amplification system
HRPO~
HRPO__' anti-mouse HRPO ~FITCA conjugate FITC
A FI1mouse anti-RVMAB
• •
Conventional ELISA format mouse anti-FITC HRPO conjugated MAB
anti-RV MAB-FITC conjugate
Rubella antigen
Human IgG (rubella specific)
anti-human IgG
SOLID PHASE
A series of experiments to optimise assay performance were performed:
Varying RV haemagglutinin concentration
RV haemagglutinin was titrated from 1:5 to 1:150 using duplicate positive and
negative serum controls for each concentration ofRV haemagglutinin examined.
Determination of optimal anti-RV MAD - FITC conjugate concentration
The anti-RV MAB - FITC conjugate was titrated from 1:300 to 1:100,000 using half
log dilutions. The conjugate dilutions were tested by GACELISA. Four positive and
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four negative serum controls were included and the experiment performed in both the
presence and absence of antigen.
Determination of optimal mouse anti-FITC
concentration
HRPO conjugated MAB
The mouse anti-FITC HRPO conjugated MAB was titrated from 1:300 to 1:100,000
using half log dilutions. The conjugate dilutions were tested by GACELISA. Four
positive and four negative serum controls were included. The experiment was
performed in the absence of anti-RV MAB - FITC conjugate to investigate any non-
specific binding of the mouse anti-FITC HRPO conjugate to other assay reagents.
Determination of optimal substrate incubation time
The rubella FITC/anti-FITC GACELISA was performed as described using a set of
six duplicate positive and negative serum controls. TMB substrate was added to each
of the six sets of control sera and the colour reaction then stopped at five minute
intervals, from 5 minutes to 30 minutes, by the addition of 2M H2S04 to one of the
sets of serum controls. The optical density was read immediately after the colour
reaction had been stopped.
Evaluation of GACELISA performance with samples incubated on a plate
shaker
The rubella FITC/anti-FITC GACELISA was performed as described using duplicate
titrations of the WHO 80 IV/ml international standard diluted in NHS from 80 IV/ml
to 0.625 IV/ml. One dilution series was incubated shaking at 500 rpm on a plate
shaker and the other being incubated stationary. Also included as a comparison was a
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system using only the mouse anti-RV MAB and an anti-mouse HRPO conjugate
(DAKO) rather than the FITC/anti-FITC system.
Final Procedure
• Wells of microtitre plates (Immuno Module Maxisorb U8 immunoplates, Life
Technologies Ltd, Paisley, UK) were coated with 100ul of rabbit antibody to
human IgG (gamma chain specific, Dako Ltd, U.K) diluted 1/1000 in 0.05 M
sodium carbonatelbicarbonate buffer pH 9.6. and incubated at 31'C for 18 h.
• After washing with phosphate buffered saline (PBS) containing 0.05% Tween
20 (T20) the wells of each plate were incubated at 31'C on a plate shaker at
500 rpm successively with 100ul of the following:
1. undiluted oral fluid or a 1 in 100 dilution of serum in PBS containing 10% fetal
calf serum (FCS) and 0.2% T20 for 30 mins;
2. RV haemagglutinin (LMR) diluted 1 in 10 in PBS containing 10% FCS and 0.2%
T20 for 1 h;
3. a 11500 dilution of the anti-RV MAB - FITC conjugate in PBS containing 10%
FCS, 5% normal rabbit serum (NRS), 2% human serum negative for anti-rubella
IgG (NHS) and 0.2% T20 for 2 h;
4. mouse anti-FITC horse raddish peroxidase (HRPO) conjugated MAB (Chemicon
International Inc. Temecula, USA) diluted 1118,000 in PBS containing 10% FCS,
10% NRS, 2% NHS and 1% T20 for 25 mins.
• Finally, 100ul of a 42mM 2'2' 4'4' tetramethyl benzidine (TMB) substrate
solution in a O.lM citrate/acetate buffer (PH 6.0) with 0.075% 20 volumes
H10z (6% w/v) was added to each well and the plate left to stand at room
temperature in the dark for 20 mins.
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• The reaction was stopped by the addition of SOul2M HzS04 to each well and
the optical density measured immediately at 450 nm (620 nm reference)
[OD450/6zo]using a Labsystems iEMS plate reader.
• Between each stage of the assay the wells were washed 5 times with PBS T20
(0.05% T20) using a Denley wellwash 4 MU.
• Included as controls were 8 wells each of the serum strongly positive for RV
IgG, NHS and the WHO 80 IU/ml international standard diluted in NHS to
give 15 IU/ml.
Determination of cut-off value.
The setting of an appropriate cut-off value is a particularly important aspect in the
development of an assay as the assay performance will be judged by this. One factor
that influences the choice of an assay cut-off is the purpose for which the assay under
development is designed to be used. Assays primarily developed to be used for
diagnosis in the individual will often employ a relatively high cut-off that errs on the
side of higher specificity at the expense of sensitivity to avoid wrongly categorising
true negatives as weakly positive. A good example of this are assays used for the
detection of RV specific IgG in determining whether or not an individual has
protective levels of antibody. Since it is critical that susceptible women of children
bearing age are accurately identified and offered vaccination to avoid the possibility
of a congenital infection during pregnancy, a high cut-off is used even though this
may result in classifying certain low positive results - that may actually reflect the
true immune status of an individual - as negative. In contrast screening assays
designed to estimate prevalence within a population can afford to use a lower cut-off
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to obtain best agreement with a gold standard assay and provide the highest sensitivity
and specificity.
A further factor to consider when setting an appropriate assay cut-off value is the
availability of well-characterised positive, and particularly negative, samples assessed
using a gold standard assay. The mean result of a population of negative samples
confirmed as such by a gold standard assay plus either two or three standard
deviations is a commonly used method to set a cut-off value (159). However, it should
be stressed that the estimate of standard deviation is subject to error as well, and
depends on the number of responses fromwhich it was calculated (88).
The radioimmunoassay used to measure rubella specific IgG in oral fluid (144)
expresses results as a test sample to negative control ratio (T:N). Since signals are
generated as measured counts of radioactivity over a specific period, the assay results
typically range from a T:N of <1.0 for negative samples to a T:N that is typically
>100 for a sample strongly positive for rubella specific IgG, samples being considered
as positive with a T:N >2.1. The spectrum across which results fall, from negative to
strong positive, represents the "dynamic range" of an assay. Signals generated by
ELISA assays are measured as optical density values and if results are expressed as
T:N values, they typically range from <1.0 for negative samples to -20.0 for a strong
positive. Therefore if results from ELISA assays are expressed as T:N ratios the
dynamic range is small in contrast to radioimmunoassay. The advantage in having an
assay with a large dynamic range is that it makes it easier to distinguish positive from
negative results, particularly those that fall close to the assay cut off.
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To enhance the dynamic range the results of the GACELISA were expressed as a
corrected percentage (%P) of the OD4S0/620 of the positive control serum included in
each assay using the following formula:
Corrected Percentage (%P) = {[(OD4501610 of the sample - OD450/610 of the negative
control)/ (OD450/610 of the positive control- OD450/610 of the negative control)]} x 100
By incorporating the OD4S0/620 of both the positive and negative controls, the formula
allowed for interassay variation. The %P values may therefore range from <0% for
those samples whose OD4S0/620 is less than that for the negative control to >100% for
those samples whose OD4S0/620 is greater than that of the positive control.
A cut-off was estimated for the GACELISA using two standard deviations of the
result from oral fluids from 26 subjects negative for serum RV IgG antibody by
Behring Enzygnost ELISA plus the mean result for all 26 samples. This gave a cut-off
value of 2.7%: samples with %P 2: 2.7 were considered RV IgG positive; those with
%P <2.7 were considered RV IgG negative.
This method generated a working cut-off. For assays designed to be used for
determining immunity in the population a more appropriate and accurate cut-off may
be set by using mathematical and statistical techniques such as mixture modelling
(137) and receiver operating characteristic (ROC) curves (23). A disadvantage of
these techniques is that they require the assay to have been already used extensively
on a suitably large population of samples. The appropriateness and suitability of the
cut-off value chosen will be appraised later using ROC curves (p. 106,p. 142).
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Statistical Methods.
Assay performance was evaluated by four methods:
1. Kappa statistic : This evaluates the degree of agreement between two
measurements and is used when neither assay is universally accepted as a gold
standard. A kappa statistic of 1 indicates perfect agreement, one of 0 corresponds to
no agreement and one of -1 indicates perfect negative agreement. 95% confidence
intervals around kappa were also calculated. If this interval is above 0 it can be
concluded that the methods show more agreement than expected by chance. Kappa
statistics were calculated using the fomula:
where P obi is the observed proportion of agreement between the two methods and Pup
the proportion of agreement expected by chance (55).
2. Spearman's Rank Correlation: This is a non-parametric measure of the degree of
association between two variables. The values of each variable are independently
ranked and the measure based on the differences between the pairs of ranks of the two
variables. Spearman's rank correlation was calculated using the formula :
where d is the difference between each pair of ranks and n the number of SUbjects.A
value of 1 corresponds to perfect agreement between the ranks of the two variables, 0
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corresponds to no relationship, and -1 corresponds to a perfect inverse agreement
between the ranks. 95% confidence intervals around r, were also calculated (5).
3. Exact binomial test : The binomial distribution was used to calculate the p-value
for comparing the agreement of results of the two oral fluid assays with the matching
serum results (5).
4. Paired t-test : A comparison of assay results when incubating the micro titre plate
shaking at 37°C and stationary at 37°C was made using a paired t-test (5).
Sensitivity, specificity, positive and negative predictive values (91).
The following fourfold table (Table 15) is useful in defining and calculating
sensitivity, specificity, positive and negative predictive values for antibody assays.
Table 15. Sensitivity, specificity, positive and negative predictive values
Screening test results True status TOTAL
Positive Negative
Positive a b a+b
Negative c d c+d
TOTAL a+c b+d a+b+c+d
a: True positives detected by the screening test
b: False positives detected by the screening test
c: False negatives detected by the screening test
d: True negatives detected by the screening test
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Sensitivity: This is a measure of the probability that any given case will be identified
by a screening test and is defined as the proportion of true positives in the screened
population who are identified as so by the screening assay.
[Sensitivity = aI(a+c)]
Specificity: This is a measure of the probability that a true negative will be correctly
identified by the screening test and is defined as the proportion of true negatives in the
screened population who are identified as so by the screening assay.
[Specificity = tV(b+d)]
Positive (PPV) and negative (NPV) predictive values: These are defined as the
proportion of cases of a condition accurately identified by a screening test.
[PPV = aI(a+b))
[NPV = tV(c+d)]
When calculating sensitivity, specificity, PPV and NPV values it is assumed that the
serum assay provided the definitive or "true to nature" result. It must be recognised,
however, that this may not necessarily be the case. Sensitivity and specificity are
absolute values associated with the screening test whereas PPV and NPV are variable,
dependent upon the prevalence of ''true'' positive or negatives in the population the
assay is used to screen.
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Receiver Operating Characteristic (ROC) Curves
Receiver operating characteristic (ROC) curves are a plot of the true positive
proportion (sensitivity) of a population against the false positive proportion
(specificity) as detected by the screening assay when evaluated compared to a "true"
or "gold standard" result. In this instance "true" results were generated by commercial
ELISA assays (Behring Enzygnost for RV specific IgG and Hepanostika for anti-
HBc) on matching serum samples to the oral fluid samples used. ROC analysis
therefore provides a graphical representation of the balance between sensitivity and
specificity of an assay. Ideally, both sensitivity and specificity would be 100%but this
is rarely - if ever - achieved. ROC curves can therefore be used to assist with setting
an assay cut-off though it is also important to consider the intended use of the assay.
Since the assays developed in this study are screening assays for determining levels of
immunity in the population a cut-off which gives maximum sensitivity and specificity
(i.e a cut-off in which sensitivity is maximised to a level of minimum effect on
specificity) should be chosen (23).
ROC curves are constructed by evaluating the sensitivity and specificity of an assay
across a range of cut-off values with respect to a true or gold standard result.
Sensitivity is then plotted against l-specificity. A perfect test (100% sensitivity and
100% specificity) will generate a curve that passes through the ideal point (0, 100) in
the upper left comer of the graph. The best cut-off for a screening assay (in which
sensitivity is maximised to a level of minimum effect on specificity) will therefore be
illustrated by the point on the curve which lies closest to the ideal point. Since the
curve will have a gradient of 1.0 at this point it can be found by drawing a line of 45°
at a tangent to the curve.
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Anti-HBe GACELISA
Sera, oral fluid and paired serum/oral fluid panels.
All samples were stored at -20°C until required for testing.
Oral fluid samples
Four oral fluids were provided by Virus Reference Division (VRD) staff. Two were
from persons confirmed as anti-HBc IgG positive and were collected by dribbling into
a sterile plastic container, and two were from persons with no history of hepatitis and
were collected using Oracols as previously described.
Oral fluids (n = 334) were obtained from the Anonymous HIV Laboratory, VRD, and
had been collected using the Salivette device (Sarstedt, Leicester, UK) as described by
Mortimer and Parry (119). Briefly, the Salivette consists of a cylindrical swab of
cotton wool contained in a plastic double tube. The subject must chew on the swab so
that oral fluid surrounding the gums is absorbed, which is then placed into the internal
tube. This is then centrifuged so the oral fluid can be recovered from the bottom of the
outer tube.
Serum Samples.
The Hepatitis and Retrovirus Laboratory (HRL), VRD, provided 23 sera which had
previously been screened for anti-HBc antibody by a commercial ELISA kit, the
Hepanostika anti-HBc Uni-Form Microelisa system (ORGANON Teknika) according
to the manufacturers instructions. This assay works on a competitive principle (see
Fig. 24, p. 158). Briefly the test sera and controls were added undiluted to the test
plate together with the conjugate provided. After incubation for the appropriate time,
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the provided substrate solution was added to each test well. The colour reaction was
stopped by the addition of provided stop solution and the absorbance read at 492 nm,
The method is described in full in Appendix 2.1 (pp.176-178).
Paired serum/oral fluid samples
Of the panel of 820 paired serum/oral fluid samples obtained from persons aged
between 0 and 84 years from the rural district of Butajira, Ethiopia, 530 had sufficient
volume remaining for screening for anti-HBc IgG. All sera were tested by the
Hepanostika anti-HBc Uniform Microelisa system (Organon Teknika) as described
above, and oral fluid samples were screened for anti-HBc IgG antibody by
GACELISA.
Measurement of total anti-UBc antibody in oral fluid
The total anti-HBc concentration in oral fluid samples was measured usmg an
adaption of the ICE HBc Detection Pack (Murex Diagnostics Limited, UK), and is
descibed in full in Appendix 2.2 (pp. 178-180). Briefly, undiluted oral fluid samples
and appropriately diluted controls were added to the test plate. The appropriate
dilution of supplied conjugate was then added followed by substrate solution. The
colour reaction was stopped by adding 0.5 M H2S04 and the absorbance read 15
minutes later at 45Onm.
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Development and Optimisation
A series of experiments to optimise assay performance were performed.
Titration of serum samples
• The anti-HBc GACELISA was performed as described titrating a serum sample
strongly positive for anti-HBc antibody and a serum sample negative for anti-HBc
(determined using the Hepanostika anti-HBc Uni-Form microelisa system) from
1:100 to 1:100,00 using halflog diluitions in NHS.
Titration of anti-mouse HRPO conjugate
• The anti-mouse HRPO conjugate was titrated sequentially from a I: 1000 dilution
to one of 1:10,000. This experiment was then repeated examining a range of anti-
mouse HRPO conjugate dilutions from 1:3500 to 1:5000. Anti-HBc positive and
negative serum controls at a dilution of 1:100 were included.
Simultaneous titration of rHBcAg and serum
• The rHBcAg was titrated from 1:1000 to 1:3,000,000 and a serum strongly positive
for anti-HBc from 1:100 to 1:300,000, both using half log dilutions.
Titration of mouse anti-HBc MAB
• The anti-HBc GACELISA was performed as described using positive and negative
control sera (identified using the Hepanostika anti-HBc Uniform Microelisa
system) and the mouse anti-HBc MAB titrated from 1:1000 to 1:3,000,000 using
half log dilutions.
Simultaneous titration of mouse anti-HBc MAB and serum
• The mouse anti-HBc MAB was titrated from 1:10,000 to 1:300,000 (using
intervals of50,000) and a serum strongly positive for anti-HBc titrated from 1:100
to 1:300,000 using half log dilutions. A negative control serum, used at a dilution
of 1:100 was also included for all dilution factors of mouse anti-HBc MAB.
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Titration of oral fluid samples
• The anti-HBc GAeELISA was performed as described using four oral fluid
samples, two from subjects positive for anti-HBc and two from subjects anti-HBc
negative. The oral fluids were titrated from neat to a 1:32 dilution, using doubling
dilutions in NHS. Also included were two serum controls, one positive for anti-
HBc and the other negative, used at a 1:100 dilution.
Investigating sources of non-specific binding
• The anti-HBc GAeELISA was carried out as described leaving out vanous
reagents at each stage so all permutations were covered to identify which reagent
was binding to which non-specifically. The experiment was then repeated
including 2% human serum negative for anti-HBc JgG (NHS) in the anti-HBc
monoclonal antibody diluent.
Final procedure
• Wells of microtitre plates (lmmuno Module Maxisorb U8 Immunoplates, Life
Technologies Ltd, Paisley, UK) were coated with 100ul of rabbit antibody to
human IgG (gamma chain specific, Dako Ltd, U.K) diluted 111000 in 0.05 M
sodium carbonatelbicarbonate buffer, pH 9.6, and incubated at 31'C for 18 h.
• After washing with phosphate buffered saline (PBS) containing 0.05% Tween
20 (T20) the wells of each plate were incubated at 37°C on a plate shaker at
500 rpm successively with 100ul of the following:
1. undiluted oral fluid or a 1 in 100 dilution of serum in PBS containing 10% fetal
calf serum (FeS) and 0.2% T20 for 30 mins;
2. recombinant HBc antigen (rHBcAg) (Murex) diluted 1 in 3000 in PBS
containing 10%FeS and 0.2% T20 for 1h;
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3. a 11100,000 dilution of a mouse anti-HBc MAD (Murex) in PBS containing 10%
FCS, 2% human serum negative for anti-HBc IgO (NHS) and 0.2% T20 for 2 h;
4. anti-mouse horse raddish peroxidase (HRPO) conjugate (Dako Ltd, U.K)
diluted 113500 in PBS containing 10% FCS, 5% normal rabbit serum (NRS) and
0.2% T20 for 30 mins.
• Finally, 100ul of a TMB substrate solution (Chemicon International Inc.
Temecula, USA) was added to each well and the plate left to stand at room
temperature in the dark for 30 mins.
• The reaction was stopped by the addition of 100ul 0.5M HCI to each well and
the optical density measured immediately at 450 nm (620 nm reference)
[OD450/61o]using a Labsystems iEMS plate reader.
• Between each stage of the assay the wells were washed 5 times with PBS T20
(0.05% T20) using a Denley wellwash 4 Mkl.
• Included as controls were 4 wells each of serum strongly positive for anti-HBc
IgG andNHS.
Determination of cut-off value.
Unlike the situation when determining a cut-off for the RV OACELISA, a panel of
paired serum/oral fluid samples was not available where the serum result was
confirmed as negative by a gold standard assay. Therefore an attempt to set a working
cut-off value was made using the results of samples once a study population of paired
serum/oral fluid samples had been screened. Of the 530 paired serum/oral fluid
samples obtained from Butajira, Ethiopia, 183 sera tested negative by the Hepanostika
anti-HBc Uni-Form Microelisa system. The mean OD4s0I620 for the corresponding 183
oral fluids samples tested by GACELISA, plus 3 standard deviations, was 0.150
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which was used as a working cut-off value (159). Three standard deviations were used
rather than two, as was used for the RV GACELISA, due to the large number of
paired serum/oral fluid sample available where serum tested negative by Hepanostika
suggesting that the estimation of the standard deviation should be accurate.
Test sample OD4S0/620 values were divided by the cut-off of 0.150, and those giving a
result greater than 1.0 considered as positive. If the assay can be demonstrated to
perform well in comparison to the Hepanostika anti-HBc Uni-Form Microelisa using
matching sera it would be useful to consider expressing results as %P values - as for
the RV GACELISA - to obtain a wide dynamic range and to allow for inter-assay
variation. The appropriateness of the cut-off value was assessed by ROC analysis (p.
142).
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RESULTS
Rubella FITC/anti-FITC GACELISA.
Optimisation of test method:
Evaluation of GACELISA performance with varying RV haemagglutinin
concentration
The results of the titration ofRY haemagglutinin from a 1:5 to a 1:150 dilution are
shown in Fig.7. These results showed that the OD4S0I620for the positive control serum
decreased in a linear manner with decreasing RY haemagglutinin concentration until
an RY haemagglutinin dilution of 1:60 was reached. An approximate 25% decrease in
the resulting signal was obtained for each doubling dilution ofRY haemaggltinin. For
RY haemagglutinin dilutions greater than 1:60 the OD4so/62oremainedconstant. For all
dilutions ofRY haemagglutinin using the negative control serum the size of the signal
generated remained constant giving an OD4S0/620 of less than 0.1.
Figure 7
Antigen concentration and assay performance of RV
GACELISA
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Determination of optimal anti-RV MAB-FITC conjugate concentration
The results of the titration of the anti-RV MAB - FIre conjugate are shown by Fig.8.
Results showed that for the negative control serum in both the presence or absence of
RV haemagglutinin and for the positive control serum in the absence of RV
haemagglutinin, signals remained constant with an 00450/620 of less than 0.1 for all
dilutions of anti-RV MAB - FITe conjugate. When the positive control serum was
used in the presence of RV haemagglutinin the size of signal generated remained
approximately constant at an 004501620 of greater than 2.0 until dilutions of anti-RV
MAB - FITe conjugate exceeded 1:3000. 004501620 readings then decreased with
decreasing anti-RV MAB - FIre conjugate concentration.
Figure 8
Titration of FITe conj RV MAB with and without Ag
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Determination of optimal anti-FITC HRPO conjugate concentration
An experiment was performed to investigate the level of non-specific binding by the
anti-FITC HRPO conjugate. The anti-FITC HRPO conjugate was titrated and the
results are shown by Fig. 9. Four positive and four negative control sera were included
for each dilution of anti-FITC HRPO conjugate. Since the experiment was performed
in the absence of anti-RV MAB - FITC conjugate to investigate any tendency for non-
specific binding the anti-FITC HRPO conjugate may have, no difference in the size of
signals for the positive and negative controls resulted. Therefore the mean combined
signal was used for both the positive and negative controls at each dilution of anti-
FITC HRPO conjugate.
Figure 9
Titration of the anti·FITC HRPO conjugate In absence of anti-
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The results show that the size of signal decreased exponentially from an OD4501620 of
0.38 to one of 0.02 as the anti-FITC HRPO conjugate was diluted down to a
concentration of I: 100,000. The lowest dilution of anti-FITC HRPO conjugate where
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the level of non-specific binding may be considered low enough not to significantly
effect the performance of the assay (OD4S0I620 - 0.05) indicates the optimal
concentration at which it should be used (see arrow in Fig. 9).
Determination of optimal substrate incubation time
The results showing variation of optical density readings with substrate incubation
time for positive and negative serum controls are shown in Fig.10. The results show
that optical density readings for the positive control serum rose from 0.8 at 5 mins to
2.35 at 25 mins after which readings remained constant. For the negative control
serum readings rose from 0.05 after 5 mins to 0.23 after 30 mins. A comparison of
results for positive (P) and negative (N) control serum shows this ratio (PIN) to be
highest at a substrate incubation time of 25 minutes.
Figure 10
RVGACELlSA: variation of substrate Incubation time
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A comparison of incubating shaking or stationary at 31'C
The results of titrating the WHO 80 IVlml standard from 80 fU/ml to 0.625 ID/ml
(diluted in NHS) and measuring the OD4S0/620 when incubated either still or shaking, at
37°C, are shown in table 16 and Fig.l l. Also shown is a comparison of the FITC/anti-
FITC system to one using unconjugated mouse anti-RV MAB and an anti-mouse
HRPO conjugate (see Fig. 6.).
Table 16. A comparison of assay performance when shaking and still
IVlml FITC/anti-FITC system anti-mouse HRPO
conjugate
OD4501610Still OD4501610Shaking OD4501620Still
(31'C) (31'C) (31'C)
80 0.36 0.41 0.270
40 0.22 0.26 0.160
20 0.14 0.21 0.150
10 0.135 0.19 0.095
5 0.09 0.13 0.085
2.5 0.07 0.1 0.075
1.25 0.07 0.095 0.07
0.625 0.08 0.08 0.07
POS control 1.251 1.412 0.950
NEG control 0.083 0.090 0.070
The results show that for the positive control serum and all dilutions of the WHO 80
fU/ml standard, with the exception of the 0.625 fU/ml dilution and for the negative
control serum, OD450/620 values were significantly higher when the microtitre plate was
incubated shaking (comparison of log OD4S0/620 using the FITC/anti-FITC system
shaking and stationary at 37°C by paired t-test : p < 0.05). A similar pattern was seen
when comparing the FITC/anti-FITC amplification system to that using an anti-mouse
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HRPO conjugate, the dynamic range of the assay being significantly higher for the
FITC/anti-FITC amplification system.
Assay Performance
Assessment of assay sensitivity
A linear relationship between IV/ml and RV GACELISA %P results was observed for
a titration of the WHO 80 IV/ml standard diluted in NHS. Putting the best line of fit
through the points showed that the sensitivity of the RV GACELISA at the 2.7% cut-
off level was 7.2 IV/ml (Fig.ll).
Figure 11
Titration of WHO 2nd International RV antibody standard (80 IU/ml)
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Serum/oral fluid panels
The results for all three serum/oral fluid panels are shown in Table 17. Overall the
amplified GACELISA showed a higher agreement than the GACRIA with the
Behring ELISA by kappa and rank correlation. The exact binomial p-value of 0.011
suggests that the amplified GACELISA was significantly different to the GACRIA in
comparison to the Behring ELISA. This was mainly due to the results from panel 3a
and partly due to the greater correlation of the amplified GACELISA than the
GACRIA with the Behring ELISA in panel 1. Compared to the Behring ELISA result
on serum from all the serum/oral fluid pairs, the GACELISA was both more sensitive
(82%) and specific (100%) than GACRIA, 74.4% and 97.3% respectively. The
positive predictive value (PPV) for both amplified GACELISA and GACRIA was
high being 100% and 99% repectively. The negative predictive value (NPV) however,
was low for both oral fluid assays due to inclusion of results from panel 3a, though the
NPV was higher for amplifed GACELISA (56.4%) than GACRIA (46.8%).
Panel 1: All of the 97 sera from this panel were positive for RV IgG by Behring
ELISA. Of the 97 oral fluids, 92 were RV IgG positive by amplified GACELISA and
93 by GACRIA giving a sensitivity of 94.8% and 95.8% respectively. The amplified
GACELISA showed a higher rank correlation with the Behring ELISA than the
GACRIA. The exact binomial p-value (p=1.0), however, showed that there was no
significant difference in the agreement of the two oral fluid assays with the Behring
serum ELISA.
Panel 2: All 24 sera were RV IgG negative by Behring ELISA. Using the amplified
GACELISA and GACRIA, the 24 corresponding oral fluids were also RV IgG
negative giving a specificity of 100% for both oral fluid assays.
119
Panel3a: Of 55 sera, 51 were RV IgG positive and four negative by Behring ELISA.
The four oral fluids corresponding to negative sera were all RV IgG negative by both
amplified GACELISA and GACRIA. Of the 51 sera which were positive, 15
corresponding oral fluids were positive by both amplified GACELISA and GACRIA,
14 positive by amplified GACELISA only and 22 negative by both assays. The
sensitivity of both oral fluid assays was low compared to the Behring serum ELISA
but was considerably higher for the amplified GACELISA (60.8%) than for the
GACRIA (29.4%) (Table 17). The specificity and PPV was 100% for both oral fluid
assays though the NPV was very low in both cases. The kappa statistic for agreement
with the Behring ELISA was higher for the amplified GACELISA than for the
GACRIA but low in both cases (Table 17). Rank correlation was also higher for the
amplified GACELISA and the exact binomial p-value showed the amplified
GACELISA agreed significantly more than the GACRIA with the Behring serum
ELISA (p= 0.0001, Table 17).
Panel 3b: Of 21 sera, 12were RV IgG positive and nine negative by Behring ELISA.
All nine oral fluids corresponding to the nine negative sera were negative by
amplified GACELISA and one oral fluid tested weakly positive by GACRIA. For the
12 sera which were positive, 10 corresponding oral fluids were positive by both
assays, one negative by amplified GACELISA only and one negative by both assays.
Both oral fluid assays showed a similar sensitivity (90.9%) but the specificity of the
amplified GACELISA (100%) was higher than that of the GACRIA (90%) (Table
17). The PPV and NPV for both assays was high, being slightly higher for amplified
GACELISA than GACRIA (Table 17). The kappa statistic was high for both assays
showing good agreement with the Behring ELISA results and the rank correlation was
0.74 for both amplified GACELISA and GACRIA (Table 17). The exact binomial p-
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value showed there was no significant difference in the agreement of the two oral
fluid assays with the Behring serum ELISA.
Overall, from all three panels, 168 serum/oral fluid pairs gave concordant RV IgG
results and 29 serum/oral fluid pairs gave discordant results. All discordant sample
pairs were serum RV IgG positive by Behring ELISA and oral fluid negative by
amplified GACELISA, with a geometric mean titre (GMT) of 38.3 IU/ml for serum
RV IgG. Twenty two of 29 serum/oral fluid pairs showing discordant results were
from panel 3a (subjects 2: 17 years). For serum/oral fluid pairs with concordant
positive results the serum RV IgG GMT was significantly higher, being 60.2 IU/ml
(comparison oflog IV/ml by t-test : p < 0.05).
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Table 17. Comparison of the amplification based GACELISA (G) and GACRIA
(R)for detection of RV-specific IgG in oral fluid with the Behring ELISA (8)
with serum- [p, 151]
Serum-saliva Panel
1 2 3a 3b Overall
No. samples 97 24 55 21 197
Age range 3.5-4 yr 4mth-6yr 17-34 yr 5mth-lOyr 4mth-34yr
Sensitivity (%):
G 94.8 NA 60.8 90.9 82
R 95.8 NA 29.4 90.9 74.4
Specificity (%):
G NA 100 100 100 100
R NA 100 100 90 97.3
PPV(%)
G 100 NA 100 100 100
R 100 NA 100 90.9 99
NPV(%):
G NA 100 16.7 90.9 56.4
R NA 100 10 90 46.8
No. samples with
the following
resultb:
B+,G+,R+ 89 0 15 10 114
B+,G+, R- 3 0 14 0 17
B+,G-,R+ 4 0 0 1 5
B+, G-,R- 1 0 22 1 24
B-, G-, R+ 0 0 0 1 1
B-, G-, R- 0 24 4 9 37
Kappa statistic
(95% Cl) for
agreement with
BC:
G NA NA 0.16 0.81 0.63
(0.01-0.31) (0.57-1.00) (0.51-0.74)
R NA NA 0.06 0.90 0.51
(-0.01-0.12) (0.72-1.00) (0.39-0.62)
Rank correlation
(950/0 Cl) with B:
G 0.74 0.21 0.58 0.74 0.68
(0.63-0.82) (-0.21-0.56) (0.37-0.73) (0.44-0.88) (0.60-0.75)
0
R 0.55 -0.06 0.35 0.74 .45
(0.40-0.68) (-0.45-0.35) (0.10-0.57) (0.46-0.89) (0.33-0.56)
Exact binomial P
valued 1.00 1.00 0.0001 1.00 0.011
(Footnotes overleaf)
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a G = amplification -based GACELISA; R = GACRIA; B = Behring ELISA; NA =
not applicable; Cl = confidence interval; + = positive result; - = negative result
b No samples fell into the categories B-,G+,R+ or B-,G+,R-
C The coefficient of agreement of the kappa statistic is based on comparison of the
results of the Behring ELISA with those of the amplification-based GACELISA and
the results of the Behring ELISA with those of GACRIA. It can be calculated only
when both samples are positive and negative by the Behring ELISA
d The P value in effect compares samples with B+,G+,R- and B-,G-,R+ results with
samples with B+,G-,R+ results, which are the totals when the results of one method
agree with those of the Behring ELISA and the results of the other method do not.
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Screening a rural Ethiopian population for rubella seroprevalence
The FITC/anti-FITC GACELISA was used to screen 831 oral fluid samples collected
by Oracol from a rural Ethiopian population living in the Butajira region. Matching
serum samples for all oral fluids were collected and screened for rubella specific IgG
using a commercial ELISA (Behring). The results are shown in Table 18, 19 and Fig.
12. Rubella seroprevalence, as measured by Behring, rose with age from 27% in those
aged 0-4 years to 100% in persons aged >20 years. A comparison of oral fluid and
serum results showed that the sensitivity of the oral fluid GACELISA relative to
serum ELISA varied with the age of subject, ranging from 92% in persons aged 5-9
years to 69% in those >50 years, and showed a generally decreasing trend with age.
The specificity of the oral fluid assay also varied according to age ranging from
89.6% in persons aged 0-4 years to 100% in persons aged >30 years. Overall, when
screening oral fluid samples from a rural Ethiopian population, the sensitivity and
specificity of the oral fluid GACELISA, relative to serum ELISA, was 79% and 90%
respectively.
Table 18. The seroprevalence of rubella in Butajira (Ethiopia), 1997
Age Grp SERUM Oral Fluid
(yrs) NEG(%) POS(%) NEG(%) POS(%)
0-4 67 (70.5) 28 (29.5) 64 (67.4) 31 (32.6)
5-9 53 (34.4) 101 (65.6) 56 (36.4) 98 (63.8)
10-19 42 (17.3) 201 (82.7) 64 (26.3) 179 (73.7)
20-29 1 (1.6) 63 (98.4) 14 (21.9) 50 (78.1)
30-49 1 (0.9) 167 (99.1) 57 (33.9) 111 (66.1)
50+ 0(0) 107 (lOO) 33 (30.8) 74 (69.2)
TOTAL 164 {19.7} 667 {80.3} 288 {J4.7} 543 {65.3}
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Table 19. Age specific sensitivity, specificity, NPV and PPV of the RV
GACELISA on oral fluid samples relative to Behring Enzygnost results on
matching sera.
Age Group Sensitivity (%) Specificity (%) PPV (%) NPV(%)
(Years)
0-4 85.7 89.6 77.4 93.8
5-9 92.1 90.6 94.9 85.7
10-19 87.1 90.5 97.8 59.4
20-29 77.8 NA* 98.0 0
30-49 66.5 NA* 100 1.8
50+ 69.2 NA* 100 0
TOTAL 78.9 89.6 96.9 51.0
*Not appropriate to be calculated as the majority of serum samples for persons aged
>20 years were positive for RV specific IgG by Behring Enzygnost.
Figure 12
Rubella seroprevalence - Butajira 1997
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Distribution of RV JgG results, Butajira 1997
The distribution by age group for the 831 oral fluid samples obtained from the rural
Ethiopian population that were screened for RV IgG antibody by GACELISA is
shown in Fig. 13. The perpendicular broken line represents the RV GACELISA cut-
off value. The distribution of results changed with increasing age of the subjects,
results shifting to the right of the assay cut-off for subjects aged 2:10 years. A
particularly clear distinction was made between those aged 0-9 years and those aged
10-19 years, whilst it was not so easy to distinguish between results from those aged
>20 years and those aged 0-9 years.
Figure 13
Distribution of RV IgG results by age group using oral fluid·
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The distribution of oral fluid results using the RV GACELISA in comparison to
matching serum results (Behring) with respect to each of the assay cut-offs is shown
126
in Fig.14. This clearly shows the ability of the Behring ELISA to categorise sera into
those that are positive and negative for RV IgG which cannot be done to the same
extent using oral fluid samples with the RV GACELISA. The broken lines represent
the serum and oral fluid assay cut-offs and divide the graph into four sections that
may be used to categorise agreement between results for the two assays. Those falling
in the bottom right hand section of the graph represent those oral fluid samples which
tested negative in the RV GACELISA but with matching sera which tested positive by
Behring.
Figure 14
Scatter graph showing a plot of serum results (Behring) against
those for matching oral fluid results (RV GACELlSA)
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Anti-HBc GACELISA
Optimisation of assay:
Titration of serum samples
Positive and negative control sera for anti-HBc were titrated (Fig. IS). The OD4S0I620 for
the positive control decreased with increasing serum dilution. The signal for the
negative control remained constant at an OD4S0/620 of < 0.1 until a dilution of
>1:30,000 had been reached where the signal began to rise. The positive control
serum was also titrated in conjunction with rHBcAg (Fig. 16) which showed that the
greatest decrease in OD4S0I620 of the positive control serum was seen when using serum
dilutions > 1:30,000 and was also useful for determining an optimal rHBcAg
concentration.
Figure 15
anti-HBc GACELlSA: titration of serum samples
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Titration of rHBcAg
A titration of the rHBcAg showed that the more concentrated this reagent was used
the higher the resulting OD450/620 for the positive control serum (Fig. 16). This was also
proportional to the concentration of positive control serum used. The OD4501620 for the
positive control serum decreased markedly when dilutions of rHBcAg exceeded a
factor of 1:30,000. For reasons of economy a rHBcAg dilution of 1:3000 was chosen,
though the development of an assay with a greater dynamic range would be possible if
the rHBcAg could be used at a higher concentration.
Figure 16
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Mouse anti-HBe MAB
A titration of mouse anti-HBc MAB using positive and negative serum controls is
shown in Fig. 17. The observed trend shows a decrease in 004501620 readings for both
positive and negative control sera with increasing dilution of mouse anti-HBc MAB,
though were considerably lower for the negative control (the increase in 00450/620 for
the positive control serum between anti-HBc MAB dilutions of 1/10,000 and 1130,000
may be a result of a dilution error or may be due to a "prozone" effect (145). At
dilutions of:;:: 1:100,000 for the MAB, 004501620 readings for the negative control were
< 0.1. A comparison of signals for the positive (P) and negative (N) controls showed
the PIN ratio to be highest at a MAB dilution of 1:30,000. However, at this dilution
the 004501620 reading for the negative control was > 0.1.
That 00450/620 readings for the negative control decreased with increasing dilution
factor ofanti-HBc MAB (from -0.8 to > 0.1) suggested this reagent had a tendency to
bind non-specifically to other components of the assay. It was therefore important to
choose a dilution of MAB which gave the greatest dynamic range and a low level of
non-specific binding (OD4S0/620 < 0.1 for the negative control). A dilution of 11100,000
for the anti-HBc MAB was therefore chosen.
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Figure 17
Titration of anti·HBc MAB
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Titrating the anti-mouse HRPO using positive and negative control sera showed a
similar pattern to the parallel experiment involving the mouse anti-HBc MAB :
signals for both the positive and negative control sera decreased with increasing
dilution of anti-mouse HRPO (Fig. 18). Signals for the negative control dropped
below an OD450/620 of 0.1 for anti-mouse HRPO dilutions 2: I :4000 and a comparison
of OD450/620 readings for the positive and negative controls showed the PIN ratio to be
greatest using an anti-mouse HRPO dilution of 1:4000. A closer examination of the
anti-mouse HRPO was made using dilutions ranging from 1:3500 to 1:5000 (Fig.19)
showed that the assay had the greatest dynamic range using the anti-mouse HRPO at a
dilution of 1:3500.
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Figure 18
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5000
Evaluation of assay performance
Non-specific binding
To investigate the cause of non-specific binding highlighted by results shown in Fig
17, an experiment was performed where individual components were omitted from the
assay as shown in Table 20.
Table 20. Investigating the cause of non-specific binding.
Row No. Reagents Included OD 450/6%0
1 anti-gamma neg control Ag MAB CONJ 0.097
2 anti-gamma pos control Ag MAB CONJ 1.862
3 anti-gamma Ag MAB CONJ 0.255
4 anti-gamma MAB CONJ 0.288
5 anti-gamma CONJ 0.05
6 anti-gamma pos control MAB CONJ 0.111
7 anti-gamma pos control CONJ 0.112
These results showed that the anti-HBc monoclonal antibody tended to bind non-
specifically to any available anti-gamma bound to the solid phase (Row 3 and 4). This
did not occur if a positive or negative control had already been added (Rows I,2 and
6). The conjugate showed no evidence of non-specific binding in the absence of anti-
HBc MAB (Rows 5 and 7).
To help overcome non specific binding it was decided to examine the effect of
including 2% NHS in the anti-HBc monoclonal antibody diluent. The results are
shown in table 21.
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Table 21. The effect of including 2% NUS in the anti-UBc monoclonal antibody
diluent.
Row No. Reagents Included OD 4501610
1 anti-gamma NHS Ag MAB CON] 0.089
2 anti-gamma NHS Ag MAB(NHS) CON] 0.115
3 anti-gamma pos control Ag MAB CON] 2.057
4 anti-gamma pos control Ag MAB(NHS) CON] 1.869
5 anti-gamma Ag MAB CON] 0.317
6 anti-gamma Ag MAB(NHS) CON] 0.115
7 anti-gamma MAB CON] 0.312
8 anti-gamma MAB(NHS) CON] 0.102
Rows 1-4 show that the inclusion of 2% NHS in the monoclonal antibody diluent did
not significantly affect the OD 4S0/620 readings obtained using the control samples.
Rows 6 and 8 show the addition of 2% NHS in the monoclonal antibody diluent
reduced the absorbance of the signal obtained to a value comparable to that of the
negative control sample. If the 2% NHS was not included the absorbance values of the
resulting signals were considerably higher (Rows 5 and 7).
Anti-HBc in blood donor sera: results of GACELISA and Hepanostika ELISA
A total of 23 blood donor sera were tested by both Hepanostika anti-HBc Uni-Form
Microelisa system (ORGANON Teknika) and anti-HBc GACELISA (Table 22). Six
sera (sera 1-6) were positive both by the Hepanostika kit and the anti-HBc
GACELISA. To simulate the low concentrations of anti-HBc expected in oral fluids,
serum samples were diluted from I: 100 to I: 10,000. Serum diluted 1:1000 has IgG
antibody concentrations approximating those found in oral fluid (Table 3). Sera 1-5
were still anti-HBc positive by GACELISA when diluted I: 10,000 whilst serum 6
was positive only at a dilution of 1:100.
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Table 22. A comparison of results from sera tested by anti-BBc GACELISA and
Organon (Hepanostika anti-BBc Uni-Form) kit.
Serum No. Organon anti-BBc GACELISA (OD 4501620)
Result ['working' cut oO"OD 4501620= 0.150)
Dilution Factor
1:100 1:1000 1:3000 1:10,000
1 POS 0.214 0.194 0.204 0.177
2 POS 1.083 0.969 1.013 0.827
3 POS 2.918 2.540 2.700 2.330
4 POS 0.762 0.650 0.704 0.624
5 POS 1.151 0.920 1.098 0.903
6 POS 0.432 0.127 0.122 0.125
7 POS 0.104 0.129 0.102 0.121
8 POS 0.106 0.111 0.127 0.107
9 POS 0.078 0.076 0.076 0.075
10 POS 0.106 0.099 0.107 0.097
11 POS 0.101 0.082 0.087 0.138
12 POS 0.130 0.086 0.084 0.082
13 POS 0.106 0.110 0.086 0.083
14 POS 0.086 0.091 0.091 0.082
15 NEG 0.087 0.081 0.092 0.096
16 NEG 0.087 0.088 0.085 0.093
17 NEG 0.077 0.071 0.073 0.086
18 NEG 0.101 0.120 0.104 0.087
19 NEG 0.088 0.094 0.092 0.091
20 NEG 0.089 0081 0.117 0.088
21 NEG 0.078 0.087 0.082 0.086
22 NEG 0.082 0.103 0.088 0.081
23 NEG 0.090 0.120 0.222 0.095
Sera 7-14 gave positive results using the Hepanostika system but were negative using
GACELISA at all serum dilutions used. Sera 15-23 gave negative results using the
Hepanostika kit and were all also negative at all dilutions using GACELISA.
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Titration of four oral fluid samples from persons of known anti-HBc status
Four oral fluids, two from persons confirmed as anti-HBc IgG positive and two from
persons anti-HBc IgG negative, were titrated and tested by anti-HBc GACELISA
(Table 23).
Table 23. Results for 4 oral fluids tested by anti-HBc GACELISA.
Dilution anti-HBc GACELISA OD 450/610
['working' cut off OD 450/610 = 0.150]
Oral fluid 1 Oral fluid 2 Oral fluid 3 Oral fluid 4
Undiluted
112
114
1/8
1/16
1/32
1.385
1.140
1.045
0.944
0.878
0.642
1.853
1.325
0.924
0.683
0.445
0.362
0.127
0.104
0.090
0.108
0.110
0.105
0.119
0.124
0.112
0.115
0.130
0.117
Oral fluids 1 and 2 were collected from persons confirmed as being anti-HBc IgG
positive and gave strong signals with high absorbance values when tested undiluted
by GACELISA and still tested positive when diluted 1132. The OD450/620 readings
given by oral fluid 1 when tested at 1132 was approximately half that when tested
undiluted. When oral fluid 2 was diluted 1/32 the absorbance value was
approximately 5 times lower than when tested undiluted. Oral fluids 3 and 4 were
collected from persons known to be anti-HBc negative and both gave OD4501620
readings low enough to be considered negative for anti-HBc at all dilutions tested.
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Screening oral fluid samples
A total of 334 oral fluid samples collected by the salivette device, were tested for total
anti-HBc by an adaption of the ICE HBc Detection Pack (Murex Diagnostics Limited,
UK), and those positive tested by GACRIA. These tests were carried out by staff at
the Hepatitis and Retrovirus Laboratory (HRL), CPHL, and the results kindly made
available. The samples were then tested by GACELISA (Table 24).
Table 24. A comparison of the ICE HBc Detection Pack and the anti-HBc
GACELISA on oral fluid samples (n = 334)
ICEHBc+ ICE HBc-
anti-HBc GACELISA + 130 18
anti-HBc GACELISA- 18 168
Performance of anti-HBc GACELISA compared to "ICE"
Sensitivity = 88% (130/148)
Specificity = 90.3% (168/186)
Positive Predictive value = 88% (130/148)
Negative Predictive value = 90.3% (168/186)
Of the oral fluids testing positive by the Murex ICE test, 10 were negative by anti-
HBc GACRIA with one of these testing positive in the anti-HBc GACELISA. Of the
18 oral fluids which were positive in the Murex ICE test but negative by anti-HBc
GACELISA, all were weakly positive by anti-HBc GACRIA (mean TIN value = 3.7).
Eighteen samples were negative by the Murex ICE test but positive by GACELISA.
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Fifteen had sufficient volume for testing by GACRIA, of which 2 were positive, 1
equivocal and 12negative.
Serum/Oral fluid Pain
A total of 538 serum/oral fluid pairs were obtained from a rural Ethiopian population.
The sera were screened for anti-HBc using the Hepanostika anti-HBc Uni-Form
Microelisa system and the corresponding oral fluid samples tested for anti-HBc IgG
antibody by GACELISA. An analysis af anti-HBc GACELISA performance
compared to Hepanostika relative to age of subject is shown in Table 25, 26 and
Fig.20.
Table 25. The seroprevalence of anti-HBc in Butajira (Ethiopia), 1997
Age Group Serum Oral Fluid
(years) NEG(%) POS (0/0) NEG(%) POS(%)
0-4 35 (79.5) 9 (20.5) 27 (61.4) 17 (38.6)
5-9 52 (60.5) 34 (39.5) 58 (67.4) 28 (32.6)
10-19 75 (49.0) 78 (51.0) 98 (64.1) 55 (35.9)
20-29 16 (34.0) 31 (66.0) 33 (70.2) 14 (29.8)
30-49 21 (16.9) 103 (83.1) 88 (71.0) 36 (29.0)
50+ 17 (21.8) 61 (78.2) 64 (82.1) 14 (17.9)
TOTAL 216 (40.6) 316 (59.4) 368 (69.2) 164 (30.8)
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Table 26. Age specific sensitivity, specificity, NPV and PPV of the anti-HBc
GACELISA on oral fluid samples relative to Organon results on matching sera
(samples: Butajira, Ethiopia 1997).
Age Group Sensitivity (%) Specificity (%) PPV (%) NPV (%)
_(years)
0-4 66.7 68.6 35.3 88.9
5-9 67.7 90.4 82.1 81.0
10-19 57.7 86.7 81.8 66.3
20-29 41.9 93.8 92.9 45.5
30-49 33.0 90.5 94.4 21.6
50+ 23.0 100.0 100.0 26.6
TOTAL 42.7 86.6 82.3 50.8
Figure 20
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The results show that anti-HBc seroprevalence, as measured by Hepanostika, rose
with age from 22% in persons aged 0-4 years to 80% in those aged >30 years. The
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analysis of oral fluid results shows a general decrease in anti-HBc GACELISA
sensitivity with increasing age of subject, ranging from 67% in the 0 - 9 year old
group to 21% in persons aged >50 years. In contrast the specificity of the anti-HBc
GACELISA increased with the age of subjects from 69% in the 0-4 year old group to
100% in those aged> 50 years. Overall the anti-HBc GACELISA showed a
sensitivity and specificity, relative to Hepanostika, of 43% and 87% respectively.
Distribution of anti-BBc IgG results, Butajira 1997
The distribution of results by age group for the 530 oral fluid samples obtained from
the rural Ethiopian population that were screened for anti-HBc IgG antibody by
GACELISA is shown in Fig 21. Similar distributions were found for each age group.
Figure 21
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The distribution of oral fluid results using the anti-HBc GACELISA compared to
matching serum results (Hepanostika) with respect to each of the assay cut-off values
is shown in Fig. 22. As was the case with the assays used to screen for RV specific
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IgG, this clearly showed the ability of the Hepanostika ELISA to categorise sera into
those that are positive and negative for anti-HBc which is not reflected in the
performance of the anti-HBc GACELISA using oral fluid. As for the RV study, the
graph was divided into four sections, determined by the respective cut-off values for
the anti-HBc GACELISA and Hepanostika ELISA, illustrating the agreement of
results from each assay. The large proportion of false negative anti-HBc GACELISA
results can be seen in the bottom right hand section of Fig. 23.
Figure 22
Serum and oral fluid anti-HBc results
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ROC analysis of RV GACELISA and anti-BBc GACELISA
ROC curves using a range of assay cut-off values were constructed for the RV
GACELISA and anti-HBc GACELISA (Fig. 23).
Figure 23
ROC analysis of RV GACELISA and anti-HBc GACELISA
* cut-off values chosen during assay development
Also included in Fig. 23 are the cut-off values chosen during assay development. the
ideal point of (0, 100) which represents 100% sensitivity and specificity with respect
to the gold standard assay, and a line representing no agreement with the gold
standard assay. The flatness of the curve for both the RV GACELISA and anti-HBc
GACELISA around the region where the gradient is 1.0 makes it difficult to select an
exact point which indicates the cut-off where sensitivity is maximised to a level of
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minimum effect on specificity. Therefore a region denoting where this point is likely
to fall is shown rather than the precise point itself. The working cut-off value used for
the RV GACELISA was located in this region but that used for the anti-HBc
GACELISA was below that indicated by ROC analysis.
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DISCUSSION
Development of oral fluid assays for virus specific IgG antibody
Having compared and evaluated three oral fluid collection devices two ELISA assays
were developed. These were designed specifically for use with oral fluid samples in
basic laboratories in developing countries. However, further simplification is needed
if the assays are to be used successfully under field conditions. Since oral fluid
contains antibody at a considerably lower concentration than that found in serum, it
was important that the assay format used provided a system that would be sufficiently
sensitive. An antibody capture format was chosen as the most suitable format for
assay development for two reasons:
• antibody capture assays measure the proportion of specific antibody in the total
antibody present in a sample rather than the concentration of specific antibody.
This proportion will, theoretically, remain constant at all sample dilutions so the
proportion of specific IgG found in a oral fluid should reflect that found in serum.
• the anti-human IgG antibody used to coat the solid phase to "capture" the IgG
present in a sample becomes saturated at low IgG concentrations. Therefore
antibody capture assays are particularly suitable for use with oral fluid samples,
where the antibody concentration is expected to be low (hence avoiding the need to
standardise for total IgG concentrations in oral fluid samples).
Assays were developed with the aim of studying the epidemiology of two vaccine
preventable virus infections, rubella and hepatitis B, in rural communities in
developing countries. Both assays were used to screen samples collected from a rural
Ethiopian population.
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Rubella FITC/anti-FITC GACELISA
Assay development
In order to develop assays for oral fluid RV IgG that could be more widely used than
the previously described GACRIA (144) it was decided to develop a corresponding
IgG capture ELISA test. Initial studies (Table 16) showed that simply substituting an
HRPO conjugate for the 12s1 conjugated antibody used in radioimmunoassays did not
result in an ELISA with sufficient sensitivity so it was decided to use the FITC/anti-
FITC amplification system (165). A comparison with the non-amplified assay showed
the FITC/anti-FITC amplification system produced an ELISA with a considerably
larger dynamic range enabling a better discrimination between positive and negative
results. The improvement in assay performance using the FITC/anti-FITC
amplification system is a result of using a second monoclonal antibody directed
against FITC, several molecules of which are conjugated to each RV MAB molecule.
This serves to enhance sensitivity. Also, since FITC is a molecule not found in
naturally occuring biological samples, it would not be involved in non specific
reactions involving other assay reagents so helping to improve assay specificity.
An alternative amplification system that could have been chosen was that which
employs the use of biotin and streptavidin conjugated reagents. The biotin-
streptavidin interaction has an extremely high affinity and has been used in a wide
variety of diagnostic tests. Whilst the use of a biotin-streptavidin system was a
feasible option, it was not chosen for three reasons (68):
• the FITC/anti-FITC system has been shown to have a similar sensitivity to the
biotin-streptavidin system.
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• labelling of antibodies with FITC is preferable to labelling with biotin. This is
because eluted fractions containing the FITC conjugate are highly coloured which
enables easy detection of the success or failure of the conjugation process. In
contrast the colourless protein fractions obtained after the biotinylation reaction
must be tested further to demonstrate the presence of a conjugate. The
fluorochrome content of a FITC conjugate can be determined simply by taking
optical density measurements at two wavelengths (28Onmand 49Srun).
• Studies show enzyme conjugated monoclonal anti-FITC antibody displays
extremely low non-specific binding (145). This enables the use of a high
concentration of labelled reagents and may contribute to the high sensitivity of
assays that employ the FITC/anti-FITC system.
The titration of RV haemagglutinin showed that the size of signal generated was
directly proportional to RV haemagglutinin concentration. The higher the
concentration ofRV haemagglutinin the stronger the resulting signal, most likely due
to the greater probability of an RV haemagglutinin molecule coming into contact and
binding with captured anti-RV IgG on the solid phase with increasing RV
haemagglutinin concentration. As the availability of this reagent was limited,
however, a compromise was made and the RV haemagglutinin used at a dilution of
1:10.
To determine optimal concentration of FITC conjugated RV MAB a titration was
performed using positive and negative serum controls in both the presence and
absence of RV haemagglutinin. The purpose of this experiment was to determine
whether the FITC conjugated RV MAB bound non-specifically either to anti-human
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IgG bound to the solid phase or to captured RV-IgG. Identical signals were obtained
at all FITC conjugated RV MAB dilutions for both the negative control serum in the
presence or absence of RV haemagglutinin and the positive control serum in the
absence of RV haemagglutinin. The signals were sufficiently low to demonstrate that
the FITC conjugated RV MAB did not bind non-specifically to other assay reagents.
In contrast, signals obtained using the positive control serum in the presence of RV
haemagglutinin were high and began to fall significantly only when the FITC
conjugated RV MAB was diluted in excess of 1:3000. Therefore a dilution of 1:2000
of the FITC conjugated RV MAB was chosen, just before the titration curve began to
fall away.
A titration of the anti-FITC HRPO conjugate enabled an optimal working dilution to
be determined (Fig.9). As for the optimisation of FITC conjugated RV MAB, the
experiment was designed to investigate non-specific binding to other assay reagents,
particularly to the RV haemagglutinin. The titration curve of the anti-FITC HRPO
conjugate in the absence of the FITC conjugated RV MAB showed the 004501620 to
decrease from 0.38 to 0.02 as it was diluted from 1:300 to 1:100,000. An 004501620
<0.1 was obtained only for dilutions greater than I: I0,000. These data suggested that
if used at dilution factors less than I: 10,000 the anti-FITC HRPO conjugate would
bind non-specifically to other assay reagents giving an unacceptably high signal.
Therefore a dilution factor of 1:18,000 was chosen for the anti-FITC HRPO
conjugate, the highest concentration that could be used without causing non-specific
binding.
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The experiment investigating variation of substrate incubation time showed that as the
substrate incubation time increased optical density readings increased for both
positive and negative control sera, the rate of increase of signal being greater for the
positive control serum compared to that of the negative control serum (Fig.I0). After
25 minutes optical density readings for the positive control serum did not appear to
increase. The difference between signals for the positive and negative control sera was
greatest after 25 minutes indicating this to be the substrate incubation time giving
maximum dynamic range for the assay.
In order to maximise assay sensitivity, incubating each stage of the assay stationary or
shaking on a plate shaker at 37°Cwas investigated (Table 16). The results show that
for the positive control serum and all dilutions of the WHO 80 IU/ml standard, with
the exception of the 0.625 IVlml dilution and for the negative control serum, OD4501620
values were higher when the microtitre plate was incubated shaking compared to
incubating the plate stationary. This difference was shown to be significant by
analysis of the logarithm of the OD4501620 values by paired t-test (p < 0.05). Incubating
the plate on a plate shaker therefore gave a wider dynamic range to the assay and
allowed a better discrimination between positive and negative results.
A reason for improved assay performance with incubation on a plate shaker is that it
is important to maximise contact between reagents already bound to the solid phase
and those in solution in order to get the highest positive signals. This can be achieved
in three ways. Either increasing the incubation temperature which increases the kinetic
energy imparted to each reagent molecule increasing the chances of complimentary
reagents meeting, increasing the surface area of the solid phase, or by shaking the
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microtitre plate. Since many of the reagents used are temperature sensitive the
incubation temperature used was optimised at 37°C which could not be exceeded
without risking damage to certain reagents. This temperature also represents
"physiological conditions" at which immunological reactions are optimal. As the
surface area of the wells of the microtitre plates could not be increased the objective
of maximising the chance of immunological reactions taking place between reagents
in solution and those bound to the solid phase in the assay was achieved by shaking
the microtitre plate on a plate shaker.
Assay evaluation
The performance of the amplified GACELISAwas compared to that of the previously
described GACRIA (144). The performance of both capture assays for oral fluid
testing was also assessed by examining matching serum samples using a sensitive
indirect ELISA (Behring) capable of detecting as little as 4 IV/ml of RV IgG. By
statistical analysis (kappa and rank correlation) for most of the individual serum/oral
fluid panels and overall, results from the oral fluid amplified GACELISA had a higher
level of agreement with the results of Behring ELISA on corresponding sera than oral
fluid GACRIA (Table 17). In addition, the overall sensitivity and specificity of the
oral fluid amplified GACELISA relative to the Behring serum assay was higher than
that of the GACRIA (Table 17).
With serum/oral fluid panels 1,2 and 3b (subjects ~ 10 years) results from the
amplified GACELISA compared favorably to the Behring serum ELISA with a
sensitivity of 94.4%, specificity and positive predictive value of 100% and a negative
predictive value of 85% and were similar to those obtained using GACRIA. By
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contrast, with panel 3a (an Indian population, subjects 2: 17 years) results from the
amplified GACELISA showed significantly better agreement with the serum Behring
ELISA than those from the GACRIA. Also, though both oral fluid assays showed a
low sensitivity compared to the serum assay with this panel, the sensitivity of the
amplified GACELISA (60.8%) was considerably higher than that of the GACRIA
(29.4%) (Table 17).
The reason for the low sensitivity of oral fluid assays with samples from panel 3a may
be due to the older age of the subjects providing samples for this panel and the type of
assay format used. Reactivity in antibody capture assays depends on the proportion of
antibody specific for the antigen under test. The proportion of IgG specific for RV
may decrease with age as a consequence of an increase in exposure to other antigens,
so may explain the lower sensitivity of capture assays for RV IgG in older subjects.
This is supported by the finding that the majority of paired samples giving discordant
(serum positive/oral fluid negative) results were from adults and of these the RV IgG
GMT of sera was significantly lower than the RV IgG GMT of sera from paired
samples giving concordant positive results.
Similar findings of the sensitivity of oral fluid RV IgG decreasing with age was made
by Nokes et al (129) using samples from urban and rural Ethiopian communities.
There is a need for further investigation of the factors affecting the performance of
oral fluid capture assays, particularly in respect to the lack of sensitivity in older age
groups. Since in this study the only oral fluid samples representative of an adult
populanon come from India, this issue may be addressed by further age stratified
studies using samples from both western and third world populations and could
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incorporate the detection of oral fluid IgG to viral antigens other than RV. More basic
investigations into the constituents of oral fluid and their affect on the performance of
virus specific antibody assays are also required. For example, a further important
consideration may be the local production ofIgG in oral fluid. Cutts et al (41) suggest
that increased local production of IgG in oral fluid may reduce the proportion of total
antibody that is specific and therefore lead to a decrease in reactivity in capture
assays.
The sensitivity, specificity and predictive values for amplified RV GACELISA (Table
17) have important implications for its use. In adult populations the sensitivity and
NPV of amplified GACELISA were low (though higher than those of GACRIA) and
there is thus a high probability of false negative results. This may compromise the
accurate identification of, for example, immunity in women of childbearing age which
is of prime importance when screening adult populations. For pediatric populations «
14 years), however, the sensitivity and predictive values of the amplified GACELISA
for oral fluid samples closely match those of the sensitive Behring serum ELISA. The
majority of susceptibles are found in this age group which represent the primary
transmission group for RV. The results suggest therefore that the amplified
GACELISA could be reliably used for the screening of children for immunity to RV.
The amplified GACELISA has now been successfully introduced for routine use with
oral fluid samples from the UK. rubella surveillance programme (152) where a high
proportion of oral fluid samples examined (92% in 1997; Dr M Ramsay, personal
communication) are from children under 14 years.
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RV IgG prevalence determined by testing oral fluid samples from a rural
Ethiopian population
The amplified RV GACELISA was used to screen 831 oral fluid samples for RV
specific IgG. All samples were collected using the Oracol device from subjects aged
between 0 and 84 years living in the rural district of Butajira in southern Ethiopia
(Fig. 3). A matching serum sample was obtained with each oral fluid and was
screened for RV specific IgG by Behring ELISA. The purpose of this part of the study
was to investigate the epidemiology of rubella in a rural Ethiopian population using
oral fluid samples, and to assess the performance of the amplified RV GACELISA as
an epidemiological tool.
The highest rate of aquisition of IgG antibody to rubella occurred in the 5-9 year old
age group (Fig. 12, Table 19). The majority of persons aged between 16 and 40 years
showed evidence of prior infection with RV suggesting that few women of
childbearing age are at risk from infection with rubella. The epidemiology of rubella
in an urban Ethiopian population from Addis Ababa described by Nokes et al (129)
showed a similar trend but there was a lower prevalence for persons aged 0-19 years
from the rural population. The highest rate of acquisition of rubella specific IgG
antibody from the urban population occurred in those aged 0-4 years. This difference
is not unexpected since rubella is an infection transmitted by the respiratory route and
so is more easily acquired at an earlier age by those living in an urban environment
where the concentration of population is more dense and contact of susceptibles with
infected individuals is more likely to occur.
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An analysis of results relative to Behring ELISA using serum samples showed the
amplified RV GACELISA had an overall sensitivity and specificity of 79% and 90%
respectively. The performance of the amplified RV GACELISA closely approached
that of Behring for the pediatric population. The sensitivity of the amplified RV
GACELISA decreased with increasing age of subjects and assay specificity did not
vary with age. These results accurately reflect the perfromance characteristics
observed using the age stratified serum-oral fluid panel used to evaluate the assay and
support the use of the amplified RV GACELISA as an epidemiological tool,
particularly for the screening of pediatric populations which contain the majority of
susceptible individuals.
The distribution of RV IgG GACELISA results for oral fluid samples (Fig. 14) from
the rural Ethiopian population is consistent with the evaluation of the assay in the
comparison with the Behring serum ELISA. The oral fluid assay performed well in
comparison to serum ELISA using samples from paediatric populations. This is
reflected in the distribution of results for subjects from the Ethiopian population aged
<20 years which showed a clear distinction between those positive and negative for
RV IgG. In contrast, the distribution of results for those aged >20 years from the
Ethiopian population is consistent with the poor sensitivity of the GACELISA in
comparison to Behring using samples from older subjects. Results from the serum
assay indicates that the majority (>95%) of subjects from the rural Ethiopian
population aged >20 years are positive for RV IgG. Therefore the distribution of oral
fluid results for these samples should, in theory, lie well to the right of the assay cut-
off. That, in practise, these results span the cut-off indicates the poor sensitivity of the
RV GACELISA using samples from older subjects. The overall performance of the
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RV GACELISA is also illustrated by the scatter graph (Fig. 14) where serum result is
plotted against matching oral fluid result for those samples collected from the rural
Ethiopian population. Results that fall in the bottom right section of the graph
represent false negative results generated by the GACELISA.
In summary, this assessment of amplified RV GACELISA showed it's performance to
be superior to that of the previously described GACRIA, with the advantage of a
substantially shorter running time in addition to all the benefits of a non-radioactive
assay. Although the oral fluid amplified RV GACELISA, like the GACRIA, was not
as sensitive as Behring ELISA for serum RV IgG particularly when testing samples
from adults, a sensitivity approaching that of the sensitive Behring serum test was
achieved when testing oral fluid from children. Moreover, as the amplified
GACELISA relative to serum ELISA correlated better and was overall more sensitive
than the RV GACRIA, it is a candidate assay for wider use in oral fluid testing.
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Anti-HBc GACELISA
The anti-HBc GACELISA was developed using experience gained when developing
the amplified RV GACELISA. There were, however, four constraints in developing
the anti-HBc GACELISA:
1. There was insufficient mouse anti-HBc monoclonal antibody available to develop
an assay using the FITC/anti-FITC amplification system as had been done with the
amplified RV GACELISA. The minimum practical amount of monoclonal
antibody required for conjugation with FITC is 6mg. Therefore assay development
was pursued using a detection system comprising the mouse anti-HBc monoclonal
antibody and an anti-mouse HRPO conjugate, a format shown to be less sensitive
than the amplified ELISA for the RV IgG assay.
2. During initial development of the assay there were no paired serum-oral fluid
samples available where the anti-HBc antibody status of the serum had previously
been determined, and only relatively few sera were available which were known to
be anti-HBc IgG positive. This presented difficulties when trying to evaluate the
performance of the assay, particularly when using oral fluid samples. An attempt to
overcome this problem was made by "simulating" oral fluid samples by diluting
sera by a factor of 1000 so producing a sample with a comparable concentation of
IgG to that found in undiluted oral fluid. Subsequently, the evaluation of the assay
was carried out using the panel of paired serum-oral fluid samples available from
subjects living in the Butajira region of southern Ethiopia.
3. When evaluating the amplified RV GACELISA the WHO 80-IU/ml standard was
used when determining assay sensitivity. No comparable standard exists for anti-
HBc so a quantitative estimate of assay sensitivity could not be determined.
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4. There is no universally accepted gold standard assay for anti-HBc serology. The
Hepanostika serum ELISA (Organon) used as a gold standard here does not give
quantitative results, unlike the Behring ELISA which was used for evaluating the
amplified RV GACELISA. Therefore since the manufacturers do not indicate that
results may be considered quantitatively and the Hepanostika serum ELISA is an
assay based on a one-step competative inhibition principle (Fig. 24), quantitative
comparison between Hepanostika and anti-HBc GACELISA (which uses an
antibody capture format) results was viewed with caution.
Figure 24: Hepanostika ELISA assay format (one-step competative inhibition
principle)
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Assay development and evaluadon
Reagent concentrations were optimised in a similar manner to that for the amplified
RV GACELISA. An initial titration of positive and negative control sera (Fig. 15)
showed that the optical density for the positive control serum decreased with
increasing dilution, with a strong signal still obtained at a dilution of 1:100,000. In
contrast, the optical density for the negative control serum remained at a constant
value of <0.1 until a dilution factor in excess of 1:30,000 was reached when the signal
began to rise. Therefore sera were tested at a dilution of 1:1000 and oral fluid tested
undiluted.
These observations suggested that when using samples that contained a particularly
low antibody concentration, as can be the case with oral fluid samples, the potential
exists for certain reagents to bind non-specifically to other assay reagents. Threfore
each reagent used during each stage of the assay was assessed for its potential to bind
non-specifically to previously added reagents and to therefore cause false positive
reactions. Experiments showed that the only reagent which bound non-specifically
was the anti-HBc monoclonal antibody, which bound to any unsaturated rabbit anti-
human IgG on the solid phase (Table 20). This phenomenon had previously been
encountered by Vyse et al (186) when developing an assay for detecting oral fluid IgG
antibody to Epstein Barr virus and was countered by including antibody negative
human sera (NHS) in the monoclonal antibody diluent. This saturated any available
rabbit anti-human IgG with antibody other than that specific for the virus that was the
target of the assay, so preventing the non-specific binding of the monoclonal antibody
without adversely affecting the resulting signal. Therefore S%NHS was included in
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the anti-HBc monoclonal antibody diluent and subsequent experiments showed that
this effectively prevented any non-specific binding (Table 21).
A titration of the rHBcAg against the positive control serum (Fig. 16) provided
information on the performance characteristics of the assay as well as assisting in
determining optimal rHBcAg concentration. The size of signal generated decreased
with increasing dilution of the positive control serum but only significantly so once
the dilution of the positive control serum had exceeded 1:30,000. These observations
suggested that the assay was sufficiently sensitive to detect the levels of virus specific
IgG expected in oral fluid. Further support that the anti-HBc GACELISA was
sufficiently sensitive for use with oral fluid samples was lent by the titration of oral
fluid samples obtained from two persons confirmed as anti-HBc antibody positive.
When tested undiluted both oral fluid samples gave a strong signal which decreased as
the oral fluid samples were diluted and signals were still strong enough to be
considered as positive at an oral fluid dilution of 1:32.
A preliminary evaluation suggested that, relative to the Hepanostika ELISA, the anti-
HBc GACELISA lacked sensitivity but was specific (Table 22). That 5 of 6 sera
testing positive by anti-HBc GACELISA still gave a positive result at high sample
dilutions indicated that the performance of the anti-HBc GACELISA may be
dependant upon the proportion of HBc IgG present in samples and the assay may only
be useful for screening those oral fluid samples containing a high proportion of anti-
HBc specific IgG. It should also be noted that the Hepanostika ELISA measures total
HBc antibody whilst the GACELISA is anti-HBc IgG specific. However, in the panel
screened, the majority of HBc antibody present was likely to be of the IgG class since
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they were not known to be from cases of recent, acute or chronic hepatitis B. Further
conclusions concerning the performance of the anti-HBc GACELISA with oral fluid
samples could not be made until the assay had been evaluated using a suitable panel
of paired serum-oral fluid samples.
An evaluation was performed using serum-oral fluid samples from Butajira. Of the
831 matched samples used for the rubella study previously described, 538 had
sufficient volume remaining to be screened for anti-HBc antibody. Sera were screened
using the Hepanostika ELISA (Organon) and the matching oral fluids screened using
the anti-HBc GACELISA. The use of this panel allowed not only an assessment of the
oral fluid anti-HBc GACELISA, but also permitted some analysis of the
epidemiology of HBV infection in a rural Ethiopian population.
The results from serum samples screened by Hepanostika ELISA showed that the
prevalence of anti-HBc increased with age from 22% in the group aged 0-4 years to
80% in those aged over 30 years (Fig. 20). These results illustrate the high prevalence
of HBV infection in African communities where approximately 8% are chronically
infected (100).
Relative to Hepanostika ELISA on serum, the anti-HBc GACELISA on
corresponding oral fluid samples (from Butajira) had an overall sensitivity and
specificity of 43% and 87% respectively, with a positive predictive value of 83% and
a negative predictive value of 50% (Table 24). An analysis of these results by age
group (Table 26) showed that, as for the amplified RV GACELISA, the sensitivity of
the anti-HBc GACELISA decreased with age. This is supported by the analysis shown
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in Fig.25 a satter graph plotting age of subject against the logarithm of anti-HBc
GACELISA result from oral fluid samples where the matching serum sample tested
positive for anti-HBc by Hepanostika ELISA. This shows the proportion of positive
results, particularly those in the upper limit of the dynamic range of the assay, to
decrease with age. Reasons for the decrease in sensitivity of the anti-HBc GACELISA
with increasing age of subject may be similar to those previously discussed for the
amplified RV GACELISA. However, the overall sensitivity of the anti-HBc
GACELISA was considerably lower than that of the amplified RV GACELISA, even
for samples from pediatric age groups.
Figure 25
Butajira study: analysis of oral f1uid* anti-HBc GACELISA
result by age
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The dynamic range of the anti-HBc GACELISA observed using the Butajira oral fluid
samples was wide, with OD450/620 values ranging from 0.034 to 4.767, and was
considerably greater than that observed for the amplified RV GACELISA. The anti-
160
HBc GACELISA. as with the amplified RV GACELISA and the majority of other
oral fluid assays described in the literature, was developed using an antibody capture
format and so measures the proportion of anti-HBc IgG antibody present in a sample
relative to the total IgG antibody present. The broad dynamic range seen when
screening the oral fluid samples from Butajira suggests that the anti-HBc IgG
antibody response varies considerably in individuals within this population, with
some individuals showing a particularly high proportion of total IgG to be anti-HBc
specific (100).
Of the 538 oral fluid samples from the Butajira study that were screened by anti-HBc
GACELISA, 48 (9%) gave a particularly strong signal (OD4S0/620 >1.0). An analysis by
age of these samples showed a high proportion amongst the younger age classes
(Table 27).
Table 27. The number of oral fluid samples with 00450/610 <1.0 and 00450/610 >1.0
by age group
Age group (years) 004SOl610 <1.0 004501610 >1.0 (0/0) TOTAL
0-4 38 6 (13.6) 44
5-9 74 12 (14.0) 86
10-19 143 10 (6.5) 153
20-29 40 7 (14.9) 47
30-49 115 9 (7.3) 124
50+ 74 4(5.1) 78
TOTAL 484 48 (9.0) 532
It is possible that samples with OD4S0/620 >1.0 came from persons recently infected
with HBV where the proportion of specific anti-HBc would be expected to be high.
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Further serology measuring HBsAg and anti-HBs would help to determine the status
of HBV infection in these cases but financial constraints and an insufficient volume of
serum remaining prevented this work being done.
The distribution of anti-HBc IgG GACELISA results for oral fluid samples from the
rural Ethiopian population (Fig. 21) is consistent with the low sensitivity of the assay
compared to that of the Hepanostika ELISA that was used for matching serum
samples. Overall, two distinct populations of results were found, one corresponding to
negative samples and another to strongly positive samples and this did not vary by age
group. Results using the Hepanostika ELISA on matching sera, which were
considered as the 'true' result for the purpose of this study, showed the prevalence of
anti-HBc antibody to increase with age from 20.5% in those aged 0-4 years to 78.2%
in those aged 50+ years (Table 25). Therefore this should be reflected in the age
stratified distribution of oral fluid results in Fig. 21. That no difference in the
distribution for corresponding oral fluid results was seen between the age groups
highlights the decrease in sensitivity with increasing age of subjects and demonstrates
that the assay performs most reliably in the younger age classes.
Further evidence of the relatively poor performance of the anti-HBc GACELISA in
comparison to Hepanostika is given by the scatter graph in Fig. 22 where GACELISA
results (log[OD4s0I62010.l50])were compared to corresponding serum results (%
inhibition). Whilst the manufacturers do not recommend such a quantitative
expression of results when using the Hepanostika ELISA, it does serve to illustrate
how individual results by each of the assays compare. The large proportion of results
which cluster in the bottom right hand section of the graph represent false negative
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results generated by the anti-HBc GACELISA whilst those in the top right hand
section represent false positives, demonstrating a lack of sensitivity and specificity.
The distribution of results with respect to the oral fluid assay also highlights the
difficulty in choosing a cut-off in contrast to that for the serum assay, where a clear
distinction can easily be made.
When evaluating the performance of the anti-HBc GACELISA with oral fluids
important considerations are the characteristics and format of the serum assay against
which the oral fluid assay is being compared. Assays that use a competitive principle,
such as Hepanostika anti-HBc Uni-Form ELISA, have been shown to give a clearer
distinction between positive and negative samples (197). They therefore tend to be
more specific than other assay formats commonly used in ELlSAs, such as the
indirect method. Since competitive assays are highly specific (139), they enable test
serum to be used undiluted or at a low dilution which enhances sensitivity with
samples containing only low levels of the antibody. The use of a competitive assay for
detecting anti-HBc in oral fluid samples was considered not suitable, since the
expected levels of anti-HBc would be considerably lower than that found in serum
and so would not be present in high enough concentrations to compete with the anti-
HBc conjugate.
Therefore, when evaluating the performance of the anti-HBc GACELISA with oral
fluid samples relative to that of Hepanostika with serum samples, the following points
should be taken into consideration:
• the Hepanostika assay measures total anti-HBc antibody whilst the anti-HBc
GACELISA measures only HBc specific IgG.
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• the competitive format used by Hepanostika, together with the use of undiluted test
serum, provides a level of sensitivity able to detect low levels of anti-HBc, such as
those present in a sample representing infection in the distant past. The anti-HBc
GACELISA was developed using an antibody capture principle, a format thought
to be that most appropriate for use with oral fluid samples, but which is not
necesssarily the most sensitive of assay formats for other sample types.
• There is no universally recognised "gold standard" assay for detecting anti-HBc
IgG.
An interesting follow up experiment would be to take serum samples which were
positive by Hepanostika but the corresponding oral fluid negative by GACELISA, and
rescreen the serum in the Hepanostika ELISA at a dilution factor of 1000 so the levels
of anti-HBc are equivalent to those found in undiluted oral fluid. This would help to
determine the limit of sensitivity of antibody capture assays with reference to the level
of specific antibody in serum. It may be that the level of antibody in individuals with
past infection can be detected in serum using suitable sensitive assays but cannot be
detected in oral fluid using the current technology available.
That the sensitivity of the anti-HBc GACELISA decreases with age of subject and
that the majoritory of oral fluid samples highly reactive were provided by persons in
the younger age classes is consistent with the the hypothesis that after infection with
HBV the initial anti-HBc response is very strong but decreases with time to a level not
always detectable in oral fluid by capture assays. Only by the use of sensitive
competitive assays where serum is added undiluted can anti-HBc be detected.
164
The performance of the anti-HBc GACELISA with 334 oral fluid samples collected
by salivette device was compared to that of the Murex ICE test which also uses a
capture format but detects total anti-HBc and can be adapted for use with oral fluid
samples. The results (Table 24) suggested there was little difference in performance
between the modified ICE and GACELISA tests. Moreover, it was not possible to
resolve discrepancies by testing with anti-HBc GACRIA, which has now been
superseded by the Murex ICE test as the method of choice for screening oral fluid
samples for anti-HBc in the Hepatitis and Retrovirus Laboratory, Central Public
Health Laboratory.
An interesting comparison between the performance of the Murex ICE test and anti-
HBc GACELISA with oral fluid samples can be made using the results of a study by
Nigatu et al (unpublished data 1996). Nigatu and colleagues collected 423 paired
serum and oral fluid samples from an urban population in Addis Ababa, Ethiopia. The
sera were screened for total anti-HBc using the Hepanostika ELISA and the matching
oral fluids tested for total anti-HBc using the Murex ICE ELISA. Analysis showed the
ICE ELISA to have an overall sensitivity and specificity of 36% and 92% respectively
compared to Hepanostika. The poor performance of ICE with these African samples
highlighted the need for an oral fluid assay with suitable performance charateristics
for use in developing countries where prevalence of HBV infection is high. The
results with the ICE ELISA were similar to those of the anti-HBc GACELISA relative
to Hepanostika (using samples from Butajira). The anti-HBc GACELISA had a
slightly higher sensitivity but lower specificity than ICE. However, unlike the anti-
HBc GACELISA, analysis of the ICE ELISA results did not show an age related
sensitivity effect. Therefore the performance of the anti-HBc GACELISA may be
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considered a minor improvement over ICE when screening oral fluid samples from
younger subjects from African populations.
The Murex ICE ELISA, however, has been shown to perform well using oral fluid
samples collected from intravenous drug users (IOUs) from Western European
populations. It has a high level of sensitivity and specificity relative to matching
serum samples tested by serum ELISA (N Parry, personal communication 1999), and
is currently the assay used for screening oral fluid samples for anti-HBc in the
Hepatitis and Retrovirus Laboratory, CPHL. The poorer assay performance seen when
using African samples may be related to the type of population used for the analysis.
Samples from IOU populations are likely to represent recent HBV infection where the
proportion of anti-HBc is high. Incontrast, the African study population also contains
persons with distant infection who thus have a much lower proportion of specific
antibody.
For epidemiological screening an oral fluid assay ideally requires a level of sensitivity
to be at least 90% relative to serum and a correction factor used to compensate for any
underestimate of prevalence. As the anti-HBc GACELISA currently stands it has only
limited used for epidemiological screening, even with the use of correction factors,
due to the low level of sensitivity relative to that of the reference serum assay. Unlike
the amplified RV ELISA, this was the case even for samples from pediatric groups
where performance of the assay was at its best. The assay appeared to perform
satisfactorily using oral fluid samples that contained a particularly high proportion of
anti-HBc antibody, possibly from persons with a recent HBV infection or those who
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may be carriers. The use of an FITC/anti-FITC amplification system could be
investigated to improve the level of sensitivity of the anti-HBc GAeELISA.
This work suggests that a successful anti-HBc ELISA that can be used with oral fluid
samples with a performance approaching that of recognised serum assays will be
difficult to achieve with the current ELISA technology available. Therefore further
work should focus upon the development of new and more sensitive detection systems
capable of producing a suitable signal even with only very low levels of the antibody.
Itwill be imperative that such systems have a high specificity, ideally 100%, to avoid
amplifying false positive reactions. It may be possible to pursue such a detection
system by coupling conventional ELISA techniques with polymerase chain reaction
(PCR) technology, producing an immuno-Pf'R. Such a technique has been described
(166) and made use of a streptavidin-protein A chimera which has a very tight and
specific binding affinity for biotin and IgG. This enables biotinylated DNA to be
attached to a MAB. The ELISA can therefore be carried out in a conventional manner
but, rather than use a detection system comprising an HRPO conjugated antibody and
a chromogenic substrate to produce a colourimetric signal, a monoclonal antibody was
used to which a piece of DNA is attached designed to contain specific primer sites
which are detected by a peR reaction. Nested peR reactions can be made sensitive
enough to detect a single copy of the target. In theory it should therefore be possible
for such a system to detect a single target antibody bound to the solid phase, though it
may not be as suitable for use in the field as a conventional ELISA for practical
reasons. In comparison to conventional ELISA, immuno-PCRs have been
demonstrated to improve sensitivity by a factor of 105 (123, 166). However, the
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technique has mostly been applied to the detection of antigen and has yet to be fully
investigated for antibody detection.
ROC analysis of RV GACELISA and anti-HBc GACELISA
ROC analysis (23) can be used to determine an appropriate cut-off for an assay. It
requires a population of samples to have been screened by both the assay under
consideration and by a gold standard assay so a "true" result is available. ROC
analysis is particularly useful for comparing assays. Mixture modelling (137) is an
alternative method which can also be used to set an assay cut-off and has the
advantage of not requiring a "true" result and is particularly useful for setting cut-off
values for screening assays. It was not used in this study as "true" results were
available for the samples screened.
The ROC curves generated for the two assays developed in this study showed that
neither performed close to "perfect" in comparison to the gold standard result
determined by commercial ELISA on matching serum samples as neither came close
to passing through the ideal point (Fig. 23). Of the two assays the RV GACELISA
performed better in this respect than the anti-HBc GACELISA. This observation
reflects the assessments made of the performance characteristics of each assay by
other criteria.
For both assays the flatness of the ROC curve around that region of the curve with a
gradient of 1.0 made it difficult to identify the precise location of the point that
represented the cut-off which gave the highest sensitivity and specificity with respect
to the gold standard results. Therefore an approximate region for this point was
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indicated (Fig. 23). That the cut-off chosen for the RV GACELISA during assay
development fell within this region suggests that this cut-off was satisfactory for use
of the RV GACELISA for determining population immunity. In contrast, the cut-off
chosen for the anti-HBc GACELISA did not fall close to the point which represented
the highest sensitivity with minimum effect on specificity, and erred on the side of a
higher specificity at the expense of sensitivity. This cut-off is therefore more
appropriate for an assay designed to be used for individual diagnosis rather than for
screening for population immunity. The ROC curve suggested that a cut-off OD4501620
of 0.1 (rather than 0.150) would provide the assay with highest combined sensitivity
(66.7%) and specificity (66.4%) for screening purposes.
This ROC analysis highlighted some of the pitfalls associated with choosing an assay
cut-off and demonstrated that the intended use of the assay is a prime consideration
influencing the approach taken when defining the cut-off. Techniques such as mixture
modelling or ROC analysis should be used to set cut-off values for assays intended for
diagnosis of immunity in the population as these techniques consider assay
performance using a population of interest and enable a cut-off to be set that ensures
maximum sensitivity and specificity. This means that the cut-off may have to be set
after the assay has been optimised and used for its intended purpose on a population
of study samples. In contrast the cut-off for assays designed for diagnosis in the
individual should be investigated using a carefully selected panel of well evaluated
samples where the true status is known as determined by a gold standard assay, and
the cut-off set to err on the side of higher specificity at the expense of sensitivity
before the assay is used. In such a situation it may therefore be appropriate to use the
signal from a population of negative samples and apply the mean plus two or three
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standard deviations as a method for setting the cut-off, particularly if the estimate for
the standard deviation is high.
Factors affecting the performance of oral fluid assays
The final part of this discussion focuses on the different performance characteristics
seen for the oral fluid assays developed both in this study and with others described in
the scientific literature, and considers the factors which may affect and influence assay
performance.
These investigations have illustrated the suitability of oral-fluid collection for large
scale epidemiological investigation of antibody prevalence to virus infections in rural
communities in developing countries. They have also highlighted the uses and
limitations of conventional ELISA systems with oral fluid samples which contain
only low levels of the specific antibody of interest compared to serum. Assay
sensitivity for both the amplified RV GACELISA and the anti-HBc GACELISA
decreased with time elapsed since original infection, assuming this to be proportional
to age. Whilst the agreement between serum and oral fluid was close for those aged
<20 years for rubella, agreement between serum and oral-fluid was poor across all age
groups using the anti-HBc GACELISA.
Subsequently, a GACELISA for the detection of measles specific IgG in oral fluid has
been developed (126). This was based on the FITC/anti-FITC amplification system
and was used to screen the same population of oral fluid samples from rural Ethiopia
as for the amplified RV GACELISA and anti-HBc GACELISA. In contrast to the
rubella and HBV assays, the agreement between serum and oral fluid for measles
170
specific IgG antibody was close for all ages, the overall sensitivity and specificity
being 97% and 93% respectively. Analysis showed that whilst measles antibody
levels were shown to decline with age for both serum and oral fluid, this did not occur
to such an extent as to effect the sensitivity of the oral fluid assay in contrast to those
for rubella and anti-HBc. A comparison of all three oral fluid assays therefore shows
considerable variation in performance characteristics, the measles assay performing
best followed by the amplified RV GACELISA and lastly the anti-HBc GACELISA.
The different performance characteristics seen for the three oral fluid assays may
simply be a reflection of the quality of reagents, in particular that of the antigen used.
However, an alternative explanation for the superior assay performance characteristics
observed for the measles GACELISA with oral fluid may be provided by a study of
nonclassic measles infections in an immune population exposed to a single index case
made by Helfand et al (70). The conclusions of this study are that mild/asymptomatic
measles infections are probably common, and may be the most common manifestation
of measles during outbreaks in highly immune populations. Infection with measles
virus under such circumstances has the effect of boosting the immune system and
maintaining a high proportion of neutralzing antibody. Therefore a measles antibody
capture assay designed for use with oral fluid samples may be expected to perform
well across the age spectrum, particularly when screening populations from
developing countries, such as those in rural Ethiopia, where there is a high level of
natural immunity, poor vaccination coverage, and regular epidemics of measles.
This leads to the hypothesis that the titre of neutralising antibody and performance of
an oral fluid assay may be related to the frequency which the immune system
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encounters the antigen in question. For viruses transmitted by the respiratory route,
such as measles and rubella, this might be estimated by measuring the basic
reproduction number <Ro) which is defined as the number of secondary cases of
infection generated by one primary infected host when introduced into a totally
susceptible population (2, 160). Infections with a high R, (and where a suitable
number of index cases occur within the population) are more likely to cause
mild/asymptomatic infections during outbreaks in highly immune populations. It can
be predicted that oral fluid capture assays for these virus infections would perform
well across the age spectrum. This hypothesis is supported by a comparison of the
performance characteristics for the oral fluid capture assays developed for measles,
rubella and anti-HBc and estimates of R, made for each of these virus infections for
the rural Ethiopian population studied (2, 192). Estimates for R, in an African
population show thatR,for measles is >R, for rubella which is >R, for HBV.
In addition, oral fluid assays for viruses causing persistent infection may perform well
across the age spectrum because the immune system encounters the virus every time it
reactivates from its latent state. This idea was supported by the development of a
successful oral fluid capture assay for IgG specific antibody to the viral capsid antigen
of EBV (186). For similar reasons oral fluid capture assays for specific IgG antibody
to antigens of HIV perform well. However, because of the high death rate following
HIV infection, the possibilities of observing the performance of such assays using
samples obtained 10 years or more after initial infection are limited.
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CONCLUSIONS
A major objective of this study was to develop simple, sensitive and robust ELISA-
based oral fluid antibody detection methods for rubella and anti-HBc IgG that can be
used to replace existing radioimmunoassay technology. They should be suitable for
use in both developing and developed countries, though the emphasis has been on
producing assays that were particularly amenable for use in basic laboratories in
developing countries. Ideally, both assays should be suitable for use in the field.
Whilst this objective has not been entirely met, the work has been valuable in
demonstrating some of the limitations in current ELISA technology available for
producing oral fluid assays with a comparable level of performance to serum ELISA.
It has also demonstrated the difficulties there are in setting the most suitable cut-off
for a screening assay.
Both the RV GACELISA and the anti-HBc GACELISA were relatively simple to
perform and less technically demanding than radioimmunoassay. In this respect both
are suitable for use in laboratories in developed countries and may be considered as
candidate assays for use in basic laboratories in developing countries. Possible
practical problems which may be encountered in transferring the assays to more basic
laboratories are the availability of reagents and the lack of equipment such as a plate
washer, ELISA plate reader and plate shaker/incubator. Whilst this equipment is
considered as standard in most laboratories in the developed world, it is relatively
expensive and requires regular maintenance and training to be used effectively. These
are requirements that are not often satisfactorily met in the developing world. Many
laboratories only possess a limited range of equipment that is often second hand or
considered as obsolete by western standards. Appropriate equipment and its
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maintenance are required if the RV GACELISA, anti-HBc GACELISA and similar
assays are to be used in laboratories in the developingworld. Iforal fluid assays are to
be used under field conditions considerable simplification is required. This will
involve making the assay running time significantly shorter (minutes rather than
hours) and eliminating the need for more complex laboratory equipment that requires
an electrical power supply. Perhaps the ideal oral fluid assay may consist of a "dip
stick" type test where appropriate reagents are immobilised on a solid phase which
can be dipped into a sample of oral fluid and the qualitative determination of specific
antibody made visually by the operator by the presence or absence of colour in a
matter of seconds. In this way a result could be provided "on the spot" and any
subsequent action needed regarding the administration of an appropriate vaccine acted
upon immediately.
Both the RV GACELISA and anti-HBc GACELISA lacked sensitivity compared to
serum ELISA, and the sensitivity of both assays was shown to decrease with
increasing age of subjects. Whilst the performance of the RV GACELISA was shown
to be an improvement over the existing radioimmunoassay (and could act as a
replacement assay) and performed particularly well with samples from paediatric
populations in comparison to serum ELISA, the performance of the anti-HBc
GACELISA was not considered good enough to warrant further use. Despite these
results, the subsequent development of a successful measles GACELISA (126)
suggests that it is possible to produce useful oral fluid assays using standard
techniques that are capable of performing well in comparison to serum ELISA.
However, the performance of the RV GACELISA and anti-HBc GACELISA indicate
that current limitations in ELISA technology need to be considered in conjunction
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with the biological characteristics of a micro-organism and the immune response
generated against it, before embarking on the development of further oral fluid assays.
This work has highlighted the need to develop a new generation of oral fluid assays
with a level of sensitivity high enough to reliably detect the low levels of specific
antibody that may be present in oral fluid samples, particularly those from subjects
where infection was in the distant past. One approach may be to use immuno-PCR
though a disadvantage of this method is that it is unlikely to be suitable for use in
basic laboratories.
The need to develop assays suitable for use on oral fluid rather than serum can be
related to the importance of an infectious disease, the availability of an effective
vaccine and the need to implement and monitor vaccination campaigns. These are
factors that will vary between countries and particularly between the developed and
developing world. To date almost all oral fluid assays described in the literature have
been specific to virus infections, with little research into those for detecting specific
antibody to bacterial or important parasitic antigens. The development of oral fluid
assays capable of detecting specific antibody against important bacterial infections,
particularly those for which a vaccine is available, is therefore an area which could be
investigated further. For example, a vaccine against meningococcus C is currently
being used in the UK in an attempt to help protect the population against
meningococcal infection (149). An oral fluid assay would therefore be useful for the
surveillance of meningitis C infection.
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APPENDIX2
2.1 Hepanostika anti-HBc Uni-Form
2.1a Reagent preparation
• Reagents should be at room temperature (15 - 30°C) before beginning the assay and
can remain at room temperature during testing.
• The foil pack containing micoelisa strips should be brought to room temperature
before opening.
• Check the phosphate buffer concentrate for the presence of salt crystals. If crystals
have formed in the solution resolubilize by warming at 37°C until crystals dissolve.
Dilute the phosphate buffer concentratel:25 with distilled water. Prepare at least
2Sml of buffer for each microelisa strip used and mix well before use.
• TMB substrate: combine the required amounts of TMB solution In a new
disposable vial in equal parts with urea peroxidase solution according to the
number of wells being run (see chart included with kit insert). Mix well. Protect the
TMB solution and TMB substrate from excessive light. TMB substrate must be
almost colourless when used.
• Sulphuric acid (analytical grade) must be prepared at a concentration of 1mol/l,
2.1b Test procedure
• Fit the stripplate with the required number of Microelisa strips.
• Pipette 100ul of each test sample into the wells. Pipette the controls after the
samples. Include three negative controls (100ul each) and three positive controls
(lOOul each) in each stripplate.
• Pipette SOul conjugate into each well with sample or control. Agitate (e.g. using a
micro shaker, speed approx. 900 rpm) for 15 seconds.
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• Incubate at 37°C for 90 minutes.
• Wash: aspirate the wells completely and fill completely with phosphate buffer and
allow to soak (30 - 60 seconds). Aspirate completely and repeat the wash and soak
procedure three additional times for a total of four washes.
• Pipette 100u1 TMB substrate into each well.
• Incubate at 15 - 30°C for 30 minutes.
• Stop the reaction by adding 100ul 1 molll sulphuric acid to each well.
• Read plate: blank reader on air (without stripplate) and read the absorbance of the
solution in the wells at 450 ±5 nm.
2.1c Results
• Calculations must be made separately for each stripplate (N = mean absorbance of
the negative controls; P = mean absorbance of the positive controls; S = mean
absorbance of the test sample).
• Elimination of outlying positive control values: before the test results are
determined, outliers in the values found for the negative and positive controls must
be eliminated:
1. Eliminate individual negative controls with an absorbance g 0.750
2. Eliminate individual positive controls with an absorbance > 0.300
3. Calculate Nand P
4. Eliminate individual negative controls with an absorbance < O.7N or> 1.3N
5. Recalculate N and repeat 4 if necessary
• Checking of test-run validity: a test-run is only valid if less than half the number of
controls have been eliminated and N - P ~ 0.500
• Calculatio of cut-off value: the cut-off value is 0.25(N+ 3P)
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• Test result: a test is positive if S .:::cut-off value; a test is negative if S > cut-off
value.
2.2 ICE HBc Detection Pack
2.2a Preparation
• Conjugate preparation: reconstitute a bottle of Conjugate with a single bottle of
Conjugate diluent. Mix well.
• Substrate solution: add a volume of colourless Substrate Diluent to an equal
volume of pink Substrate Concentrate (alternatively pour the entire contents of the
bottle of Substrate Diluent into the bottle of Substrate Concentrate, which provides
sufficient reagent for S plates).
• Wash Fluid: dilute the contents of one bottle of Wash Fluid to a final volume of
2S0Oml with distilled water.
• Stop Solution: prepare O.SM sulphuric acid (analytical grade).
2.2b Test Procedure
• Reconstitute and mix the conjugates and prepare the substrate solution.
• Use only the number of wells required for the test.
• Add 50ul of sample diluent to each well.
• Add 50ul of samples or controls to the wells. For each plate use the first column of
wells for the assay Controls. Add the Controls to the designated wells after
dispensing the samples. Pipette SOul of the Negative Control into each of three
wells Al to Cl and SOulofHbc Positive Control into wells Dl and El.
• Cover the wells with the lid and incubate for 30 minutes at 37°C.
• Wash plate: perform S wash cycles using working strength Wash Fluid ensuring
that:
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1. The 'fill volume' is 500ul/well
2. The 'dispense height' is set to completelyfill the well without causing an overflow.
3. The time taken to complete one aspirate/wash/soak cycle is approximately 30
seconds.
4. Wherepossible a 'double aspirate' step is used on thefinal cycle to ensure that no
liquid is left in the well.
• Add SOul conjugate to each well.
• Cover the wells with the lid and incubate for 60 minutes at 37°C.
• Wash as previously described.
• Add 100ul of substrate solution to each well.
• Cover the wells with the lid and incubate for 30 minutes at 37°C. Keep away from
direct sunlight.
• Add 50ul of Stop Solution (O.5M sulphuric acid).
• Read the absorbance at 450 nm using 620 nm to 690 nm as the reference. Blank the
instrument on air.
2.2c Quality Control
• Results of an assay are valid if the mean absorbance for the Negative Control is <
0.2, the mean absorbance for the Positive Control is more than 0.8 above the mean
absorbance of the Negative Control.
2.2d Results
• Each plate must be considered separately when calculating and interpreting results
of the assay.
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• Calculate the mean absorbance of the Negative Control. If one of the Negative
Control Wells has an absorbance of> 0.15 above the mean of all three discard that
value and calculate the new Negative Control mean from the two remaining
replicates.
• Cut-off Value: calculate the cut-off Value by adding 0.2 to the mean of the
Negative Control replicates .
• Samples giving an absorbance < the Cut-off Value are considered negative.
• Samples giving an absorbance 2: the Cut-off Value are initially considered reactive
in the assay. Such samples should be retested in duplicate using the original source.
Samples that are reactive in at least one of the duplicate retests are considered
repeatably reactive in the ICE HBc test and are presumed to contain antibodies to
HBc. Such samples should be investigated further. Samples that are non-reactive in
both wells on retest should be considered non-reactive for HBc antibodies.
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CHAPTER3
THE MOLECULAR EPIDEMIOLOGY OF
RUBELLA VIRUS USING RT-PCR, AND THE
ROLE OF ORAL FLUID IN THE
DETECTION OF VIRUS GENOME
Objectives:
• To develop a reverse transcription polymerase chain reaction (RT-PCR) assay
suitable for studying the molecular epidemiology of rubella and assisting with
diagnosis.
• To use the RT-PCR assay to study the molecular epidemiology of RV using
suitable specimens.
• To investigate the role of oral fluid as a suitable clinical specimen for the detection
of measles, mumps and rubella virus genome.
Introduction
To date there have been few studies investigating the molecular epidemiology of
rubella, in contrast to other vaccine preventable virus infections such as measles and
mumps. The work presented in this section of the study will contribute to the
understanding of the extent ofRV strain diversity.
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This study investigated the geographic and temporal distribution of RV strains that
were available using a reverse transcription polymerase chain reaction (RT-PCR)
assay designed to target a region of the El gene of RV. The El gene was chosen
because previous studies have shown that humoral responses are directed mainly
against the glycoprotein encoded by the El gene during RV infection. This therefore
indicates that the El gene product may be a site of antigenic variation (143)
suggesting that it may be interesting formolecular epidemiological studies ofRV.
The role of oral fluid samples for the detection of measles, mumps and rubella virus
genome was investigated. The extent to which oral fluid may be used in molecular
epidemiological studies of infections with these viruses was studied. This is of interest
as oral fluid is a clinical specimen with significant compliance advantages over other
types of specimen that are currently used which include throat swab, nasphyrangeal
aspirate, blood and urine. Measles, mumps and rubella were chosen for this part of the
study because they are all important vaccine preventable virus infections that are
transmitted by the respiratory route. The close proximity of the oral cavity to the
respiratory tract (which is a portal of entry and initial site of replication for respiratory
transmitted viruses) suggests that oral fluid is likely to be a suitable specimen for
genome detection and subsequent genotyping work for respiratory transmitted viruses.
This does not imply, however, that the use of oral fluid for the detection of virus
genome is exclusive to viruses transmitted by the respiratory route. It should also be
possible to detect in oral fluid the genome of any acute virus infection that gives rise
to a viraemia due to transudation of virus from the blood to the crevicular fluid. Other
viral genomes that have been detected in oral fluid by peR include HIV-1 (98),
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human T-Iymphotropic virus type 1 (HTLV-I) (I), hepatitis e (HeV) (83), hepatitis
G (HGV) (22), transfusion transmitted virus (TTV) (162), rabies (38), human herpes
viruses (HHV)-6, HHV-7, HHV-8 (99), Epstein-Barr virus (EBV) (78),
cytomegalovirus (eMV) (99) and herpes simplex virus type 1 (HSV-1) (176).
Practical aspects such as timing of oral fluid collection and storage of samples prior to
peR analysis were also investigated.
An outline plan of the study is shown in the flow chart (Figure 26).
igure 26: A plan of the study (chapter 3)
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MATERIALS AND METHODS
The development of an RT -peR assay for rubella virus:
Specimens
A total of 311 clinical specimens recieved at the Enteric, Respiratory and
Neurological Virus Laboratory (ERNVL) from suspected cases of rubella were used.
These included 49 serum samples and 200 oral fluid samples submitted for MMR
surveillance for screening for virus specific IgM antibody (111); and 41 throat swabs
(TS), 19 oral fluid samples and 2 foetal tissue samples (both obtained from
pregnancies terminated during the first trimester) collected specifically for RV RT-
PCR (Table 1). The standard laboratory strain (JUD-UK62) (57) grown in vero cells
was used as a positive control. Throat swabs, oral fluid samples and foetal tissue
collected specifically for PCR were stored at -70°C whilst sera and other oral fluid
samples, initially submitted for antibody testing for MMR surveillance, were stored at
-20°C. Oral fluid was collected and extracted from sterile foam swabs (Oracol,
Malvern Medical Developments, Worcester, United Kingdom) as described
previously (19).
RNA extraction
Total RNA was extracted from clinical specimens using the guanidinium thiocyanate-
silica method (16) as described by Jin et al (1996) (81). A detailed description of this
method is given in Appendix 3.1 (pp. 239-230). Before extraction, foetal tissue was
first homogenised in a Griffiths Grinder with Nuclease Free Water (Promega), the
tissue sample making up 10%of the final volume. This was followed by two cycles of
freeze thawing at -70°C.
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RT-PCR
eDNA synthesis
RNA was transcribed to cDNA using Moloney murine leukaemia virus reverse
transcriptase and random hexamers as primers as described by Jin et al (81). A
detailed description of this method is given in Appendix 3.1 (pp. 229-230).
Nested RT-PCR Development and Optimisation
After a series of experiments to optimise the nested RT-PCR performance, as
described below, the following procedure was used.
Nested RT-PCR used to amplify a region of the RV El gene
Specific primers were chosen for the nested RT-PCR to amplify a SS3nt region of the
El gene from a S80 nucleotide amplicon produced by a first round reaction. The first
round of PCR mixture contained 20u! of cDNA, lOpmo! each of primers RE1.la
(S'GTTCCATACAGAGACCAGGA) and RE1.2Ra
(S'ACTGGTAGCACCCGGTCACA), 200umol of deoxynucleoside triphosphates
(dNTPs), 4.0 U of Taqpolymerase (Life Technologies, UK), SuI of 10xPCR buffer
(Bioloine UK), I.Sul ofSOmMMgCl2 and made up to SOulwith Nuclease Free Water
(promega). PCR mixture was then overlaid with one drop of light mineral oil. The
PCR cycle used was an initial denaturation for 2 min at 9SoCfollowed by 2S cycles of
1 min at 9SoC, 1.Smin at SSoC,and 2 min at ire. For nested (n) PCR, IOul of the
first round product was added to 25pmol each of primers REI.3 (S'
ACCGTCTGGCAACTCTCCGT) and REI.4R (S'
ACCCGGTCACACGCACATTG), 200umol of deoxynuc1eoside triphosphates
(dNTPs), 4.0 U of Taqpolymerase (Life Technologies, UK), SuI of lOxPCR buffer
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(Bioloine UK), 1.5ul of50mM MgCl2 and made up to 50ul with Nuclease Free Water
(Promega). After an initial denaturation for 2 min at 95°C, 30 cycles of 1 min at 95°C,
1.5 min at 57.5°C, and 2 min at 72°C were used. 10ul of the nPCR product was
analysed on a 2% agarose gel and visualised by ethidium bromide staining.
Primer design
The oligonucleotide primers used in this work were designed for determining the
nucleotide sequences of a region of the El gene of rubella and were based on
published sequence data available in the Genbank. Their design followed some of the
recommendations of Saiki (163) and Compton (30), though the limited sequence data
available for rubella and high GC content of the rubella genome made this difficult.
Each primer sequence was selected within a conserved region of the El gene, and the
region each primer pair encompassed was designed to be variable. Each primer was
20 nucleotides in length with base compositions that ranged from 50-60% GC. Ideally
base compositions should be in the range of 35-55% GC. However, it was not always
possible to achieve this due to the particularly high GC content of the rubella genome.
All the primers were synthesized by Cruachem Ltd.
Primer concentration
To determine optimal primer concentration the first round primers were used at
concentrations of 2.5 pmol/ul, 5 pmol/ul and 10 pmol/ul in conjunction with second
round primers at concentrations of 5 pmol/ul, 10 pmol/ul, 15 pmol/ul, 20 pmol/ul and
25 pmol/ul using the positive control (JUD-UK62) grown in vero cells.
Annealing temperature
An optimal annealing temperature for the nested RT-PCR was determined using a
temperature gradient consisting of 10 separate temperatures using a Mastercycler
Gradient thermocycler (Eppendorf), and the RT-PCR performed using cDNA
prepared from the positive control. The temperature gradient used ranged from 55.5°C
to 74.8°C for the first round reaction, and from 57.5°C to 76.7°C for the second round
reaction.
A dilution series of the positive control from 10-1 to 10-8, prepared in Nuclease Free
Water (Promega), was used to examine three annealing temperatures in more detail.
For the first round reaction annealing temperatures of 55.5°C, 63.4°C and 73.6°C were
chosen, and for the second round temperatures of 57.5°C, 65.4°C and 75.5°C.
The primers REl.la and REl.2Ra were used at a concentration of 10 pmol/ul and
REl.3 and REl.4R used at 25 pmol/ul for these experiments.
Sensitivity of the nested RT-peR
Once the final conditions of the assay had been optimised, the sensitivity of the nested
RT-PCR was assessed in serial dilutions containing estimated copy numbers of cloned
first round peR amplicon, as follows.
The first round PCR product from an oral fluid specimen strongly positive for RV
RNA was cloned using the TOPO kit (Invitrogen) according to the manufacturers
instructions. Briefly, the first round product was incubated at 72°C for 10 minutes. 2
ul of product, I ul of cloning vector and 2ul nuclease free water (Promega) were
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gently mixed, left to stand at room temperature for 5 minutes and then placed on ice,
after which 2ul was added to a vial of competent cells with 2ul of O.5M
Bmercaptoethanol. This was incubated on ice for 30 minutes and the cells then "heat
shocked" for 30 seconds at 42°C without shaking. This was then incubated on ice for
2 minutes after which 2S0ul of SOC medium (2% Tryptone, 0.5% Yeast Extract,
10mM NaCI, 2.SmM KCI, 10mM MgCI2, 10mM MgS04, 20mM glucose) added and
the mixture incubated shaking at 37°C for 30 minutes. 100ul was then spread evenly
across an agar plate containing 50ug/ml ampicillin and incubated overnight at 37°C.
Using a sterile loop, culture from colonies was added to 50ul ofPCR mix. After single
round PCR using the outer set of primers the presence of the cloned 580 nt RV
amplicon was demonstrated by electrophoresis and visualisation of the correct size
band on a 2% agarose gel. A detailed method is described in Appendix 3.2 (pp. 230-
232).
A clone containing the 580 nt RV amplicon was grown overnight at 37°C in Sml L-
broth containing SOug/ml ampicillin and purified using a combination of reagents
from the Quiagen (Quiagen Ltd, Crawley, UK) and Gene-Clean (Bio 101 Inc., USA)
kits. In brief, cells were lysed and washed using the buffers from the Quiagen kit and
the DNA purified using the "glass milk" (silica matrix) and "New Wash" (a solution
of NaCI, Tris, EDTA, ethanol and water designed to maintain a pH of 7.0-8.S) from
the Gene-Clean kit (Bio 101 Inc., USA). An estimation of the copies/ul present was
made by measuring the absorbance at 260nm (A260) given that 1 A260 represents
50ug/ml DNA, that the length of the vector plus the insert is 4.480 kb and that a single
copy of lkb dsDNA weighs 6.S x io' daltons (=1.08 x 10-12 ug). Amplification by
nested RT -PCR of a dilution series containing cloned copies of the lst round product
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ranging from 0 to 2 x 109 in the 20ul volumes added to the first round reaction enabled
an estimate of the sensitivity of the nested RT-PCR to be determined by
electrophoresis and visualisation of the second round product on a 2% agarose gel
after ethidium bromide staining.
TOPO-Cloning exploits the ligation activity of topoisomerase. Since ligation of the
vector with a PCR product containing 3' A overhangs is very efficient and occurs
spontaneously within 5 minutes at room temperature (169), the manufacturers
estimate the efficiency of the kit to be -95%. The calculations used therefore assume
that there is one copy of the inserted RV amplicon per copy of the plasmid.
Specificity of the nested RT -peR
The specificity of the nested RT-PCR was determined by testing specimens
containing other single stranded RNA viruses including hepatitis C virus (HCV),
measles virus and polio virus (cDNA was tested) and specimens containing the rash
causing DNA viruses parvovirus B 19 and human herpes virus 6 (HHV -6).
HCV cDNA was provided by the Hepatitis and Retrovirus Laboratory (HRL), Central
Public Health Laboratory (CPHL). Polio cDNA was provided by the Gastroenteritis
Unit, ERNVL, CPHL. Measles virus eDNA, parvovirus B 19 DNA and HHV -6 DNA
were provided by the Immunisation and Diagnosis Unit, ERNVL, CPHL.
"Hot start" technique
Platinum Taq (Pt Taq) DNA polymerase is a recombinant Taq which is complexed
with a proprietary antibody which inhibits activity. Pt Taq is provided in an inactive
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form and is blocked at ambient temperatures but activity is regained after
denaturization at 94°C.This is a "hot start" technique (87) and can help improve PCR
specificity by reducing the production of non-specific amplicons.
To evaluate the "hot start" technique RT-PCR was performed using two reaction
mixes, one containing 4.0 U of Taq DNA polymerase and the other 4.0 U of Pt Taq
DNA polymerase.
Optiprime kit
The Stratagene Opti-Prime PCR Optimisation kit was used in an attempt to improve
RT-PCR performance, particularly specificity, using a range of buffers and adjuncts
(an incidental component that may be added to any of the buffers used to improve the
specificity and/or increase the yield of the desired amplicon). A detailed method is
described in Appendix 3.5 (pp. 235-236).
Optimal buffer determination - Twelve buffers were available in the Stratagene Opti-
Prime PCR Optimisation kit. Each was used including MgCl2 at concentrations of
1.5mM and 3.5mM and KCI at concentrations of 25mM and 75mM. The pH of
reaction mixes ranged from 8.3 to 9.2.
Adjuncts - Six adjuncts were included in the first and second round PCR reaction
mixes. These included 5ul fonnamide, 2.5ul DMSO, 7.5ul glycerol, luI 750mM
(NH4)2S04, 3ul 1.5mglml BSA and 0.5ul (=0.5U) Perfect Match DNA Polymerase
Enhancer (a commercial product produced by Stratagene which destabilises
mismatched primer-template complexes and helps to remove secondary structures
which could impede normal extension). The positive control (JUD- UK62) was used
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for each adjunct investigated and as a control the positive control (JUD- UK62) was
included using the optimised RT-PCR conditions as previously described.
Nucleotide sequence determination
The nested RT-PCR products were excised from agarose gels, purified using a Gene-
Clean Kit according to the manufacturers instructions (Bio 101 Inc., USA) and
sequenced directly using the internal primers for the RT-PCR. A detailed method for
using the Gene-Clean Kit is described in Appendix 3.3 (pp.232-233).
The nucleotide sequences were determined using the Taq DyeDeoxy-terminator cycle
sequencing kit (Applied Biosystems) with the forward and reverse primers for the
nested PCR (REl.3 and REl.4R) used at a concentration of 3.2pmol/ul. A detailed
method is described in Appendix 3.4 (p. 234). The 2' ,3' -dideoxynucleoside
triphosphates are telogens, nucleotides which cause chain termination because they
lack a 3' hydroxyl group for extension. The dideoxynucleotides used are labelled with
fluorescent dyes. Four dyes are used, one for each base, and each emitts a different
wavelength of light. Four sequencing reactions are carried out in parallel, each of
Which generates nested fragments ending at a defined base and differing in length in
steps of a single nucleotide. The side-by-side electrophoresis of these reactions allows
the sequence to be read directly from the electrophoresis gel (183).
Computer analysis
Nucleotide sequences were analysed with the SeqEd version 1.0.3 program. A
phylogenetic tree was constructed using PAUP 4 Neighbour joining software with
1000 bootsraps. Bootstraping is a technique for estimating the variance and the bias of
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an estimator by repeatedly drawing random samples with replacement from the
observations at hand (91).
RV antibody detection
Oral fluid or serum samples were tested for RV specific IgM antibody by antibody
capture radioimmunoassay as previously described (144). Results were expressed as a
test:negative ratio (T:N) and specimens considered reactive for RV IgM if they gave a
T:N greater than 3.0. All serological testing of sera and oral fluid samples used in this
part of the study was carried out by staff of the Immunisaton and Diagnosis Unit,
ERNVL, CPHL and the results kindly made available.
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Investigating oral fluid as a specimen for detecting virus genome
This section of the study was designed to investigate the extent to which oral fluid
specimens may be used for detecting virus genome. This involved comparing the
results of oral fluid samples subjected to measles, mumps and rubella RT-PCR
collected from patients with clinical or serological evidence of these infections at
different intervals after the onset of symptoms.
A total of 1047 oral fluid samples were used in this part of the study. All were
collected using the Oracol device (Malvern Medical Developments) and oral fluid
extracted as previously described (19). All oral fluid samples were collected as part of
the MMR surveillance programme in the UK (62, 63, 111) and had previously been
screened for IgM to either measles, mumps or rubella (144) with the exception of 55
which were obtained specifically for measles RT-PCR and 26 specifically for rubella
RT-PCR. These samples were collected from patients with clinical evidence of these
infections, from a rural district of Ethiopia and a Thessaloniki in northern Greece
respectively (kindly provided by Professor V. Kyriazopoulou-Dalaina). They were
cryopreserved and only made available for virus specific IgM testing after they had
been screened by RT-PCR. All other samples were stored at -20°C and had been
subjected to at least one freeze/thaw cycle prior to being used for RT-PCR testing.
The period, in days, between onset of symptoms and timing of sample collection was
recorded and the samples classified into categories of 0-7 days, 8-14 days or > 14 days
after onset of symptoms. A "not known" category was used to classify samples where
the date of onset or date of sample collection had not been recorded.
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Virus genome was extracted using the guanidinium thiocyanate-silica method as
described by Boom et al (16) and reverse transcribed to produce cDNA as previously
described (81) using the method described in Appendix 3.1. The 553 nucleotide
region of the El gene of the rubella virus genome was then amplified by nested RT-
peR as previously described, and regions of the measles (N and M) and mumps (SH)
genes amplified by specific nested RT-peR as described by Jin et al (79,81) Detailed
methods are described in Appendix 3.6 and 3.7 (pp. 237-238). All three RT-peR
methods produce second round amplicons of a size suitable for both diagnosis and
molecular epidemiology. The second round amplicons were visualised by staining
with ethidium bromide after electrophoresis on a 2% agarose gel, and results
classified as positive or negative depending upon the presence or absence of the
appropriate sized bands. The results of mealses and mumps nested RT-peR assays
were kindly provided by Dr Li lin (Immunisation and Diagnosis Unit, Enteric,
Respiratory and Neurological Virus Laboratory, ePHL), the laboratory work having
been carried out by Mr Stuart Beard and Mr Rashpal Hunjan (also of the
Immunisation and Diagnosis Unit). The analysis ofRT-peR results in relation to the
timing of sample collection was subsequently carried out in this study.
Statistical Methods
Logistic regression was used to compare rates of detection of measles, mumps and
rubella virus genome with time after onset of symptoms (5).
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RESULTS
The development of a PCR assay suitable for the molecular epidemiology of RV
and assisting with diagnosis
RT-PCR optimisation
The results of varying the concentrations of both the first and second round primers
are shown in Table 28 and Fig. 27.
Table 28. nested RT -peR result with varying primer concentration
1st round primer 2nd round primer cone. (pmol/ul)
cone. (pmol/ul) S 10 IS 20 2S
2.S NEG [1]* NEG [2] NEG [3] POS [4] POS [S]
S NEG [6] NEG [7] POS [8] POS [9] POS [10]
10 POS [11] POS [12] POS [13] POS [14] POS [IS]
*[ _] refers to gel lane number in Fig. 27
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Figure 27: 2% Agarose gel of nested RT-PCR products produced with varying
primer concentration (see Table 28)
...
Gel lane number .gr-------------------------------~ ~
.0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ~
*The larger of the two products seen is the 553 nt RV specific amplicon
The results showed that the lower the first round primer concentration the higher the
second round primer concentration needed to successfully amplify the target and
produce a positive result. Therefore a first round and second round primer
concentration of 10 pmol/ul and 25 pmol/ul respectively was chosen. At these
concentrations primers were present in excess and primer concentration was not a
limiting factor in RT-PCR sensitivity. These concentrations have also been
successfully used for measles and mumps RT-PCR (79,81).
Annealing Temperatures
Tables 29, 30, and Fig. 28 show the effect of altering the annealing temperatures for
both the first and second round nested RT-peR reactions.
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Table 29. Gel lane and corresponding annealing temperature (see Fig. 28)
Gel Lane ANNEALING TEMPERATURE (OC)
lst round 2nd round
1
2
3
4
5
6
7
8
9
10
11 (1 kb ladder)
55.5
56.5
58.3
60.7
63.4
66.3
69.1
71.6
73.6
74.8
57.5
58.5
60.3
62.7
65.4
68.3
71.1
73.6
75.5
76.7
Figure 28: RT-PCR result and corresponding annealing temperature (see Table
29)
Gel lane number
1 2 3 4 5 6 7 8 9 10 11
- -U-U· U·-----·-·-O
U .... _li~~---;;
* The larger of the two products seen is the 553 nt RV specific amplicon
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Table 30. Nested RT-PCR result at three annealing temperatures for a dilution
series of the positive control.
Dilution of POS Annealing temperatures (,C) : lst round [2nd round]
control
55.5 [57.5] 63.4 (65.4] 73.6 (75.5]
10-1 POS POS POS
10-1 POS POS POS
10-3 POS POS NEG
10-4 POS POS NEG
10-5 POS NEG NEG
10-6 NEG NEG NEG
10-7 POS NEG NEG
10-8 NEG NEG NEG
These results showed that RT -PCR sensitivity was highest using annealing
temperatures of 55.5°C and 57.5°C for the first and second round reactions
respectively.
Sensitivity of the nested RT-PCR
The sensitivity of the nested RT -PCR was assessed by testing the cloned first round
PCR amplicon at dilutions containing estimated copy numbers from 2x 109 to 2x 10-3
copies. The nested RT-PCR was able to detect rubella genome in dilutions containing
between 1 and 10 copies of target (Table 31, Fig. 29).
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Figure 29: Sensitivity of the nested RT-PCR
estimated copies/zoul
No rubella genome was detected by the RT-PCR in the dilution estimated to contain
20 copies of rubella genome in the 20ul added to the first round reaction, though
genome was detected in that estimated to contain 2 copies. This may be a result of
poor preparation of the original dilution series or innaccurate pipetting when
transfering target at this particular concentration to the first round reaction which
could result in no copies of the genome being transfered to the first round reaction and
therefore give a negative result. Alternatively, this may be due to the probability that
no copies are transfered when small volumes that only contain a very low
concentration of the target at the end point of the dilution series are transfered by
pipetting.
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Specificity of the nested RT-PCR
The specificity of the rubella nested RT-peR was established by testing specimens
containing genome of other rash causing virus infections (parvovirus B19, measles
and HHV-6 ) and those containing cDNA from polio virus and HeV, both of which
possess a single stranded positive sense RNA genome with Hev having a similar
genomic organisation to that of RV. No cDNA or DNA molecules were amplified
(results not shown).
Two of the 219 oral fluid samples tested by RT- peR produced an amplicon of weak
intensity that could not be visually distinguished in size from the 553 nucleotide
rubella specific amplicon produced by the nested reaction, though no specific rubella
gene sequence was identified (Fig 30). The presence of amplicons other than the 553
nucleotide rubella specific amplicon produced by the nested reaction, in particular one
approximately 350 nucleotides in size (Fig 30), were also seen with a large proportion
of the samples. These were later confirmed to be parts of human genome by direct
sequencing.
Hot start - No improvement in the nested RT-peR specificity was observed when
comparing Pt Taq DNA polymerase and Taq DNA polymerase (results not shown).
Stratagene Opti-Prime PCR Optimisation kit - No improvement in nested RT-peR
specificity was observed by using any of the buffers or adjucts included in the
Stratagene Opti-Prime peR Optimisation kit (results not shown).
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RT -peR detection of RV genome in clinical specimens
All 49 serum samples and 214/219 oral fluid samples were positive for RV specific
IgM, indicating recent infection. Of the five oral fluid samples which were RV IgM
negative, four were positive by nested RT-peR and all five were collected :s 2 days
after the onset of symptoms.
The proportion all samples peR positive for RV RNA are shown in Table 31.
Table 31. Samples tested by peR for RV RNA
Specimen Collection purpose Total RT-PCR Period: onset of symptoms to
POS(%) saml!le collection {where known)
n mean range
{da~s) {dars)
Serum Antibody detection 49 6 (12.2)
Saliva Antibody detection 200 14 (7) 147 20.1 1-56
Saliva RT-PCR 19 13 (68.4) 19 5.1 1-12
Throat RT-PCR 41 26 (63.4) 32 4.1 0-13
swab
Foetal RT-PCR 2 2 (100)
Tissue
TOTAL 311 61 {l9.6)
The results obtained from the four different types of specimen used in this study
which were oral fluid, serum, throat swab, and foetal tissue are illustrated in Fig. 30.
The non specific bands of 350 and 553 nucleotides in size were described above.
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Figure 30: Agarose gel analysis ofRV RT-PCR products from a range of clinical
specimens
553nt ---+
350nt ---+
Of 49 sera and 200 oral fluid samples originally collected for antibody detection,
12.2% and 7% respectively were positive by RT-PCR, as were 13/19 (68.4%) oral
fluid samples collected specifically for RT-PCR (Table 31). Overall 12.3% oral fluid
samples were positive by RT-PCR. A total of 26 (63.4%) throat swabs and 2 (100%)
foetal tissue samples were positive by RT-PCR. The geographical location of
representative samples is listed in Table 32.
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Table 32. Origin of samples directly sequenced
Strain name' City/province Country Year Specimen
(OB/Spor)! collected type
Sy2CHN99 Shenyang city China (Spor) 1999 Throat swab
Sy7CHN99 Shenyang city China (Spor) 1999 Throat swab
Thes1 GRE99 Thessaloniki Greece (OB) 1999 Oral fluid
Thes2GRE99 Thessaloniki Greece (OB) 1999 Oral fluid
Thes3GRE99 Thessaloniki Greece (OB) 1999 Throat swab
Thes4GRE99 Thessaloniki Greece (OB) 1999 Throat swab
Thes5GRE99 Thessaloniki Greece (OB) 1999 Throat swab
Lon2UK96 London UK (OB) 1996 Oral fluid
BStEdlUK96 Bury St Edmunds UK (OB) 1996 Oral fluid
BstEd2UK96 Bury St Edmunds UK (OB) 1996 Oral fluid
DurUK96 Durham UK (OB) 1996 Oral fluid
AberdlUK99 Aberdeen UK (Spor) 1999 Oral fluid
Aberd2UK99 Aberdeen UK (Spor) 1999 Oral fluid
Col IUK99 Colchester UK (Spor) 1999 Oral fluid
Col4UK99 Colchester UK (Spor) 1999 Oral fluid
SalUK99 Salford UK (Spor) 1999 Oral fluid
LonUK99 London UK (Spor) 1999 Oral fluid
ShropUK99 Shropshire UK (Spor) 1999 Oral fluid
Lon1 tUK99-CRS3 London UK (Spor) 1999 Foetal tissue (Foetus)
Lon ImUK99-CRS3 London UK (Spor) 1999 Serum (Mother)
Man2tUK99-CRS3 Manchester UK (Spor) 1999 Foetal tissue (Foetus)
Hj1CHN94 Heilong jiang prov. China (Spor) 1994 Serum
Hj2CHN94 Heilong jiang prov. China (Spor) 1994 Serum
Hj3CHN94 Heilong jiang prov. China (Spor) 1994 Serum
Sy114CHN98 Shenyang city China (Spor) 1998 Serum
Lon IUK96 London UK (OB) 1996 Oral fluid
NyorkUK96 North Yorkshire UK (OB) 1996 Oral fluid
RioiBRAZ99 Rio de Janiero Brazil (Spor) 1999 Serum
I __ (City/proYince)_(sample no.) __ (Country)_(Year collected); 2 OB = outbreak,
Spor = sporadic case; 3congenital rubella
The interval between onset of symptoms and sample collection was recorded for 147
of the 200 oral fluid specimens originally submitted for antibody detection, for 32 of
41 throat swabs and for all 19 oral fluid specimens specifically collected for RT-PCR
(Table 32). For the 147 oral fluid samples originally submitted for antibody detection
the mean period between onset of symptoms and sample collection was 20.1 days,
ranging from 1 to 56 days, whilst for the 19 oral fluid specimens collected for RT-
PCR the mean period between onset of symptoms and sample collection was 5.1 days,
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ranging from 1 to 12 days. For the 32 throat swabs the mean period between onset of
symptoms and sample collection was 4.1 days, ranging from 0 to 13 days.
Genetic characterisation of RV strains
Of the 61 samples that were positive by RT-PCR, 28 were directly sequenced using
the internal primers for the nested PCR reaction. The geographical location and other
relevant information is listed in Table 32. Figure 31 shows a phylogenetic tree with 28
sequences from samples used in this study and 24 sequences from previously reported
data (57).
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Figure 31: Genetic relationship between rubella virus strains used in this study
and previously reported strains
Europe 1978·93
J.pan,US
1990.97 MTS·IA66(V)
• ~.US96
/' ~~IA90
O.G!
0.1
*Circled strains were used in this study. The numbers indicate bootstrap values
x = genetic distance
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The samples used in this study clustered to form three branches on the phylogenetic
tree. Those clustered on Branch 1 consisted of 14 samples from the UK collected in
1996/99, 5 samples from Greece collected during an outbreak in 1998/99 and two
sporadic cases from China obtained in 1999. Branch 2 consisted of 4 samples from
sporadic cases that occured in China in 1994/98. Two strains obtained in the UK in
1996 (LonlUK96 and NyorkUK96) were grouped on Branch 3. The strain obtained
from a sporadic case in Rio de Janiero, Brazil, in 1999 (RioIBRAZ99), is similar to
those from the branch previously described as Europe 1978-93 by Frey et al (57).
The greatest divergence in nucleotide sequence, 12.0%, was seen when comparing
strain RioiBRAZ99 (Europe 1978-93) from this study to the BASlnd95 strain
(Genotype II) isolated in India in 1995 (17, 57). The single sequence analysed from
China collected in 1998 (Sy114CH98) was more closely related to the three isolates
collected in China in 1994 (Branch 2) than to those isolated in 1999 (Branch 1), which
had very similar nucleotide sequences to those from Europe obtained in 1996 and
1999 grouped on Branch 1. Sequences analysed from European strains obtained in
1999 forming part of Branch 1 showed little divergence in nucleotide sequence,
differences ranging from 0.2% - 1.6%. The majority of samples from the UK in 1996
used in this study also showed little difference in nucleotide sequence compared to
those from the UK in 1999 (0.2 - 2.6%). However, the two samples collected in 1996
that formed Branch 3 - Lonl UK96 and NyorkUK96 - were more closely related to the
standard laboratory strain (JUD-UK62) isolated in Liverpool in 1962 with a 0.4%
difference in nucleotide sequence than to others from 1996, from which they showed a
2.0 - 3.8% difference in nucleotide sequence.
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The El gene encodes 412 amino acids and the RT-PCR assay described amplifies a
region encoding 171 of these, from amino acid 171 to 342 (25). Of the samples
analysed by direct sequencing in this study, the maximum number of amino acid
changes observed compared to the concensus sequence was three (1.8%), with no
more than a single amino acid change being observed between amino acids 214-285.
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Oral fluid as a specimen for detecting virus genome
A total of 1047 oral fluid samples tested by RT-PCR for measles, mumps and rubella
were analysed in this study and the results for each virus relative to time of sample
collection are shown in Table 33.
Measles
A total of 448 oral fluid samples were screened for measles virus genome and were
categorised into those previously tested for specific IgM for surveillance and those
which were collected specifically for RT-PCR from persons with symptoms of
measles. These were mostly obtained within 7 days of the onset of symptoms (Table
33). Of 393 oral fluid samples previously tested for antibody, all contained measles
specific IgM and the period between collection of sample and onset of symptoms was
known for 293 (74.6%). Measles virus genome was detected in 53.8%, 40.3% and
20.7% of those collected in the first week, second week and after the second week of
onset of symptoms respectively. Of 55 oral fluid samples collected specifically for
RT -PCR from patients clinically diagnosed as having acute measles infection, 54
were collected during the first week after onset of symptoms with measles virus
genome being detected in 52 (96.3%). Measles virus genome was also detected in the
single oral fluid sample collected in the second week after the onset of symptoms.
Mumps
Of 354 oral fluid samples screened for mumps virus genome, the period between
collection of sample and onset of symptoms was known for 305 (86.2%). Mumps
virus genome was detected in 68.7%, 20% and 1.6% of those collected in the first
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week, second week and later than two weeks after the onset of symptoms respectively.
All samples had previously been tested for antibody and all contained mumps specific
IgM.
Rubella
A total of 245 oral fluid samples were tested for rubella virus genome. As for measles,
these samples were categorised into those previously tested for specific antibody for
surveillance and those which were collected specifically for RT-PCR from persons
with symptoms of rubella. Of the 219 oral fluid samples previously tested for
antibody, rubella specific IgM was detected in 214 (98%) and the period between
collection of sample and onset of symptoms was known for 156 (71.2%). Rubella
virus genome was detected in 41.7%, 4.2% and 2.8% of those collected in the first
week, second week and after the second week of onset of symptoms respectively. Of a
total of 26 oral fluid samples specifically collected for RT -PCR from patients
clinically diagnosed as having acute rubella, virus genome was detected in 75% of
those collected within a week of the onset of symptoms and in 30% of those collected
in the second week after the onset of symptoms.
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Table 33. Analysis of measles, mumps and rubella RT-PCR results by time from
onset of clinical symptoms on 1047 oral fluid samples from serologically and
clinically confirmed cases
Virus Collection RT-PCR Days after onset (% +ve) TOTAL
purpose Result
0-7 8-14 >14 Not
Known
Antibody Positive 28 (53.8) 27 (40.3) 36 (20.7) 19 (19) 110 (28)
detection Negative 24 40 138 81 283
TOTAL 52 67 174 100 393
Measles
RT-PCR Positive 52 (96.3) 1 (100) 53 (96.4)
Negative 2 0 2
TOTAL 54 1 55
Mumps
Antibody
detection
Positive
Negative
TOTAL
46 (68.7) 11 (20.0)
21 44
67 55
3 (1.6)
180
183
4 (8.2)
45
49
64 (18.1)
290
354
Antibody Positive 10 (41.7) 1 (4.2) 3 (2.8) 2 (3.2) 16 (7.3)
detection Negative 14 23 105 61 203
TOTAL 24 24 108 63 219
Rubella
RT-PCR Positive 12 (75.0) 3 (30.0) 15 (57.7)
Negative 4 7 11
TOTAL 16 10 26
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DISCUSSION
The development of a RT-peR assay suitable for molecular epidemiology and
assisting with RV diagnosis
The aim of this aspect of the study was to develop a RT-peR assay that is useful for
diagnostic purposes and which also allows subsequent sequencing of the amplicons
for epidemiological comparisons of different RV strains. PCR primers were selected
from the El gene because humoral responses are directed mainly against the El
glycoprotein. El is more exposed than E2 and studies with monoclonal antibodies
showing that neutralizing epitopes reside mainly on El (56, 86, 114, 195). A region of
the El gene was selected which is sufficiently conserved so that all known genotypes
would be detected but is also suitable for distinguishing between different genotypes.
The primers encompassed a region which codes for amino acids 245-285 that have
been shown to be antigenically important (56). The nested product was designed to be
of sufficient length (553nt) to provide useful sequence data.
PCR assays have been described previously for detecting RV RNA (18, 155, 175).
However, their application for genetic characterisation has been limited as most had
been specifically designed for diagnostic purposes. To date there have been three
other studies analyzing RV sequences, both targeting the entire El gene. The first was
described by Bosma et al and used 22 rubella virus isolates from Europe, USA and
Asia obtained between 1963-1995 (17).That described by Katow et al (86) used
samples from three east Asian countries whilst Frey et al (57) conducted a more
extensive study of the molecular epidemiology of RV using samples from the
continents of North America, Europe and Asia collected between 1961 and 1997.
Their results suggested that two genotypes existed with nucleotide sequences that
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differed from each other by 8% - 10%. However, no major antigenic variation was
observed and only a small proportion of those RV strains sequenced were categorised
as genotype II.
The primers used in this study successfully amplified the cDNA target sequence of the
control RV RNA (JUD-UK62 strain) and of some clinical specimens. Experiments
showed the nested RT-PCR assay was most sensitive when using annealing
temperatures of 55.5°C and 57.5°C respectively for the first and secound round
reactions. The assay detected between 1 and 10 copies of target (Fig. 29, Table 31).
This level of sensitivity is similar to that described by RT-PCR assays for other virus
infections (18, 81).
The specificity of the assay was assessed using samples containing genome of other
rash causing virus infections (parvovirus B19, measles, HHV-6) and those containing
cDNA from polio and HCV. No amplicon was produced from these samples
suggesting that the RV RT-PCR assay is not subject to cross reaction. However, two
of the 311 clinical specimens used in this study produced an amplicon which appeared
visually to be similar in size to that of the positive control by gel detection (Fig. 30).
An explanation for this may be the unusually high proportion of guanosine and
cytidine found in the rubella genome (69.5%), a phenomenon common to the human
genome and a feature which makes the design of appropriate rubella primer sites
difficult. In clinical samples, such as oral fluid specimens and tissue samples in
particular, it is likely that human genome will also be present. The primers may
therefore bind to and amplify certain regions of the human genome and in some cases
produce an amplicon of similar size to that of the desired nested product. This idea
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was supported by an internet blast search of the rubella primer sequences used in this
study in comparison with all available genome sequences. The primers showed a
homology of >90% with certain regions of the human genome. Further evidence was
provided by direct sequencing of the amplicon approximately 350 nucleotides in
length, often seen migrating further than the 553 nucleotide rubella specific amplicon
produced by the nested reaction (Fig. 30). Sequence analysis, in combination with a
blast search on the internet, showed it to match a region of the human genome.
Furthermore, none of the extensive range of buffers or adjuncts provided with the
Stratagene Opti-Prime PCR Optimisation kit improved the specificity of the RT-PCR
and no improvement was seen by employing a hot start technique. However,
amplicons that appear to be true positives can be confirmed by direct sequencing but
this approach is not cost effective. An alternative method could involve hybridisation
of amplicons with a RV specific probe. However, for this method to be feasible more
extensive sequence data is required for RV to enable the design of an appropriate
probe that is useable with all strains ofRV.
It might be possible to improve the specificity of the RT-PCR by increasing the
annealing temperatures for both the first and second round reaction because primer
sequences bind to their complementary target sequence with a specificity that
increases with temperature. The major problem with this approach is that sensitivity
decreases with increasing annealing temperature so such a solution should be viewed
with caution.
All serum samples and the majority of oral fluid specimens (214/219 [98%]) used in
this study showed serological evidence of recent RV infection by the presence of
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specific IgM. Of five oral fluid samples which did not contain RV specific IgM, RV
genome was detected in four and all five were collected ::s 2 days after the onset of
symptoms. This suggests that when these samples were collected sufficient time had
not elapsed for a suitable IgM reponse to have been mounted (69). The fifth oral fluid
sample which did not contain RV specific IgM and in which RV genome was not
detected may represent a case that was wrongly diagnosed as rubella, or the virus
genome may have degenerated due to either cycles of freeze-thawing or being kept for
a period at an inapproprate temperature (as described below).
Although not comprehensively investigated, some useful information about suitable
samples for RV RT-PCR was identified. In discussing this it is useful to divide the
samples into two categories: those that were collected specifically for RV RT-PCR
and those used first for RV IgM tests and only then made available for RV RT-PCR.
Those collected specifically for the purpose ofRV RT-PCR were cryopreserved at -
70°C until required for testing whilst samples obtained for RV IgM tests were stored
at -20°C and had been subjected to at least one cycle of freeze-thawing before being
tested by RV RT-PCR.
A proportion of oral fluid samples used (9%) and all throat swabs were collected and
cryopreserved specifically for RT-PCR at -70°Cuntil required for testing. These were
found to be the most reliable specimens for detecting RV RNA by PCR. This may
reflect the fact that these samples were stored under conditions most likely to preseve
virus genome and had not been subjected to cycles of freeze-thawing for other
laboratory tests prior to RT-PCR. In contrast to these samples, all sera and the
majority of oral fluid samples (91%) were collected for RV IgM testing and had
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therefore been subjected to cycles of freeze-thawing before becoming available for
RT-PCR. They were also stored at -20°C, a temperature which may be less efficient
than cryopreservation at -70°C for preserving virus genome. RNA is a very labile
molecule and prone to the degradative effects of any nucleases - such as ribonuclease
(RNase) - that may be present in clinical samples. Coupled to freeze-thawing, this is
likely to reduce the likelihood of detecting RV genome in a sample. This is supported
by the observation that of those oral fluid samples collected specifically for RT -PCR
from suspected cases of rubella, 13/19 (68.4%) were positive for RV genome by PCR
in contrast to 14/200 (7%) of those previously used for RV IgM testing (Table 24).
Therefore storage temperature and cycles of freeze-thawing are factors which may be
effecting the likelihood of detecting RV genome in a sample by nested RT-PCR and
should be investigated further.
A third consideration is the period between onset of disease and sample collection.
The detection rate was shown to decline with increasing time between onset and
sampling (Table 32). For instance, oral fluid samples originally obtained for RV IgM
testing were collected a mean of 20.1 days after the onset of symptoms (range 1-56
days) and only 7% were RT-PCR positive. In contrast, oral fluids and throat swabs
obtained specifically for RT-PCR were collected a mean of 5.1 (range 1-12 days) and
4.1 days (range 0-13 days) respectively after the onset of symptoms and 68.4% and
63.4% were RT-PCR positive. Therefore, it is possible that the length of period
between onset of disease and sample collection may be proportional to the likelihood
of detection of RV genome. Reasons for this observation and the suitability and extent
to which oral fluid specimens may be used for detecting RV genome and other virus
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genomes - particularly in relation to the timing of their collection - is discussed in
detail later (pp. 223-228).
These data therefore suggest that if appropriately collected and stored, oral fluid is a
suitable non-invasive specimen to use for RV RT-PCR. Further types of specimen
should also be investigated for the detection of RV RNA and include urines and
nasopharyngeal aspirates (NPA).
Foetal tissue from two pregnancies terminated due to suspected CRS, were positive by
RV RT-PCR and confirmed by direct sequencing. This suggests that the assay
described here may be useful for the diagnosis of CRS. The assay, however, needs to
be more fully evaluated using amniotic fluid or chorionic villus samples from
suspected cases of CRS if it is to be used for pre-natal diagnosis.
Genetic analysis of RV strains
The most extensive study of the phylogeny ofRV to date was carried out by Frey et al
in 1998 (57) using specimens collected from North America, Europe and Asia
between 1961-1997. Two genotypes were described (Genotype I and II). A proportion
of those categorised as Genotype I were classified into three branches that were
geographically and chronologically distinct (57). The divergence seen between
Genotype I and II ranged from 8.1% to 12%. The divergence between the three
branches identified within Genotype I (57) ranged from 2.8% to 6.5%.
In the present study, 61 specimens collected between 1994 and 1999were positive for
RV RNA by RT-peR. For the purpose of epidemiological investigation 28
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representative specimens from each country included in the study were analysed by
nucleotide sequencing. All 28 were classified as Genotype I and clustered on a
phylogenetic tree to form at least three new branches when compared with previously
reported strains (Fig. 31). Strains grouped on branch 1 showed a divergence ranging
from 2.0% to 7.0% compared to others classified as Genotype I, and from 8.6% to
10.8% to strains classified as Genotype II (57). Strains grouped on branch 2 showed a
divergence ranging from 3.0% to 7.3% in comparison to others classified as
Genotype I, and from 9.3% to 11.8% to those classified as Genotype II (57). Two
strains obtained in the UK in 1996 (LonIUK96 and NyorkUK96), grouped on Branch
3, and were most closely related (0.4% divergent) to the standard laboratory strain
isolated in Liverpool, UK, in 1962 (JUD-UK62) (57). This suggested that RV strains
in Branch 3 may represent an indigenous strain that has been circulating in the UK
since the early 1960s. The Brazilian strain investigated in this study, RiolBRAZ99,
was most closely related (4.9% - 5.8% divergent) to previously reported strains
obtained from Europe in 1978-93 that formed a separate branch of Genotype I (57)
(Fig. 32). This strain could be the result of an importation into Brazil. It was the only
strain from this study to be clearly classified in a previously reported branch. A
further strain collected in the UK in 1996 (Lon2UK96) could not be classified on any
existing branches and the degree of divergence (1.8% - 5.9%) from all other strains of
Genotype I suggested that it may form an additional branch if similar strains are
identified. The results of this study therefore suggest that it may be possible to group
and classify RV strains further than has previously been described.
The last resurgence of RV infection in the UK occurred in 1996 (111). The majority
of confirmed cases were young adult males who had never been offered rubella
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vaccine and outbreaks occured nationwide, especially in residential establishments
such as university campuses (111). That RV sequences analysed in samples collected
from the UK during this period were grouped in two branches of the phylogenetic tree
(Branch I and Branch 3) and that a further strain (Lon2UK96) may form a new branch
suggests that more than one strain of RV was circulating in this outbreak. There was
little difference in nucleotide sequence (0.4 - 1.8%) for RV sequences analysed from
Greece and the UK collected in 1999. Cases of rubella reported in the UK during 1999
are likely to be the result of importations from the outbreak which occured in Greece
during 1998/99 (136, 154) since the majority of confirmed cases were university
students who were Greek or had contact or connections with Greek students (181,
188). The two samples from sporadic cases in China (Sy2CH99, Sy7CH99) obtained
in 1999 also had a very similar nucleotide sequence (1.0% - 2.0%) to those circulating
in the UK and Greece at this time and may therefore be the result of an importation
from Europe.
Very little difference in the ammo acid composition derived from nucleotide
sequences - particularly between amino acids 214 to 285 - was found for the samples
analysed. This suggests that RV is not prone to major antigenic variation within the
El gene and supports the findings of other studies (57, 86) that there is little or no
antigenic variation within the El gene. Explanations for the small amount of sequence
variation within the region of the El gene studied may be that it is assisting the virus
to optimise its replication. Alternatively, the small amount of variation seen may be
due to errors that occur during RNA replication (56).
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This study highlights the need for further work using specimens from areas of the
world that are as yet unsampled such as Africa, Eastern Europe and Australia. this
needs to be supplemented with further isolates from those regions that are currently
under represented including South America, India, and China. This will help
determine the geographic extent of RV strain variation and whether other genotypes
exist. Sequencing the entire RV genome from a variety of strains will also confirm
which genomic region is most suitable to target for molecular epidemiological studies.
220
The role of oral fluid as a clinical specimen for detecting virus genome
The suitability of oral fluid for the detection of virus genome was investigated to a
limited extent for RV in the work described in the previous section of this chapter on
the development of the RV specific RT-PCR. In this section, the role and usefulness
of oral fluid for the detection of virus genome is described more extensively for
measles and mumps as well as for rubella. However, as mentioned in the introduction
to this part of the study, this work is not exclusive to measles, mumps and rubella and
could be extended to include other virus infections since a range of viruses have been
detected in oral fluid (1, 22, 38, 78, 83, 98, 99, 162, 176).
In interpreting the relationship between measles, mumps and rubella RT -PCR results
and time from onset of clinical symptoms it was assumed that all samples were
obtained from cases correctly diagnosed as measles, mumps or rubella. That 966/1047
(92%) of the oral samples were shown to contain either measles, mumps or rubella
specific IgM and had therefore been collected from persons who had recently been
infected by these diseases supports this assumption. The remaining 81 (8%) samples
were collected from persons who were clinically diagnosed as having acute measles or
rubella, and whilst serological data was not available on all these samples, measles or
rubella genome was detected in 68 (84%) samples suggesting the diagnoses were
reliable.
The analysis performed in this study has shown that meales, mumps and rubella virus
genome can be reliably detected in oral fluid samples by RT-PCR from patients with
evidence of recent infection. The most important factor affecting the success of this
approach was the timing of sample collection since viral RNA levels decline after the
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onset of disease. The results (Table 34) indicated that RT-PCR can detect viral
genome in acute oral fluid specimens collected for early diagnosis whereas viral JgM
may not be detectable until several days after onset of symptoms, the optimal timing
of collection for this purpose being two to three weeks after onset of symptoms (69).
There are several reasons why measles, mumps and rubella virus may be detected in
oral fluid. The close proximity of the oral cavity to the respiratory tract may
contribute, the respiratory tract being a portal of entry and initial site of replication for
all three viruses before spreading to lymph nodes, subsequent viraemia and spread to
other tissues. Once viraemia has been established it is also possible that there may be
transudation of virus from the blood to the crevicular fluid via the capillary beds in the
gingival crevice. Characteristic symptoms of measles and mumps infection are
associated with the oral cavity and this may also contribute to the presence of the
virus at this site. Measles virus has been cultured from the mouth and Koplik's spots,
visible on the buccal mucosa, often coincide with the first symptoms of disease (67).
Swelling of the salivary glands (parotitis) is a common feature of mumps infection
and suggests that mumps virus may invade and be shed from these glands (194).
Factors which lead to the decline in viral RNA levels after the onset of disease include
virus clearance by the immune system and RNA degeneration. The length of the
period between onset of disease and sample collection is proportional to the extent of
the immune response mounted by the host to clear the virus and thus inversely
proportional to the amount of virus present. Since this is a biological phenomenon
important for the limitation of disease it is not therefore surprising that the likelihood
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of detecting each virus genome was shown to decrease as the period between onset of
symptoms and sample collection increased.
It is well established that RNA is a labile molecule and is decayed by such
degradative nucleases as ribonuclease (RNase) which are likely to be present in oral
fluid and may be human, bacterial or viral in origin (125). Therefore it is likely that
the period between onset of disease and sample collection will be inversely
proportional to the amount of virus genome present. This argument can be extended to
include the handling of samples prior to RT-PCR. Subjecting an oral fluid sample to
cycles of freeze thawing for other laboratory purposes such as antibody detection proir
to RT-PCR, is likely to increase virus genome exposure to any RNase that may be
present in the sample The likelihood of detecting virus genome is decreased because
enzyme activity is increased at room temperature compared to _20DC or -70DC. This is
illustrated by a comparison of results with samples collected specifically for measles
and rubella RT-PCR with those first screened for virus antibody for surveillance, virus
genome being detected in a considerably higher proportion of oral fluid samples
collected specifically for RT-PCR. Further experiments need to be carried out to
investigate more precisely the effect of cycles of freeze-thawing and loss of target
RNA. This could involve "spiking" oral fluid samples with rubella virus and then
subjecting them to a range of cycles of freeze-thawing before RT-PCR is carried out.
Therefore, if oral fluid specimens are to be used for the detection of virus genome it is
preferable to collect them specifically for this purpose followed by appropriate storage
rather than referring to samples which have been previously subjected to other
laboratory tests.
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Analysis of results (Table 34) from samples originally collected for MMR
surveillance within a week of the onset of symptoms showed the percentage of oral
fluid samples in which genome was detected was highest for mumps (68.7%),
followed by measles (53.8%) with the lowest percentage for rubella (41.7%). The
most likely explanation why the percentage of oral fluid samples collected 0-7 days
after onset of symptoms in which virus genome was detected was highest for mumps
virus is that viral load in the oral cavity is highest for mumps. This is suggested by the
characteristic swelling of the salivary glands with mumps infection and that mumps
virus is also actively shed in oral fluid for up to 6 days before the onset of clinical
disease (194). Other considerations include the comparative stability of the three
viruses and the sensitivity of the three peR detection assays.
Analysis of results from samples collected more than 7 days after onset of symptoms
(Table 34) shows the percentage of oral fluid samples in which genome was detected
decreased for each virus, though the proportion in which measles virus genome was
detected was considerably higher than for mumps and rubella, especially when
considering those samples collected >14 days after onset of symptoms. The
proportion in which rubella virus genome was detected was particularly low for those
samples collected >7 days after the onset of symptoms. Logistic regression analysis
showed the difference in the detection of measles genome compared to mumps or
rubella with time after onset of symptoms was significant (p < 0.001).
In attempting to explain these observations the incubation period of each virus
infection must be considered spanning the time from exposure to the appearance of
disease. All samples collected for this study were obtained after the onset of
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symptoms. The incubation period of measles is 10-14 days, -18 days for mumps and
16-21 days for rubella (67, 194, 195). Therefore once symptoms become evident, the
immune system will have had greater opportunity to react and clear mumps and
rubella virus in comparison to measles virus, particularly for those samples collected
>7 days after onset of symptoms. Once symptoms of rubella become evident the
entire clinical syndrome clears rapidly over several days (195) which is consistent
with the low proportion of samples collected >7 days after the onset of symptoms in
which rubella genome was detected. It may also be possible that a longer lasting
viraemia occurs with measles than mumps or rubella, and that the immune system
may take longer to clear measles virus.
Finally, the differences in terms of the proportion in which each virus genome could
be detected as collection time increased after the onset of symptoms, may reflect
protection afforded to the virus genome from degradative enzymes and the effects of
freeze-thawing by the capsid and envelope. Results in this study suggest that the
measles virus genome may be better protected in this respect than that of mumps and
rubella. This may be determined by the extent to which enzymes which degrade
nucleic acid are able to penetrate the capsid or how exposed or near the capsid surface
the viral RNA is. Alternatively, viral RNA may form an important structural
component of the capsid for those viruses where the genome is more easily degraded
which may be the case for rubella (56).
In conclusion, this and other studies (29, 80) have shown that oral fluid can be used
for the detection of measles, mumps and rubella virus genome and subsequently be
useful for both the diagnosis and the molecular epidemiology of each of these virus
225
infections. This represents an important new application for the use of oral fluids in
infectious disease testing. Apart from a few studies in which HBsAg was detected in
saliva (21, 26, 146, 158), oral fluids have mainly been used for the detection of virus
specific antibody (82, 119, 120, 139-141, 144, 157, 186, 187). The work described
here shows that oral fluid can also be used to detect and characterise virus genomes.
It is of practical significance that oral fluid specimens should be collected soon after
the onset of clinical symptoms, ideally within a week, stored at -70°C and subjected to
as few cycles of freeze-thawing as possible prior to RT-PCR assay. Measles, mumps
and rubella virus genome was detected in oral fluid samples collected more than 14
days after onset of symptoms, though the likelihood of doing so was greatly reduced,
particularly for rubella and mumps. Oral fluid samples are a safe and practical
alternative to other types of clinical specimen for detecting measles, mumps and
rubella virus genome. Coupled to the compliance advantages for collector and
convenience to the patient, this procedure has potential to gather much interesting data
on the genetic variation of viruses.
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CONCLUSIONS
The work described in this part of the study focused on the development of aRT-PeR
assay for rubella which enabled the molecular epidemiology of the virus to be
investigated. A knowledge of molecular epidemiology can be used:
• to investigate transmission patterns
• to assess and measure the effectiveness of control strategies
• to link or unlink outbreaks and assist in the analysis of severe or unusual cases
This information augments that provided by serological studies to give a more
complete understanding of the epidemiology of important vaccine preventable
infectious diseases.
The RT-peR assay developed was designed to be useful for both clinical diagnosis
and the molecular epidemiology of rubella virus. This enabled the assay to be used to
assist in the rapid diagnosis of suspected cases of congenital rubella syndrome. To
date there have been few studies investigating the molecular epidemiology of rubella.
Whilst the current understanding of the molecular epidemiology of rubella is far from
complete, the application of the RT-peR to the genetic characterisation of rubella
virus strains in this study has contributed to the understanding of how the virus varies
geographically, in identifying strains of the virus recently circulating in Europe and in
demonstrating that it is possible to classify RV further than has previously been
described.
The final part of this study focused on technical aspects of using oral fluid samples for
molecular studies. It was demonstrated that in addition to being used for antibody
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detection, oral fluid is also a viable clinical specimen to use for the detection and
amplification of virus genome and particularly useful for early diagnosis of measles
and mumps as well as rubella virus infections. The timing of sample collection and
subsequent storage was shown to be critical. For optimal PCR results samples should
be collected within 14 days of the onset of symptoms and stored at least at -20°Cprior
to testing. The use of samples for other laboratory purposes (such as antibody
detection) and subsequent cycles of freeze thawing prior to RT-PCR was associated
with a decreased rate of detecting virus genome, though further work is required to
investigate this in detail.
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APPENDIX3
3.1 Nucleic acid extraction and R T-PCRfor cDNA synthesis
3.1a "Boom extraction" (silica method)
• 860ul L6 (Severn Biotech Ltd, Cat. No. 20-8600) and 40ul silica (Severn Biotech
Ltd, Cat. No. 20-8000) are added to 100ul specimen and the mixture vortexed for
10 seconds and kept at room temperature for 10 minutes (mix or vortex every 2-3
minutes).
• The mixture is centrifuged for 15 seconds and the supernatant discarded.
• The silica pellet is washed twice with L2 (Severn Biotech Ltd, Cat. No. 20-8200),
twice with 70% ethanol and once with 100% acetone (lml wash solution, vortex
briefly, centrifuge for 15 seconds and discard supernatant).
• The silica pellet is dried at 56°C with an open lid for 10 minutes.
• Add 59ul of Nuclease-free water (Promega) and lul of RNA sin (Promega), vortex,
and incubate for 10 minutes at 56°C and overnight at 4°C.
• Centrifuge for 2 minutes and take 40ul of the supernatant for RT-PCR for cDNA
synthesis.
3.1b RT-PCRfor cDNA synthesis
• 60ul of the following reaction mixture is added to 40ul of extracted RNA:
REAGENT
lOul
3ul
2ul
2ul
lul
lul
41ul
VOLUME
lOx PCR buffer*
50mMMgC12*
10mMdNTPs*
Reverse Transcriptase (200U/ul)*
RNAsin (40U/ul)**
pd(N 6) [" random primers" ]*
Nuclease-free water**
TOTAL 60ul
*Gmco BRL, ** Promega (Promega Corporation 608-274-4330 Madison, WI
53711-5399 USA)
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• The reaction mixture is incubated at room temperature for 10 minutes, at 37°C for 1
hour, at 95°C for 5 minutes and cooled on ice for 3 minutes.
• The synthesized cDNA is then stored at -20°C or used for PCR.
3.2 TOPO TA Cloning Kit
3.la Preparation
• For each transformation one vial of competent cells and one selective plate is
needed.
• Equilibrate a water bath to 42°C.
• Thaw the vial of SOC medium from Box 2 and bring to room temperature.
• Warm LB plates containing 50 ug/ml ampicillin OR 50 ug/ml kanamycin at 37°C
for 30 minutes.
• Spread 40 ul of 40 mg/ml X-gal on each LB plate and incubate at 37°C until ready
for use.
• Thaw on ice I vial of One Shot™ cells for each transformation. Place the B-
mercapto-ethanol on ice.
3.2b TOPO-Cloning Reaction
• In general, 0.5 to 2 ul of a typical PCR sample (10 ng/ul) with an average insert
length of 400 to 1000 bp will give the proper insert:vector ratio for TOPO-Cloning.
• Set up the following 5 ul TOPO-Cloning reaction:
Fresh PCR product
Sterile Water
pCR- TOPO vector
0.5 to 2 ul
add to a final volume of 4 ul
1ul
Final Volume 5 ul
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• Mix gently and incubate for S minutes at room temperature (-2S0C). For the best
possible results, do not leave for more than S minutes or the transformation and
cloning efficiencies will decrease.
• Briefly centrifuge and place tube on ice. Proceed immediately to One Shot
Transformation Reaction, below.
3.2c One Shot Transformation Reaction
• Add 2 ul of O.S M B-mercaptoethanol to each vial of competent cells and mix by
stirring gently with the pipette tip. DO NOT MIX BY PIPETTING UP AND
DOWN.
• Add 2 ul of the TOPO-Cloning reaction into a vial of One Shot cells and mix
gently.
• Incubate on ice for 30 minutes.
• Heat shock the cells for 30 seconds at 42°C without shaking.
• Immediately transfer the tubes to ice and incubate for 2 minutes.
• Add 250 ul of room temperature SOC medium.
• Cap the tube tightly and shake the tube horizontally at 37°C for 30 minutes
(ampicillin selection) or 1 hour (kanamycin selection). Place on ice.
• Spread SO-100ul from each transformation on a prewarmed plate and incubate
overnight at 37°C.
• An efficient TOPO-Cloning reaction will produce hundreds of colonies. Pick -10
white or light blue colonies for analysis.
3.2d Analysis of positive clones (peR method)
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• Prepare a peR cocktail consisting of peR buffer, dNTPs, appropriate primers, Taq
polymerase and RNAse free water. Use 50 ul reaction volumes.
• Pick 10 colonies and resuspend them individually in 50 ul of the peR cocktail.
• Incubate the reaction for 10 minutes at 94°e to lyse the cells and inactivate
nuc1eases.
• Amplify as appropriate for the peR reaction being used.
• Visualise by agarose gel electrophoresis.
3.3 The GENECLEAN II Kit BIO 101 Inc.
3.3a Excision of DNA band
• The DNA band is excised from the ethidium bromide-stained agarose gel with a
scalpel/razor blade.
• Long-wave UV light is used for a short a time as practical to minimise damage to
the DNA sample.
• The approximate volume of the gel slice is determined (lgm = - lrnl) and
transferred to a plastic tube (DO NOT use glass as the DNA will bind to it).
3.3b Add 3 volumes of NaI stock solution
• The volume of Nal added to a gel piece that contains DNA is approximately 3
times the volume of the solution (or weight of gel slice). For agarose with TBE add
112volume ofTBE Modifier and 4.5 volumes ofNaI to a given volume of agarose.
• This keeps the final concentration ofNaI above 4 molar.
• The tube is incubated at 55°e for 2 minutes, mixed, and incubated again at 55°e
for 5 minutes until the agarose gel has completely dissociated.
3.3c Add GLASSMILK
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• Vortex the insoluble silica matrix stock until all the contents are in suspension.
• Add 5ul of GLASSMILK suspension to solutions containing 5ug or less of DNA.
Add an additional lui for each 0.5ug of DNA above 5ug.
• Mix well and incubate on ice for 5 minutes to allow binding of the DNA to the
silica matrix.
3.3d Pellet the silica matrix with the bound DNA
• Spin the suspension in a microcentrifuge for 10 seconds.
• Discard the supernatant.
3.3e Wash pellet three times with NEW WASH
• 1ml of ice cold NEW WASH is added to the pellet.
• The pellet is resuspended.
• The suspension is spun in a microcentrifuge for 10 seconds and the supernatant
discarded.
• This procedure is repeated twice.
3.3e Elution of DNA from GLASSMILK
• The washed pellet is resuspended in 20ul RNAse free water.
• The tube is incubated at 55°e for 2 minutes and centrifuged for 30 seconds.
• The supernatant containing the eluted DNA is carefully removed and stored in a
new tube. It can either be used immediately or stored at -30De until required.
• The presence of DNA the correct size can be checked by running 2ul of eluted
product on a 2% agarose gel.
3.4 ABI Prism Dye terminator cycle sequencing ready reaction kit
• Prepare two sequencing peR tubes for each purified peR amplicon DNA sample.
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• To the first tube add 8ul of ABl Prism Dye terminator mix, l Oul of the first DNA
sample and I.5ul of 5'second round primer (at 3.2pmollul). To the second tube add
8ul of ABl Prism Dye terminator mix, l Oul of the first DNA sample and I.5ul of
3'second round primer (at 3.2pmoVul). Repeat this process for subsequent samples.
Therefore each DNA sample has a 5' strand tube and a 3' strand tube.
• Briefly centrifuge.
• Place the tubes In a thermocyc1er with a heated lid and run a sequencing
programme.
• Add 50u195% ethanol and 2ul3M NaOAc to each tube and incubate on ice for 10
minutes.
• Centrifuge at 13,500 rpm [I7,000xg] (IEC Micromax) for 30 minutes.
• Remove the supernatant with a fine tip pastette.
• Add 200ul of70% ethanol.
• Centrifuge at 13,500 rpm [I7,000xg] (lEC Micromax) for 5 minutes.
• Remove the supernatant with a fine tip pastette.
• Leave the tubes to dry with an open lid at room temperature.
• Store the tubes at -20°C until ready to send for sequencing.
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3.5 Opti-Prime PCR Optimization Kit (Stratagene Cloning Systems, 1011 North
Torrey Pines Road, La Jolla, CA 92037)
3.5a Optimal Buffer Determination
• Label12 sterile microcentrifuge tubes with the numbers I through 12. Add SuI of
each of the 12 Opti-Prime lOx buffers to its corresponding microcentrifuge tube.
• In a separate microcentrifuge tube (on ice) make up an appropriate volume peR
mix containing Mgel2, dNTPs, primers, Taq polymerase and Nuclease-free water
for the peR reaction being optimised.
• Add 25ul of the peR reaction mix to each of the 12 microcentrifuge tubes and add
one drop of mineral oil to seal the reactions.
• Add 20ul of positive control to each of the 12 microcentrifuge tubes.
• Place the microcentrifuge tubes in a thermocycler and run the appropriate
programme.
• If the peR being optimised is a nested reaction, repeat the above steps adding 35ul
of appropriate peR reaction mix to each of the 12 microcentrifuge tubes with IOul
of first round product. Add one drop of mineral oil to seal the reactions. Place the
microcentrifuge tubes in a thermocyc1er and run the appropriate programme.
• Load lOul of each of the 12 final peR products onto a 2% agarose gel.
Electrophorese, stain with ethidium bromide and evaluate the peR products for
their correct size, for the desired peR product yield and for the amount of non-
specific background amplification products present.
• Determine the best buffer(s) and further optimise by the addition of adjuncts if
necessary.
235
3.Sb Optimal Adjunct Determination
• Select the appropriate lOx buffer and prepare a reaction mixture of all the
components for the PCR reaction (excluding the adjuncts, which are added
separately).
• Label seven sterile microcentrifuge tubes with the numbers 1 through 7. Add the
adjuncts to each of the seven microcentrifuge tubes as indicated in the table below:
Adjunct Final ConcentrationTube No.
5.0ulofformamide
2.5ulofDMSO
7.sul of glycerol
l.Oul of 750mM (NH4)2S04
3.0ul of l.Smg/ml BSA
O.5U of Perfect match DNA polymerase
enhancer (genomic templates)
5.0ul of sterile dH20
1
2
3
4
5
6
7
5%
5%
15%
15mM
100uglml
O.5U
Control
• 30ul PCR reaction mix and 20ul positive control is added to each of the seven
microcentrifuge tubes with a drop of mineral oil to seal the reactions.
• Place the microcentrifuge tubes in a thermocyc1er and run the appropriate
programme.
• lfthe PCR being optimised is a nested reaction, repeat the above steps adding 35ul
of appropriate PCR reaction mix to each of the 7 microcentrifuge tubes with 10ul
of first round product. Add one drop of mineral oil to seal the reactions. Place the
microcentrifuge tubes in a thermocycler and run the appropriate programme.
• Load 10ul of each of the 7 final PCR products onto a 2% agarose gel.
Electrophorese, stain with ethidium bromide and evaluate the PCR products for
their correct size, for the desired PCR product yield and for the amount of non-
specific background amplification products present.
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3.6 Measles RT-PCR (81)
This assay is designed to detect measles virus RNA in a variety of clinical specimens
using primer pairs in the nucleocapsid (N) and matrix (M) genes in one reaction (dual
target-PeR).
• The first round of peR mixture contained 20ul of cDNA, 5 pmol of each primer
(Mnl, Mn2R, Mml and Mm2R), l.OU of Taqpolymerase (Life Technologies, UK),
3ul of lOx peR buffer (Bioline, UK) and made up to 50ul with sterile water (no
dNTPs were added as they were already present from RT reaction).
• peR mixture was then overlaid with one drop of light mineral oil.
• An initial denaturation step for 2 min at 95°e was followed by 25 cycles of I min
at 94°e, I min at 500e and I min at 72°e.
• For nested peR, 3 ul of first round peR product was added to 25 pmol of each
primer (Mn3, Mn4R, Mm3 and Mm4R), 200mM of each dNTP and 1.0U of
Taqpolymerase, 5uI of lOx peR buffer and made up to 50ul with sterile water.
• The reactions were processed for 25 cycles of 1 min at 94°e, 1 min at 55°e and I
in at 72°e after an initial denaturation for 2 min at 95°e.
• The two differently sized peR products were produced in a single peR mixture
and detected by electrophoresis in a 3% agarose gel.
• The primers for the M gene gave an amplification product of 187 base pairs and
those for the N gene gave a product of 317 base pairs.
3.7 Mumps RT-PCR (79)
• 20ul of cDNA was added to the first round peR, and 10ul (2ul for positive control)
of the first-round peR amplicon was then used as a template for the nested peR.
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• Nested PCR amplification of a 639-bp fragment encompassing the entire small
hydrophobic (SH) gene was done with 2 sets of primers.
• Primers SHI and SH2R, each at a concentration of 10 pmol, were used for the first-
round PCR, and SH3 and SH4R were used at a concentration of 25 pmol for the
nestedPCR.
• The PCR amplification was done as follows: an initial incubation for 2 min at 95°C
was followed 25 cycles of 1 min at 95°C, 1.5 min at either 50°C (for the first round)
or 55°C (for the nested PCR), 2 min at 720C, and a final extension step for 5 min at
72°C.
• Tissue culture fluid of a mumps virus isolate (the Taylor strain [TayIUK50s]) was
used as a positive control.
SUMMARY
This study was designed to investigate the extent to which oral fluid can be used to
study the epidemiology of vaccine preventable virus infections, taking rubella and
hepatitis B as examples. This involved the measurement of virus specific IgG
antibody and the detection of virus genome in oral fluid to investigate both the
seroprevalence and the molecular epidemiology of infection by these two viruses. The
major advantage of using oral fluid for these purposes is based around the
accessibility and compliance advantages of obtaining oral fluid samples In
comparison to more invasive types of clinical specimens that can be used.
Assays which measure specific IgG may be used in two ways:
• fordetecting evidence of past infection in the individual
• the determining levels of immunity in a population
The performance characteristics of the assay will determine for which purpose it is
best suited. Assays which demonstrate a particularly high level of sensitivity and
specificity in comparison to a recognised gold standard may be used for testing in the
individual. Those whose performance characteristics are not so good may none the
less still be usefully employed in population immunity testing where correct diagnosis
on an individual level is not critical. The availability and performance characteristics
of suitable serological assays which utilise body fluids more accessible than blood -
such as oral fluid - make them particularly useful for the studies of immunity in
populations and for the surveillance and laboratory confirmation of clinically
diagnosed cases.
The detection, amplification and subsequent nucleotide sequencing of virus genome
present in a sample enables strain variation to be studied and chains of transmission to
be investigated. This information is particularly useful when effective vaccination
programmes are in place and clinical cases identified occur mainly as a result of
importations of infection aquired abroad.
The work described in Chapter 1 addressed the important practical issue of how to
collect oral fluid samples. Three types of oral fluid collection devices were compared
to identify the most suitable in terms of the quality of oral fluid collected and its
suitability for specific IgG antibody screening. Two populations in which an
understanding of the epidemiology of vaccine preventable virus infections is
important were used to provide samples. These were a rural African population where
vaccination coverage is low or absent and limited to certain infections only and a
population of young children from the UK, a developed country where an extensive
vaccination schedule is in place. This work showed that all three of the oral fluid
collection devices yielded a sample that could be used for the qualitative
determination of virus specific IgG. However, the Oracol yielded oral fluid of the
highest quality in terms of the total and specific antibody concentration and was the
most acceptable device to participants from both populations in the study. The Oracol
was also considerably cheaper than the other two makes of device. Therefore the
Oracol was identified as the oral fluid collection device of choice.
A comparison of the total IgG concentration in samples from the two study
populations was made and was shown to be approximately five times higher in those
subjects from Ethiopia. This may reflect the developmental stage or maturity of the
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immune system of the participants involved as the Ethiopian population covered a
broad age spectrum whilst the children from north Hertfordshire were all aged
between 3.5 and 5 years. Alternatively, susceptibility to infectious disease and level of
humoral response may he genetically determined and therefore vary between ethnic
groups.
The second chapter dealt with the development of simple robust ELISA assays that
could he used to measure virus specific IgG antibody in oral fluid samples. The assays
developed were designed to replace existing radioimmunoassays and needed to be
suitable for use in basic laboratories in developing countries. There is currently no
vaccination programme in place in rural Africa for rubella and only some African
countries (e.g. Gambia, South Africa) have a programme of vaccination for hepatitis
B, the virus infections chosen for this study. Suitable ELISA tests capable of detecting
specific IgG in oral fluid against both these infections would provide a means to
investigate the epidemiology of rubella and hepatitis B in populations from rural
Africa. By utilising the compliance advantages of oral fluid such tests would assist in
the design of suitable vaccination strategies and monitor their effectiveness.
The rubella GACELISA developed used the fluorescein isothiocyanate (FITC)-anti-
FITC amplification system and was shown to be more sensitive than
radioimmunoassay and, in comparison to a commercial serum ELISA, performed well
using samples from pediatric populations, However, sensitivity was shown to
decrease with age. The anti-HBc GACELISA was developed using a conventional
detection system comprising of an anti-mouse HRPO conjugated antibody due to the
lack of a suitable volume of anti-HBc monoclonal antibody for FITC conjugation. The
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overall sensitivity of the resulting assay was poor in comparison to a commercial
serum ELISA and was also shown to decrease with age. Overall, the rubella
GACELISA was most suitable for population immunity testing rather than for
diagnosis in the individual, though did perform well with samples from paediatric
populations. In contrast, the performance characteristics of the anti-HBc GACELISA
were not high enough for it to be used for either purpose.
Subsequent development and use of a measles FITC/anti-FITC GACELISA suitable
for use with oral fluid developed by Nigatu et al (126) showed it compared well with
serum ELISA and performed well in all age groups. These results suggested that the
performance of virus specific IgG capture ELISAs designed for use with oral fluid
may be dependant on the biological characteristics of the particular virus infection and
the humoral response directed against it as well as the quality of reagents available.
Future work on the development of assays designed to detect specific antibody in oral
fluid should focus on three main areas:
• Improvin~ assay sensitivity. This is likely to involve the development of new
detection systems that are able to accurately detect the low levels of virus specific
antibody found particularly in oral fluid from older age groups, a major limiting
factor of the GACELISAs for rubella and hepatitis B.
• The conversion and subsequent optimisation of the current ELISA assays that
detect mecific I~G in oral fluid to those that detect virus mecific IrM in oral fluid.
This will enable the laboratory diagnosis and confirmation of important vaccine
preventable infections to be made in basic laboratories in developing countries.
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• The development of further ELISA assays for the detection of specific IgO in oral
fluid against other important infections. including parasites and bacteria as well as
other viruses. that will be useful in both the developed and developing world.
The work described in chapter 3 investigated the molecular epidemiology of rubella
and studied the extent to which oral fluid samples may be used for the detection and
characterisation of the virus genome.
The extent to which oral fluid samples may be used for the detection of measles,
mumps and rubella genome was investigated with regard to (a) collection period after
the onset of symptoms, (b) storage and (c) prior use of samples. Results showed that
virus genome for all three infections was detectable in oral fluid samples up to 14
days after the onset of symptoms. However the detection of virus genome was greatly
increased if samples were collected specifically for RT-peR and stored at .so-c or
below prior to use. Oral fluid samples are therefore a safe and practical clinical
specimen for molecular studies involving measles, mumps and rubella. They are
useful for early diagnosis since specific IgM may not be detectable for a number of
days after the onset of symptoms.
A nested RT-peR assay was developed that targeted a region of the El gene of the
rubella genome and generated a second round amplicon of suitable length for both
diagnosis and phylogenie analysis. This was then used on a variety of clinical
specimens, including oral fluid, collected from Europe, Asia and South America. The
assay was also shown to have potential for the diagnosis of congenital rubella.
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Genotyping demonstrated that rubella can be classified further than has previously
been described and could be used to monitor circulating strains.
Future studies on rubella peR and genotyping should focus on:
• the characterisation of rubella from parts of the globe as yet unsampled (e.g.
Africa) and under represented (e.g. India, South America) and the development of a
more extensive typing scheme. This may then enable the development of a probe
system which could be used for rapid and more cost effective detection and
genotyping of rubella.
• sequencing the complete rubella genome and the development of an RT-peR that
targets other regions of the genome which may be suitable for diagnosis and
molecular epidemiology of rubella.
• the extent to which other more appropriate clinical specimens, such as amniotic
fluid, may be used in the RT-peR assay for the diagnosis of congenital rubella.
• the development of a real time RT-peR assay that uses high speed thermal cycling
(e.g. Lightflycler). This would be very useful for the rapid investigation of
suspected cases of congenital rubella.
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